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Abstract
DANIEL MARTIN MCCALLEY. Developing a Neural Circuit-Based Therapeutic Tool for
Alcohol Use Disorder: The Impact of Structure and Function on Transcranial Magnetic
Stimulation Treatment Response. (Under the direction of COLLEEN A. HANLON).

Alcohol Use Disorder (AUD) is the third leading cause of preventable death in the
United States. While there are several treatment options available, none of these
interventions specifically target the neural circuits known to contribute to alcohol use,
abstinence, and relapse. In the following chapters, this dissertation will introduce
transcranial magnetic stimulation (TMS) as a potential neural-circuit based therapeutic
tool for AUD.
Following a brief introduction to the neural circuitry involved in AUD (Chapter 1),
Chapter 2 reviews the results of a multimodal randomized, double-blind, sham-controlled
trial evaluating 10 sessions of TMS delivered to the frontal pole as a therapeutic tool for
AUD. In this study, active TMS significantly reduced brain reactivity to alcohol cues and
improved 3-month sobriety rates relative to sham, however there was high degree of
individual variability in response to treatment.
To explore neurobiological sources of variability that may influence TMS efficacy,
Chapters 3 and 4 address three unique aspects of brain structure in AUD: grey and white
matter integrity (Chapter 3) and scalp-to-cortex distance (Chapter 4). Chapter 3
demonstrates that individuals with AUD have lower cortical grey and white matter volume
in areas frequently targeted with TMS, suggesting a greater dose of TMS may be needed
to modulate cortical-striatal circuits. Chapter 4 demonstrates that while scalp-to-cortex
distances (and TMS induced electric fields) are not significantly different between
individuals with AUD and controls, overall, males have a longer scalp-to-cortex distance

xvi

than females. This suggests that men may need a higher intensity of stimulation to achieve
a comparable electric field strength at the cortex.
Following the observations from Chapters 3 and 4, we conclude with a secondary
analysis of Chapter 2. Additionally, we explore the influence of individual patterns of brain
reactivity to alcohol cues as a factor associated with treatment response. The results
demonstrated that individuals with overlapping electrical field and patterns of brain
reactivity to alcohol cues were significantly more likely to remain sober at 3 months.
Collectively, these findings provide strong evidence that TMS is an effective treatment for
AUD and that integrating individual brain function and structure may robustly enhance
treatment response.

xvii

Chapter 1: Developing a brain-based, non-invasive treatment for
Alcohol Use Disorder
The natural history of alcohol
The first evidence of alcohol consumption in human society was uncovered in what
is now modern-day Israel. Amidst the recovery of ancient bones, tools, and fossils,
archeologists discovered remnants from 13,000-year-old clay pots. Forensic and
archeological testing of these ancient pots revealed that fermentation of yeast occurred
within them. Alcohol likely existed as early as 11,000 B.C. (1).
Since its invention, alcohol has maintained a central position in human civilizations
across the globe. In ancient Greece, the equal sharing of wine at high-society functions
became dubbed ‘Demokratia’, the root word for modern political term democracy (2). The
cultivation of wheat, which brought about massive sociocultural shifts in farming practice
and land ownership, was sparked not by hunger for bread, but thirst for beer (3). Most
religious systems throughout history have incorporated wine and alcohol into sacred
ceremony. Great American works of literature and theatre like The Odyssey or A Streetcar
Named Desire were penned under the influence alcohol.
For as long as there has been alcohol use, there has also been alcohol misuse.
Restrictions on alcohol use were documented in Hammurabi’s code, the first known
description of law in human society (4). In the millennia following, religious groups, nations
and communities issued their own rulings limiting alcohol consumption. At the turn of the
20th century, endemic alcohol use in United States society spurred prohibition, an outright
ban of consumption and sale of alcohol. Prohibition, however, was short lived and alcohol
once again reinstated its presence in American life. Nearly a decade later, researchers
have begun to address the variety of issues that occur with chronic alcohol use. Chief
among them: Alcohol Use Disorder.
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Alcohol Use Disorder
Alcohol is the most commonly used substance of abuse worldwide (5). In the United
States, roughly approximately 179 million (65.1% of U.S. population) individuals drink
alcohol in the past year (6). A relatively small, but highly significant portion of these
individuals who drink ultimately reach criteria for an Alcohol Use Disorder (AUD). In the
past year, this amounted to 14.5 million individuals or 5.3% of U.S. population (6).

Alcohol Use Disorder: Symptoms and diagnostic criteria
Despite a longstanding history of alcohol misuse, the exact definition of what
constitutes an AUD has changed rapidly throughout the last few decades. In its first
iteration, the Diagnostic and Statistical Manual of Psychiatric Disorders (DSM) described
an individual with AUD as someone with “well-established addiction to alcohol”. Future
iterations (DSM III) of this manual came to acknowledge two core features of AUD: alcohol
abuse and alcohol dependence. Alcohol abuse, in this early context referred to the
combination of daily alcohol use, an inability to stop drinking once initiated, an inability to
recall events while drinking, and continued use despite negative personal or social
consequences. Alcohol dependence, referred to the presence of alcohol abuse cooccurring with an increased tolerance to alcohol and the presence of withdrawal
symptoms. Notably, these diagnostic criteria were binary in nature, suggesting
homogeneity among individuals with AUD (7, 8).
The current iteration of the DSM (DSM-V) upholds similar core symptoms with an
updated recognition that Alcohol Use Disorders are more likely to occur on a continuum.
The DSM-V criteria for AUD also added a question assessing craving for alcohol,
acknowledging its centrality as a core feature of AUD. In total, the DSM-V dictates that
there are 11 diagnostic criteria for AUD, wherein the presence of 3-4, 5-6, or 7 plus
symptoms indicates a mild, moderate, or severe Alcohol Use Disorder, respectively (9).
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These criteria also underscore a clinical recognition that AUD patients are highly
heterogenous. For example, the 11 diagnostic criteria of an AUD can be combined in 165,
462, and 330 unique ways to constitute a mild, moderate, or severe AUD, respectively.

Transition from social drinking to high-risk drinking
There is substantial interest in understanding the individual factors that contribute to
the transition from social drinking to an AUD. Generally, the development of an AUD is
characterized by a shift from impulsive, social drinking to compulsive, heavy drinking that
occurs with the above symptoms (e.g. craving, reductions to executive control, tolerance,
withdrawal). The exact combination of determinants that leads to the development AUD
remains

unknown.

Biological,

environmental,

sociocultural,

demographic,

and

psychological variables, however, are likely to contribute to the development of AUD.
Biological influences: The earliest and perhaps most concrete evidence of a genetic
component of AUD stems from twin studies. Monozygotic (identical) twins were nearly
twice as likely as dizygotic (fraternal) twins to share an AUD diagnosis (10). Recent
advances in genetic testing have provided further support for biological and genetic
components which contribute to AUD. Briefly, single nucleotide polymorphisms within the
enzymes critical to alcohol metabolism (alcohol dehydrogenase and acetaldehyde
dehydrogenase) can decrease efficiency in alcohol breakdown and reduce the likelihood
of transitioning from social to heavy drinking (11, 12). Further, genetic variations in the
receptors for various neurotransmitters, including GABA (13), glutamate (14), serotonin
(15), dopamine (16), and acetylcholine (17) have been associated with the development
of AUD. For further discussion of the influence of genetics determinants of AUD, the reader
is further referred to Tawa et. al, 2016 (18).
Environmental, sociocultural and demographic influences: The influence of
environmental and sociocultural factors that contribute to the development of AUD have
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been explored extensively. Briefly, environmental factors such as socioeconomic status,
education, and mean income have been associated with the development of an AUD (19).
Sociocultural and demographic influences such as race (20), gender (20, 21), gender
identity and sexual orientation (22) similarly impact overall prevalence of AUD. Taken
together, it is likely that these factors influence the likelihood of developing AUD.
Psychological influences (depression, anxiety, stress, PTSD):

Epidemiological

research has suggested that among individuals with an AUD between 40-70% are likely
to already have or develop a co-occurring psychiatric disorder (23). Elevated rates of
major depressive disorder (24), anxiety (25), and PTSD (26) have been reported among
individuals with AUD. It is possible that depression, anxiety, or PTSD are developed after
the onset of an AUD. However, it has also been suggested that prior history of psychiatric
disorders accelerates the transition to alcohol misuse and heavy drinking (24, 26, 27). It
is likely, then, that these disorders contribute to both the development and maintenance
of AUD.

Clinical trajectories among individuals with AUD
Despite the negative consequences of alcohol use in the United States, fewer than
15% of individuals who meet criteria for an AUD seek treatment (28), likely due to social
stigma surrounding AUD or the belief that the individual can independently manage
alcohol use (29). Unfortunately, among those who do not seek treatment, achieving and
maintaining sobriety is generally unsuccessful (30).
Among those who do seek treatment, clinical outcome is generally improved (See:
Current treatment options for AUD). Early treatment efforts for AUD aimed to help
individuals achieve and maintain lifelong sobriety or total abstinence from alcohol. Popular
mutual-help groups such as Alcoholics Anonymous endorsed a “90 meetings in 90 days”
policy, suggesting 90 days of abstinence is needed to maintain long-term sobriety. Other
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treatment approaches endorsed that a longer period of 12 months of abstinence is
required in order to maintain sobriety (31, 32). Today, the US. Food and Drug
Administration (FDA) recognizes that total sobriety is not the only successful outcome
among individuals in AUD. Subsequently, reductions in heavy drinking are now accepted
as a primary endpoint in Phase III clinical trials for AUD (33).
Regardless of treatment end point, relapse and return to heavy drinking following a
variety of treatment approaches is common, with nearly 60% of individuals returning to
alcohol use within 6 months (34). There is increasing recognition, however, that a single
lapse in drinking does not always lead to sustained heavy drinking. In assessing follow-up
drinking data from 2 of the most extensive AUD treatment trials conducted (Project
MATCH and COMBINE), Witkiewitz and colleagues have argued that individuals resume
one of three drinking patterns after an initial lapse: 1) frequent heavy drinking, 2) infrequent
heavy drinking, and 3) infrequent light to moderate drinking (35-37). While this is still an
active area of research, these data underscore the complexity of defining successful
treatment outcomes in AUD trials. For example, while a single bout of heavy drinking
followed by infrequent light drinking may confer clinical benefits, it is likely to be reported
as relapse.
While there is a high prevalence of relapse and harmful drinking patterns following
treatment for AUD, there is a small, but substantial population of individuals who
successfully recover from AUD. Currently, stable AUD recovery is defined by the National
Institute of Alcohol Abuse and Alcoholism as 1) cessation of heavy drinking for a period of
5 years and 2) meeting 0 out of 11 DSM-V criteria for AUD for a period of 5 years (38).
Taken together, the clinical course to achieve remission from AUD is exceptionally difficult,
with the fastest road to stable recovery taking at least 5 years. Despite these challenges,
several psychosocial and pharmacological treatment options are available to improve
AUD treatment outcomes and increase the likelihood of achieving sobriety and recovery.
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Current treatment options for Alcohol Use Disorder
Psychosocial interventions such as mutual help, group-based intervention (e.g.
Alcoholics Anonymous), and outpatient rehabilitation programs are among the two most
popular treatment strategies for AUD (6). Both of these approaches leverage evidencebased strategies in the use of psychosocial and pharmacological interventions.

Psychosocial intervention
The 1950s witnessed a paradigm shift in psychosocial interventions across many
disorders, with the leading school of thought changing from behaviorism to individualized
psychotherapy (39). Built upon this framework, modern psychosocial interventions are
commonplace for individuals with AUD and occur within both outpatient and inpatient
settings. On the front of line of psychosocial intervention strategies is motivational
interviewing – a brief, patient-centered intervention aiming to increase an individual’s
willingness to reduce drinking or achieve sobriety (40).
Motivational interviewing (also referred to as motivational enhancement therapy) is
most often indicated for individuals with a mild to moderate alcohol use disorder (41).
Motivational interviewing substantially reduces drinking in the short (1-6 months), but not
the long term (7-12 months) (42, 43). However, this form of intervention does not appear
to yield any increased benefit relative to other forms of intervention, such as mutual help
groups and cognitive behavioral therapy (43).
The second line of psychosocial intervention for AUD typically includes two treatment
approaches which may occur simultaneously or independently: cognitive behavioral
therapy and 12-step mutual help groups. Cognitive behavioral therapy (CBT) focuses on
addressing negative thoughts and behavioral patterns that contribute to the
symptomology. CBT is most often provided during or immediately following motivational
interviewing and is often applied alongside 12-step programming such as Alcoholics
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Anonymous (44). While this treatment is widely used, the clinical efficacy in reducing
drinking has shown only small to moderate effect sizes, which appear to last for about 1
year following intervention (45).
Mutual help groups such as Alcoholics Anonymous (AA) are the most popular form of
intervention sought out by individuals with AUD (6), with nearly 2 million members
participating in AA within the past year alone (46). Most peer-led programs use a 12-step
program that centers largely on acceptance, spiritual growth, and self-competency. While
it is difficult to assess the efficacy of these programs through standard randomized, clinical
trial methods (e.g. individuals self-select their length and frequency of attendance), these
programs have shown laudable efficacy in reducing drinking and maintaining sobriety. AA,
for instance, boasts an estimated sobriety rate of 40-50% within 1-3 years (47). Notably,
individuals participating in AA only, relative to individuals participating in formalized
treatment programs, achieved similar rates of sobriety at 1 and 3 years after treatment
initiation (47).
In recognition that different psychosocial treatments may be more of less efficacious
on an individual basis, project MATCH (Matching Alcoholism Treatment to Clinical
Heterogeneity) was conducted from 1993-1997 (48). Nearly 1,500 patients receiving both
inpatient and outpatient care were randomized to receive 1 of 3 therapy programs:
motivational interviewing, cognitive behavioral therapy, and 12-step facilitation (similar to
AA). Unfortunately, none of the three tested therapies demonstrated substantial efficacy,
with each approach achieving relatively equivalent rates of sobriety (49). In clinical
decision making, it is notable that only 12-step programs such as AA are peer-led and
highly cost-effective for patients.
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Pharmacological intervention
While the 1950s witnessed a boom in the development of multiple psychosocial
interventions for AUD, the development of pharmacotherapies lagged. During this time,
only one medication was FDA-approved for AUD – disulfiram. Disulfiram acts as a global
inhibitor to acetaldehyde dehydrogenase and interrupts the metabolism of alcohol in the
body (50). The resulting buildup of the toxic byproduct, acetaldehyde, produces
unpleasant side effects such as nausea, skin flushing, elevated heart rate, and vomiting.
These side effects are intended to deter future alcohol consumption. While this medication
prevailed as the primary pharmacologic treatment for AUD for over 50 years, several trials
have shown that disulfiram does not significantly reduce drinking (51) and that adherence
to the medication is poor (52). Today, several more effective pharmacological treatment
options have emerged, placing disulfiram among the last treatment options to be
prescribed (53).
Nearly half a decade later, preclinical research described the influence of endogenous
opioid signaling in response to alcohol and drug intake. Building upon this body of
literature, in 1982, Myers and Critcher first described that blockade of opioid receptors
resulted in reduced alcohol consumption among rodents (54). In clinical trials, naltrexone,
an opioid antagonist, resulted in significantly reduced drinking and improved sobriety rates
(55, 56). These early successes led to subsequent FDA-approval for naltrexone in 1994.
There is some variability in the field however suggesting that naltrexone may be more
efficacious in reducing drinking, but not achieving total sobriety (57). To address low
adherence rates to naltrexone, an injectable, slow-releasing delivery of the medication has
been developed and approved by the FDA in 2010. Efficacy rates of this medication,
however, remain low, yielding only a 26% decrease in heavy drinking days (58).
Nevertheless, the relatively favorable profile of side effects and efficacy of this drug have
earned it a position as a first line of treatment among individuals with AUD (53).
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Parallel to the development of naltrexone as a treatment for AUD, acamprosate was
similarly being tested in animal models and human clinical trials. While it’s mechanism of
action is poorly understood, acamprosate is thought to re-balance the elevated
glutamatergic and dampened GABAergic tone among individuals with AUD (59, 60).
Among early research studies acamprosate combined with psychosocial intervention
yielded significantly improved abstinence rates (61, 62). However, more recent multi-site,
large-scale trials have failed to replicate this result (63). As such, acamprosate is typically
administered as second-line treatment option, given a patient has counterindications for
naltrexone, or naltrexone was ineffective in achieving a reduction in drinking (53). For an
expanded discussion on the above medications, as well as drugs currently under clinical
development, the reader is referred to Swift et. al 2015 (64).

Combined interventions
While increasing the number of available treatments is immensely valuable, it also
leaves researchers with a critical pragmatic question: which combination of psychosocial
and pharmacological therapies achieves the best outcome? The landmark 2006
COMBINE study (combined pharmacotherapies and behavioral interventions) for alcohol
dependence addressed this question robustly (65). Within this trial, individuals were
randomized to receive naltrexone alone, acamprosate alone, naltrexone and
acamprosate, or placebo medication. Each group was further divided in halves such that
one half received cognitive behavioral therapy while the other received no psychosocial
intervention. Among the various combinations tested, the best clinical outcomes
(reductions in drinking) were found amongst individuals who received naltrexone and
cognitive behavioral therapy alone. These provocative results further underscore the
complexity of treating AUD and suggest that pragmatic, singular approaches may
effectively reduce drinking.
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Limitations of current interventions
It is possible that existing pharmaceutical and psychosocial treatments are limited in
that they modulate the brain in a relatively global fashion. While the above treatment
strategies were being developed, the development of novel tools such as optogenetics
and DREADDs offered preclinical scientists in the field a unique look into the neural
circuitry mediating AUD. Similarly, clinical neuroscientists were rapidly developing
advanced neuroimaging techniques to assess brain function and structure in AUD.
Several decades of convergent preclinical and clinical insight has now created a robust
body of knowledge regarding the influence of brain function and structure on the
development and maintenance of AUD.

The case for AUD as a brain-based disorder
Brain function in AUD: a theoretical framework
A model of Alcohol and Substance Use Disorder as a cyclic pattern of
psychophysiological states and behaviors with associated neural correlates was elegantly
described by Koob and Volkow in 2010 (66). The nearly 5,000 citations of this work reflect
the field’s overwhelmingly positive reception of this model Briefly, Koob and Volkow
elegantly describe SUDs as a composite of three phases: 1) binge and intoxication, 2)
withdrawal and negative affect, and 3) executive control and craving; with each phase
corresponding to functional and neurochemical alterations within specific brain regions
and circuits.
Binge and intoxication – the midbrain and basal ganglia:
The initial phase of this cycle, “binge and intoxication” houses two separate but closely
linked components – drug reward and incentive salience. Drug reward, defined as the
perceived positive hedonic components of alcohol/drug use, has been widely investigated
for several decades. The predominant hypothesis of this line of research is that
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understanding acute neural response to drugs may reveal the processes behind the
development of addiction (67). Preclinical evidence laid the foundation for our
understanding of the brain circuits mediating this process. Briefly, rodents were implanted
with intracranial stimulation devices situated within the basal and medial forebrain. When
given the opportunity to press an operant lever to receive self-stimulation, rodents reliably
seek this form of stimulation in lieu of other natural rewards (68-70). Following this work,
the basal and medial forebrain, as well as its associated neural circuitry in the ventral
striatum have long stood out as the relevant neural loci of drug reward. In humans, use of
alcohol and other drugs of abuse, elevates the relative concentrations of dopamine and
opioid peptides within these brain regions (71, 72).
Incentive salience refers to individual motivation for reward and designation of value
to given stimuli. Notably, incentive salience can be directed at a drug, but also at
environmental cues related to a drug (e.g., paraphernalia). This concept stems from early
non-human primate research which demonstrated that upon initial receipt of a reward,
dopaminergic cells in the midbrain spiked rapidly. When the delivery of a reward was
preceded by an external stimulus (e.g. an auditory or visual stimuli), the spiking of
dopamine transmission occurred during the conditioned stimulus, rather than during the
reward itself (73). This phenomenon formed the basis of cue-induced reinstatement in
humans and animals. In animals, cue-induced reinstatement is a research tool wherein
following extinction of operant behavior, animals will reliably seek drugs and alcohol when
presented only with a paired auditory or visual stimulus.
A ventral-dorsal shift in striatal processing may also mediate a shift in motivations from
impulsive to compulsive (or habit-like) drug seeking. Preclinical research using advanced
optogenetic tools has elucidated two, dissociable circuits mediating goal-oriented and
habit-oriented reward seeking. Briefly, inhibition and excitation of the prefrontal cortex and
its afferent projections in the ventral striatum can reliably decrease or increase goal-
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oriented drug seeking. Activity within dorsal striatal circuitry however is elevated during
compulsive, habit-like behavior in rodents (74). A similar striatal shift has been detected
in human drinkers. Light drinkers tend to recruit the ventral striatum in response to the
rewarding effects of alcohol, while moderate to severe drinkers preferentially recruit the
dorsal striatum (75). Our understanding of this shift in behavior is not limited to corticostriatal circuits. In fact, there is compelling evidence that intra-striatal signaling may
mediate this change. Specifically, in rodents, lesioning the connection between the ventral
and dorsal striatum can interrupt habitual alcohol and drug seeking (76).
Withdrawal and negative affect – the ventral striatum, amygdala and habenula:
Decreased sensitivity to natural rewards coupled with heightened stress, anxiety, and
negative affect following the cessation of drugs and alcohol are well documented among
substance using populations (77). One early theory regarding the physiological basis for
this rebounding effect following binge/intoxication is the idea of ‘anti-reward’ – a
homeostatic process to limit reward intake (78, 79). This physiological state is primarily
regulated by changes in dopaminergic tone within the ventral striatum, with accompanying
increases in stress-related hormone concentrations driven by the amygdala and lateral
habenula.
As previously described, the ventral striatum holds a central role in reward processing.
Reductions in dopaminergic tone within the ventral striatum have consistently been found
to occur during withdrawal in both rodents and humans (71, 80, 81). This effect may be
driven by the lateral habenula, which projects directly onto the ventral striatum to reduce
dopaminergic cell firing in response to reward (82). While a causal relationship has not yet
been established, it has been suggested that this change in dopaminergic tone may
contribute to a decreased sensitivity to natural rewards other than drugs (83).
While dopamine is decreased within the striatum, stress-related hormones (e.g.
corticotropin-releasing factor, norepinephrine) are increased during withdrawal and
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negative affect – driven by the extended amygdala (79, 84). Increases in corticotropinreleasing factor (CRF) within the amygdala have shown particular therapeutic and
behavioral relevance in that blocking CRF specifically within the amygdala can decrease
anxiety-like, compulsive (e.g. habitual) behavior during withdrawal (85). Lastly, in human
PET imaging studies of individuals with AUD, endogenous cannabinoid receptors are
reduced (86), possibly resulting in a hampered ability to mitigate the negative affect
caused by amygdala-driven stress-related hormone signaling (87).
Executive control and craving – the prefrontal cortex, insula, and striatum:
This third phase of the cycle of substance use disorders consists of two separate and
opposite decision-making neural processes: executive control and craving. The concept
of opposing decision making systems was first put forward by Descartes (then dubbed
Cartesian Dualism) in the 17th century (88). While this theory has undergone many
revisions, in the 21st century, there is continued support for the presence of two
distinguishable, brain-based decision-making systems (89). The overarching framework
for this contemporary model suggests an imbalance between two circuits: a DLPFC-dorsal
striatal mediated executive control circuit and a MPFC-ventral striatal mediated craving
circuit. Converging preclinical and clinical evidence suggests that among individuals with
alcohol and substance use disorders, executive control circuitry is down-regulated, while
craving and drug-seeking circuitry is up-regulated (89).
Executive control, mediated by the dorsolateral prefrontal cortex and its efferent
projections in the dorsal striatum, is generally down regulated in alcohol and substance
use disorders (90). In cognitively demanding human fMRI task trials designed to assess
inhibitory control (e.g. go/no-go task, stop signal reaction time task, Stroop task), the
dorsolateral prefrontal cortex as well as the dorsal regions of the anterior cingulate cortex
are generally hypo-activated among substance using individuals relative to healthy
controls (90). This relationship may also be transdiagnostic, such that hypoactivation of
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the DLPFC and dorsal anterior cingulate during cognitive control tasks has been shown
among cocaine (91), nicotine (92), opioid (93), and alcohol users (94). Clinically,
decreased executive control has been associated with reductions in recovery rates for
Alcohol Use Disorder (95).
Limbic drive, mediated by the medial prefrontal cortex and its efferent projections in
the ventral striatum, is generally elevated in alcohol and substance use disorders. In
rodents, optogenetic inhibition of the infralimbic and prelimbic cortices and their
projections to the striatum reliably decreases drug-seeking behavior (96-98), while
optogenetic activation of these same regions increases drug seeking behavior (99). In
human fMRI studies, several large-scale analyses have observed that individuals with
AUD consistently demonstrate elevated brain reactivity within the MPFC-ventral striatal
circuit (100-102). Further underscoring the importance of the MPFC-striatal loop, activity
within this circuit may predict relapse to cocaine (103), nicotine (104, 105), opioids (106),
and alcohol (107, 108). In human PET research, Volkow and colleagues elegantly
describe an inverse relationship in dopamine concentrations within the medial prefrontal
cortex and the ventral striatum (71), suggesting the MPFC may exert top-down control on
both functional and neurochemical processes contributing to alcohol and substance use
disorders.
All three phases put forward in this model have clear translational and ecological value
and are critical for future research. From a therapeutic development standpoint,
rebalancing competing drives between executive control and incentive salience is
particularly attractive for several reasons: 1) the prefrontal cortex exerts top-down
regulation on both binge/intoxication and withdrawal/negative affect phases of the
addiction cycle, 2) cortical plasticity is readily inducible with a variety of existing therapeutic
tools and 3) cortical prefrontal brain regions mediating these processes are relatively
superficial.
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Brain structure in AUD: alcohol induces atrophy
Early post-mortem assessments of chronic alcohol users first described the
deleterious influence of chronic alcohol use on brain structure. In 1955, Courville and
colleagues documented gross morphological changes within the cerebrum, cerebellum,
corpus callosum, suggesting these changes were consistent with chronic anoxia, or lack
of oxygen reaching the brain (109). The development of neuroimaging techniques such
as computerized-tomography and magnetic resonance (MR) imaging quickly corroborated
this post-mortem research. Subsequently, the 1980s and 1990s witnessed rapid
advancements in our knowledge of the influence of alcohol on brain structure (110).
Today, alcohol-induced reductions in grey and white matter integrity as well as the
relationship between these structural deficits and clinical outcomes have been well
described.
Influence on grey matter integrity
MR imaging techniques such as voxel-based morphometry have helped to defined
reductions in grey matter volume as a hallmark of Alcohol Use Disorder (111-115). Briefly,
voxel-based morphometry refers to the measurement of local concentrations of grey
matter volume between two groups (116). Using this technique, focal reductions in gray
matter volume within the prefrontal cortex (including the MPFC and DLPFC) have been
consistently reported in AUD patients (113, 114, 117-121). Volumetric reductions in grey
matter have also been reported broadly throughout the brain, within the insula (113, 118,
120-122), anterior cingulate cortex (118, 121-123), cerebellum (117, 120), motor cortex
(113, 117, 121) and subcortical structures such as the hippocampus (112, 120, 121),
striatum (113), and amygdala (112, 121).
Influence on white matter integrity
Voxel-based morphometry can also be used to assess white matter volume among
AUD patients. Focal reductions in white matter volume have been most consistently
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reported within the anterior portion of the corpus callosum (117-119) as well as within the
cerebellum and brainstem (124). A more common approach to assessing white matter
integrity, though, is through the measurement of fractional anisotropy. Briefly, fractional
anisotropy (FA) is a scalar measure ranging from 0 to 1, reflecting the non-Gaussian
movement of water within white matter. A value of 0 would indicate that water is able to
move freely in any direction, without restriction (isotropic). A value of 1 would indicate that
water is only able to move along a singular axis (anisotropic). Physiologically, axonal
sheaths are likely to restrict the movement of water within an axon (125). Among AUD
individuals, compromises to white matter integrity are thought to yield a ‘leakier’ axon,
such that FA values are reduced. Reductions in FA among AUD patients have been
reported within the anterior regions of the corpus callosum (126-128) as well as within
frontal white matter tracts such as the superior longitudinal and uncinate fasciculi (128,
129).
Alcohol-induced atrophy or a predisposition to AUD?
It remains an open question whether chronic alcohol use directly reduces grey and
white matter integrity, or whether reduced brain volume is a common feature among those
vulnerable to developing an AUD. Three convergent lines of evidence, however, point to
a direct role of alcohol in the induction of atrophy in grey and white matter. The first line of
evidence stems from empirical studies exploring the cellular mechanisms through which
alcohol damages neuronal structures. In cellular cultures and animal models, alcohol is
known to damage neurons through at least 3 mechanisms: 1) alcohol-induced
inflammation within the brain (130), 2) build-up of the neurotoxic alcohol byproduct,
acetaldehyde (131) and 3) dietary deficiencies in amino acids (thiamine) that occur
alongside AUD (132). The relative contribution of each of these mechanisms to overall
loss in brain volume, however, is unclear. It is likely that a combination of these processes
contributes to alcohol-induced atrophy.
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The second line of evidence stems from association studies demonstrating the
relationship between overall alcohol consumption and subsequent reductions in brain
volume. Specifically, increased alcohol consumption has been negatively associated with
grey matter volume in the prefrontal cortex (115, 133), insula (134), striatum (113, 117),
and the cingulate cortex (117, 134). Similarly, increased alcohol intake has been
negatively associated with white matter integrity in the corpus callosum (127) as well as
the uncinate and superior longitudinal fasciculi (128). Lastly, a third line of evidence stems
from longitudinal studies of AUD patients during maintained abstinence. Specifically,
several groups have found the grey and white matter volumes recover rapidly with 1-6
months of maintained abstinence (114, 117, 121-123, 127).
Relevance to brain function and relapse
Changes to brain structure have also been reliably associated with future relapse and
aberrant brain function in AUD. Grey matter volume within the prefrontal cortex, for
instance, has been used to reliably distinguish individuals who will later relapse versus
remain abstinent at 1 month, 3 months, and 6 months (112, 122, 135). Similarly, white
matter integrity within fronto-striatal tracts has shown considerable validity in serving as a
biomarker for increased alcohol cue-reactivity (136) and future relapse (135, 137). Further,
many of the regions most likely to atrophy in AUD exert top-down regulatory control onto
reward circuitry involved in reward processing. Specifically, structural compromises in the
prefrontal cortex may result in, or contribute to, functional changes within fronto-striatal
circutry. Therefore, it is likely that both functional and structural changes mediate the
development and maintenance of alcohol use disorder.
Collectively, neural-circuit specific aberrations to brain function and structure underlie
the core features of AUD, opening a new avenue for treatment: brain-based interventions.
Non-invasive forms of brain stimulation offer cutting edge methodologies to precisely
manipulate brain circuits. While there are many of these technologies (e.g. transcranial
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direct current stimulation, transcranial electric stimulation, low-intensity focused
ultrasound), this dissertation aims to develop one well-established tool, Transcranial
Magnetic Stimulation, as a novel treatment for Alcohol use Disorder.

Transcranial Magnetic Stimulation
Transcranial magnetic stimulation (TMS) is a non-invasive form of brain stimulation
which can be used as a therapeutic tool. At its core, TMS capitalizes on several of
Maxwell’s equations, a collection of four equations (derived with influence from Gauss,
Faraday and Ampere) describing electromagnetic induction (138). This first critical
discovery relevant to the development of TMS stems from Faraday’s law. Faraday first
described that time varying electrical currents, when passed throughout a coil of wire,
produce magnetic fields. The resulting induced varying magnetic field then produces a
perpendicular electrical field (138). Most modern TMS coils consist of 100-200 circular
windings of metal wire. When a biological substrate is placed underneath of the coil, and
time varying electrical current is passed through the coil, an electrical current is produced
within that substate. This was most clearly demonstrated by Baker and colleagues in 1985.
Dr. Barker, the driving force behind the development of TMS, was the first to demonstrate
that placing a TMS coil over the arm would elicit an evoked potential from the muscle
under the coil (139). Further, this evoked muscular twitch increased with increasing
intensity from the stimulator, suggesting the effects of TMS may be dose-dependent.
The term transcranial is rooted in the knowledge that TMS pulses readily cross through
the scalp, skull, and dura to reach the cortex underneath. This contrasts with forms of
electrical non-invasive brain stimulation, such as transcranial electrical stimulation or
transcranial direct current stimulation, which are subject to a loss of strength due to the
resistance within tissues. Magnetic forms of non-invasive brain stimulation, such as
transcranial magnetic stimulation, are not subject to tissue resistance. Instead, the
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strength of the induced electromagnetic current decays only as a function of distance
(138). It follows then, that upon moving the TMS coil further away from his arm, Dr. Barker
observed reductions in the amplitude of his muscular twitch (139).
TMS pulses, when applied to the motor strip, can elicit motor evoked potentials
(MEPs) in the corresponding muscle. For example, a TMS pulse applied to the deep and
medial portions of the motor strip reliably elicit movement from the leg and foot (140). TMS
pulses applied to the hand knob can be used with such focality that a MEP can be elicited
within a single finger. The reliability with which TMS can elicit an MEP within specific
muscles sparked the rapid development of two critical TMS research tools: single-pulse
TMS as an investigatory tool and the resting motor threshold.

Single pulse TMS as an investigatory and calibration tool
A single pulse of TMS can travel throughout a neural circuit. This is most readily
evidenced by the application of TMS to the motor cortex. Upon reception at the cortex, the
pulse travels throughout the corticospinal tract, the spinal cord, ultimately reaching the
downstream effector muscle. The amplitude of the resulting muscular response, the MEP,
can be easily measured with electromyography (EMG).
Given the relative simplicity of this process and measurement, the MEP is often used
a dependent measure to assess the influence of various TMS treatments on cortical
excitability. Generally, average MEP amplitude is measure at baseline and followed by an
experimental TMS or brain stimulation treatment. The change in average MEP amplitude
following the treatment is typically used a proxy to infer whether that given treatment
increases or decreases cortical excitability (141).
While MEPs are reliable within individuals, MEP amplitude can vary substantial across
individuals (142). In an early recognition of this variability, the field of brain stimulation
developed the resting motor threshold (rMT) as a tool to calibrate individual stimulation
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intensity. The rMT can be defined as the minimum machine stimulator output required to
produce a motor evoked potential 50% of the time (143). The rMT is then used to
determine an individual’s ‘dose’ for TMS treatment. Notably, the rMT is also a critical safety
metric, as improper or overestimations of the rMT have been associated with increased
seizure risk (144, 145).

Repetitive pulses of TMS as a therapeutic tool
While single pulses of TMS are often used as an investigatory tool, repetitive pulses
of TMS are commonly applied as a therapeutic tool. Landmark research in the late 1990s
established that high-frequencies of rTMS (>5Hz) induce an LTP-like effect in the targeted
neural circuit (146) while low-frequencies of rTMS (1Hz) induce LTD-like effects (147).
Several fixed frequencies of TMS are now commonly applied in therapeutic treatment,
including 1, 10 and 20 Hz frequencies (141). Therapeutic use of rTMS began in the 1990s
and accelerated dramatically with the 2008 FDA approval of rTMS for depression following
positive clinical trial results (148). The therapeutic use of rTMS has now been explored in
alcohol and substance use disorders (149), pain (150), OCD (151), and many other
psychiatric disorders.

Theta Burst Stimulation as an efficient therapeutic tool
Human Theta Burst Stimulation (TBS) is a form of TMS in which pulses are delivered
in triplets that occur 5 times per second. Initial support for TBS arose from in vitro
electrophysiology research which suggested that theta burst stimulation to the
hippocampus can induce long-term potentiation (152-155). In 2005, under the direction of
Dr. John Rothwell, Huang and colleagues delivered two forms theta burst stimulation to
the human motor cortex via a conventional figure of eight TMS coil (156). The first form,
intermittent theta burst stimulation, was delivered in the aforementioned pattern for 2
second trains, followed by an 8 second inter-train interval for a total of 600 pulses
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(approximately 3 minutes). The second form, continuous theta burst stimulation, was
delivered with no spacing between trains, for a total of 600 pulses (40 seconds). In this
small sample (n=9), iTBS and cTBS were found to increase and decrease motor cortex
excitability, respectively. Since then, TBS has been widely embraced by researchers and
clinicians due to its relatively high efficiency as a brain stimulation tool (157).
Today, TBS is now commonly applied to various cortical targets as a tool to probe
cortical excitability and treat psychiatric disorders (158). In 2018, TBS was also given FDA
clearance in treating medication resistant major depressive disorder. While there has been
substantial support for the use of TBS as high-efficiency treatment tool, TBS itself is
subject to high-degrees of individual variability. In fact, the original group developing TBS,
Huang and colleagues, have recently conceded that less than half of individuals receiving
TBS experience the expected change in cortical excitability (159). This discrepancy is
further underscored by mechanistic work in the motor cortex, wherein large, shamcontrolled studies applying TBS have often failed to observe reliable increases or
decreases in cortical excitability following iTBS and cTBS, respectively (160-176).
While therapeutic use of TBS has advanced rapidly, it remains unknown how many
pulses of iTBS or cTBS in a single session are required to optimally increase or decrease
cortical excitability. For further discussion regarding individual variability in response to
TBS and the influence of pulse number in a single treatment session, the reader is referred
to Supplemental Chapter 1 of this dissertation.

TMS and AUD: a literature review
As of February 2022, there were 16 sham-controlled studies published on the use of
rTMS for alcohol addiction (Table 1.1). A handful of case studies and studies which did
not report alcohol-related outcomes have been published but are outside the scope of this
dissertation. Leveraging the neural-basis of AUD [See: Chapter 1, The case for AUD as a
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brain-based disorder], two emergent TMS strategies have been developed in the
treatment of AUD: 1) targeting the DLPFC to enhance executive drive and its associated
circuitry and, 2) targeting the MPFC to reduce craving and incentive salience associated
with alcohol. While many other brain regions are implicated in craving and relapse in AUD,
only a few groups have targeted regions other than the MPFC and DLPFC, which likely
reflects an important gap in the field’s knowledge.
All of the published work stimulating the DLPFC has delivered high-frequency rTMS
(> 5 Hz) for at least 10 sessions to enhance executive drive. Six groups targeted the right
DLPFC, while 4 targeted the left.
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Table 1.1 Summary of TMS for AUD. Columns indicate total number of subjects,
stimulation site, TMS frequency (in Hz), % RMT at which treatment was given, pulses per
session (PPS), number of sessions (S#); statistically significant effects on the brain (fMRI,
EEG), alcohol craving, and length of improved abstinence are reported; blinding procedure
and control conditions are summarized. a: theta-burst stimulation is given based on
pattern, rather than frequency. Rows highlighted in blue (bold text) found significant
reductions in drinking following DLPFC TMS; rows highlighted in maroon found significant
reductions in drinking following MPFC TMS.
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Stimulating the DLPFC in Individuals with AUD
The first study to apply rTMS as a therapeutic intervention for individuals with AUD
was done by Mishra et al. in 2010 (n=45). This sham-controlled study applied 10-Hz rTMS
to the right DLPFC over ten days, yielding a significant decrease in alcohol craving scores
immediately after treatment (177). In a subsequent study (n=20), ten days of 10-Hz rTMS
stimulation to either the left or right DLPFC significantly reduced craving (178). In the years
following, several studies applying similar protocols (≥ 10 days, high-frequency rTMS)
have corroborated this finding (e.g., reduced craving reported in Herremans et al. (179),
decreased alcohol consumption in Addolorato et al. (180) and Belgers et. al (181), and
reduced obsessive-compulsive drinking score in Rapinesi et al. (182), Girardi et al. (183),
and Belgers et al. (181)). Important caveats to these supporting studies, however, are that
Herremans et al. did not include a sham condition and Addolorato et al. used an H-coil
TMS design which has a broader and deeper stimulation profile than other devices (179,
180).
Several studies, however, did not find reductions in craving and drinking behavior
following rTMS. Höppner and colleagues (n=19) applied ten days of 20-Hz rTMS to the
left DLPFC yet did not note any significant decrease in drinking after treatment (184).
Notably, other studies that used fewer TMS sessions did not find reduced craving or
alcohol use (185-187).
Several rTMS studies in AUD have incorporated neuroimaging to characterize the
neurobiology of their findings. 15 sessions of 20-Hz rTMS over four days did not affect
cue-reactivity to alcohol as measured by fMRI (179). However, using a focused, regionof-interest analysis in a subset (n=19) of participants, higher baseline BOLD signal in the
left dorsal anterior cingulate (dACC) was associated with greater alcohol abstinence
following TMS (188). Following ten days of 10-Hz rTMS to the right DLPFC, Jansen et al.
(n=38) observed increases in resting-state functional connectivity within the left
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frontoparietal network (189). Lastly, Addolorato et al. (n=11) revealed that elevated
concentrations of striatal dopamine transport receptor (DAT) availability were reduced
following 12 sessions of H-coil rTMS (180).
Further, several groups examined the efficacy of DLPFC-rTMS in enhancing cognitive
and executive function in AUD. Del Felice et al. (n=17) found that four sessions of real 10Hz rTMS improved performance on inhibitory control tasks (i.e., Go/No-Go, Stroop)
compared to sham stimulation (187). Herremans et al.(n=29) reported a significant
reduction in attentional lapses during the Go/No-Go task after real but not sham 20-Hz
rTMS (186). Höppner et al. (n=19) found a decrease in attentional bias to alcohol cues
among individuals who received ten sessions of 20 Hz TMS, versus sham (184).
Conversely, McNeill and colleagues (n=20) applied a single session cTBS to the right
DLPFC and overserved subsequent decreased inhibitory control and increased alcohol
consumption (190). High-frequency stimulation of the DLPFC, therefore, is an efficacious
strategy to enhance executive control in individuals with AUD.

Stimulating the MPFC in Individuals with AUD
An alternative strategy for improving alcohol abstinence is to decrease activity in the
ventral MPFC with an attenuating form of TMS. Despite the translational promise of this
goal, few research groups have pursued this effort.
The first study to apply rTMS to the MPFC was done by De Ridder et al. (n=1). In this
case study, 15 days of 1-Hz rTMS to the MPFC led to a significant reduction in craving
and activity of the dACC and posterior cingulate cortex (191). Ceccanti et al. (n=18)
applied 10 sessions of 20-Hz rTMS to the dorsal MPFC. They found significant reduction
in alcohol craving associated with real stimulation that lasted for one month, as well as
less daily alcohol consumption for three months (192). Hanlon et al. (n=25) found that
3600 pulses of continuous theta burst stimulation to the MPFC can reduce TMS-evoked
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frontal–striatal activity (193), and Kearney-Ramos et al. showed that this stimulation can
decrease alcohol cue-reactivity as measured by BOLD signal (194).
A recent study conducted by Harel and colleagues applied 10 Hz TMS to the dorsal
MPFC using the H7 coil, which has a decidedly broader and deeper stimulation profile.
Following 15 sessions of real TMS, heavy drinking rates and craving for alcohol was
markedly reduced, relative to sham for 3 months. This change in drinking also occurred
alongside a decrease in cingulate-striatal connectivity as measured by resting-state fMRI
(195). Consistent with this study, McCalley et al. applied cTBS to the ventral MFPC.
Following 10 sessions of real TMS, alcohol craving was reduced, and sobriety rates
improved. This change occurred with similar decrease in fronto-striatal connectivity during
an alcohol cue-task (McCalley et al, In Press).
It is notable that while the overarching framework for this treatment approach is to
decrease MPFC-associated craving and limbic drive, most of the existing work that was
successful in treating AUD applied a high-frequency, or excitatory protocol. This
discrepancy underscores the continued importance of determining the optimal TMS
parameters (e.g., stimulation frequency, number of sessions and target). Collectively,
however, MPFC has tremendous potential as a therapeutic tool for AUD.

A scientific gap: the influence of brain structure on TMS efficacy
While both TMS strategies have shown efficacy in treating AUD, it is notable that only
a few studies have successfully reduced drinking (177, 180, 181, 192, 195). There are
likely to be many TMS parameters that contribute to TMS efficacy in AUD (e.g. stimulation
site, frequency used, number of sessions). Given that Alcohol Use Disorder is a brainbased disorder, encompassing both functional and structural aberrations, these AUDspecific factors may need to be integrated into TMS-AUD treatment.
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A working understanding of the functional circuitry underlying AUD has long guided
treatment design. As stated, the two leading TMS-AUD strategies target the two frontostrital loops with the goal of moderating incentive salience and executive control. Brain
structure in AUD, however, has not yet been comprehensively folded into TMS treatment
design for AUD.
Preliminary evidence has made a strong case that brain structure is likely to influence
treatment outcome in AUD. In two recent analyses of individuals with cocaine use and
alcohol use disorder, the ability of MPFC TMS to modulate downstream regions in the
striatum was directly dependent on three factors: 1) grey matter volume at the stimulation
site (frontal pole), 2) white matter integrity between the stimulation site and the striatum,
and 3) scalp-to-cortex distance (194, 196). Consequently, while TMS may be promising
intervention for AUD, widespread cortical atrophy and white matter tract degradation may
influence the efficacy of TMS. Therefore, this dissertation will address unique features of
brain structure and function among AUD patients, with specialized considerations
regarding how these variables may influence treatment.

Overview
Briefly, the following chapters of this dissertation will describe a series of experiments
which ultimately contribute new knowledge regarding the influence of brain structure in
AUD on TMS treatment efficacy. Chapter 2 of this dissertation will evaluate a randomized,
double-blind, sham-controlled clinical trial applying 10 days of MPFC cTBS in a sample of
50 treatment-seeking individuals with AUD. The following chapters will explore
neurobiological sources of variability that may influence treatment response within this
clinical trial. Chapter 3 will discuss the overall changes to grey and white matter
morphology that occur in AUD patients, and the relevance of those changes to TMS
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treatment. Chapter 4 will address the hypothesis that grey matter volume loss in AUD may
increase cortical distance in AUD patients.
Further, chapter 4 will discuss the importance of sex/gender as a biological variable in
TMS treatment designs. Drawing on the observations from chapters 3 and 4, chapter 5
will present a retrospective analysis of the clinical trial data from chapter 2. Specifically,
this chapter will explore the influence of individual treatment variables, such as baseline
brain response to alcohol cues and TMS electrical fields on treatment outcome. This
chapter will further demonstrate that integrating functional and structural maps may greatly
enhance treatment outcome. The dissertation will conclude with Chapter 6, wherein I will
discuss the collective value of these findings and how the field may move forward in
developing TMS for AUD.
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Chapter 2: Medial prefrontal cortex theta burst stimulation
improves treatment outcomes in Alcohol Use Disorder: a doubleblind, sham-controlled neuroimaging study

Introduction
Alcohol Use Disorder is an intransigent health problem that affects over 1,000,000,000
individuals worldwide, levying a financial burden to society similar to cancer. Alcohol use
disorders affect a wide variety of individuals (adolescents to senior citizens, low to high
socioeconomic status). All of these populations are united by a common feature – elevated
behavioral and brain reactivity to environmental cues for alcohol, a common cause of
relapse (100, 107, 108, 197-199). The brain regions most commonly engaged by alcohol
cues include the medial prefrontal cortex (MPFC), ventral and dorsal striatum, anterior
cingulate cortex (ACC), and anterior insula (102, 108, 198-201).
Recently, there is growing interest surrounding the use of non-invasive
neuromodulation of these brain regions as a unique treatment tool for AUD treatment (149,
202). To date, there have been 18 studies to evaluate the efficacy of Transcranial
Magnetic Stimulation (TMS) as a therapeutic option to decrease drinking. The majority of
these studies have focused on increasing activity within the dorsolateral prefrontal cortex,
a brain region involved in executive control. An alternative approach, however, is to
decrease activity within regions associated with alcohol cue reactivity (e.g. MPFC,
striatum, insula, ACC). For example, a single session of continuous theta burst stimulation
(cTBS) applied to the left frontal pole of the MPFC decreases brain reactivity to alcohol
and drug cues within the frontal-striatal and frontal-insular circuits (194). Therefore, the
next step in this treatment development pipeline is to determine if multiple sessions of
cTBS to the frontal pole decreases brain reactivity to alcohol cues and alcohol
consumption.
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This chapter presents the results of a randomized double-blind, sham-controlled trial
evaluating cTBS to the left frontal pole as a tool to decrease alcohol use and brain
reactivity to alcohol cues for up to 3 months after treatment initiation. The primary aims of
this study were to evaluate the 1) feasibility and 2) efficacy of frontal pole TBS as a tool to
improve retention & relapse rates among individuals engaged in an intensive outpatient
treatment program, as well as the 3) effects of this intervention on brain reactivity to alcohol
cues. The scientific rationale was based on a conceptual model that TBS to the frontal
pole decreases drug-cue induced activity in the MPFC, ACC, insula, and striatum – critical
nodes of the Salient Reward network (89). To determine if the TBS intervention was, in
fact, modulating these circuits, functional neuroimaging data was obtained for all
individuals at baseline, 1 month, 2 month, and 3 month timepoints.

Materials and Methods
Participants
The goal of this study was to comprehensively explore the influence of 10 days of
MPFC-TMS on alcohol cue-reactivity and clinical outcomes. Fifty treatment-seeking
individuals with Alcohol Use Disorder (30 men, 20 women; 45.9±11.7 years old) were
recruited from the Intensive Outpatient Program at the Center for Drug and Alcohol
Problems (CDAP) at MUSC in Charleston, South Carolina. In the CDAP Intensive
Outpatient Program participants attend daily group therapy sessions with clinicians trained
in several different modalities of evidence-based treatment for Alcohol Use Disorders
(e.g., Motivational Enhancement Therapy, Cognitive Behavioral Therapy, Twelve Step
Facilitation, and Acceptance and Commitment Therapy). Additionally, alumni from this
program are invited to attend monthly continuity visits. As part of this program, urine
screens are performed intermittently to evaluate the presence of Ethyl Glucuronide (EtG),
a biomarker for recent alcohol consumption. Exclusion criteria included current or prior
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dependence on prescription or psychoactive drugs other than nicotine (current smokers
n=26), history of head injury with loss of consciousness, unstable medical illness,
pregnancy or breast feeding, ferromagnetic metal in the body, history of seizures, and a
Clinical Institute Withdrawal Assessment score > 5. Prior to each study visit, participants
received a multi-panel urine drug screen (QuikVue 6-panel urine drug screen; Quidel, San
Diego, CA). TMS was not delivered to individuals if they had a positive UDS for
amphetamine (1000 ng/mL), cocaine (300 ng/mL) barbiturates (300 ng/mL), opiates
(morphine 300ng/mL), tetrahydrocannabidiol (50 ng/mL), or benzodiazepines (300
ng/mL). If an individual was positive form one of these substances, they were allowed to
reschedule the visit.
The Intensive Outpatient Program consists of 20 total treatment days (3 hours/day).
Participants attend daily group therapy sessions with clinicians trained in several different
modalities of evidence-based treatment for alcohol use disorders (e.g., Motivational
Enhancement Therapy, Cognitive Behavioral Therapy, Twelve Step Facilitation, and
Acceptance and Commitment Therapy). There is a Day program (Mon-Fri, 9am-12pm)
and an Evening Program (Mon-Thu, 530pm-830pm). Of the 50 individuals in this study 24
were enrolled in the Day program and 26 were enrolled in the Evening program. 26 of the
50 participants received their daily TBS sessions before their IOP sessions (typically within
1 hour). 24 participants received TBS after their IOP visits (all of whom were in the Day
program). [Note: from a conceptual perspective it is possible that delivery of the TBS
before versus after the IOP therapy sessions may influence treatment outcomes. Although
there are not enough data points to evaluate this hypothesis in the present experiment,
there did not appear to be a qualitative difference in returning to drinking rates between
the individuals in the Day program that received real TBS before their IOP visits (66%)
versus those that received TBS after their IOP visits (50%) at the 3-month time point.]

32

Experimental Timeline: Following consent and screening, eligible individuals were
randomized to receive 10 sessions of real or sham TBS (Figure 2.1). Average time to
completion of the 10 sessions was 14.80±4.90 business days. Functional MRI scans were
collected at baseline (pre-TMS), and 1, 2, and 3 months after treatment initiation. The
following clinical assessments were collected: Timeline Followback (TLFB) for alcohol use
(60 days at intake; daily thereafter; 30 days at the follow ups) (203), ObsessiveCompulsive Drinking Scale (OCDS) (65), Alcohol Urge Questionnaire (AUQ) (204), Beck
Depression Inventory-II (BDI) (205), State-Trait Anxiety Inventory (STAI) (206), and the
Barrat Impulsivity Scale (207). Additionally, the Alcohol Use Disorders Identification Test
(208) and Fagerström Smoking Inventory (209) were taken at baseline.
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Figure 2.1 Experimental design. All participants were enrolled in the study during the
first week of Intensive Outpatient Programming (IOP). During weeks two and three of this
program, participants were randomized to receive ten days of Real or Sham TBS. A: At
each visit, various safety measurements were performed, including urine screening for
other drugs of abuse that might affect the motor threshold, changes in medical history,
and Clinical Institute Withdrawal Assessment (CIWA-Ar). TMS tolerability and any adverse
events were also collected. B: Self-reported drinking was collected at each study visit for
all days since the previous study visit, including the follow-up periods. Quantitative urine
metabolites for EtG were taken intermittently during the treatment and follow-up phases.
C: AUDIT scores (baseline only, BDI, STAI, OCDS, AUQ. D: Left frontal pole, one
session/10 days, continuous theta-burst stimulation, 3600 pulses/session, cueprovocation prior and during session, 110% resting motor threshold.
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Continuous TBS
TBS procedures were performed using a figure-of-eight Cool B-65 A/P coil
(Magventure, Farum, Denmark). At baseline, individual resting motor threshold (RMT) was
determined using Parameter Estimation by Sequential Training (PEST), an automated
algorithm used to determine TMS thresholds (143). The TMS coil was positioned at the
left frontal pole (FP1) using the standard EEG 10-20 landmark location. TBS was
administered at 110% of each participant’s RMT. Pulses were administered in a burstfiring pattern (3 pulse burst, 50Hz; 5Hz (200ms) interburst intervals; 1800 pulses/train with
a 60-second intertrain interval (3600 pulses/day)). To enhance the tolerability of FP1 TBS,
stimulation intensity was gradually escalated from 30% to 110% rMT over the first 30
seconds of each train.
This double-blinded study used the MagVenture MagPro integrated active-sham
system. A USB key, coded with participant numbers, was inserted into the machine prior
to each participant’s visit and electrodes (Natus Inc.) are placed on the left frontalis muscle
under the coil. During stimulation, current was passed through the surface electrodes at
an intensity scaled to their motor threshold. After each TMS treatment, individuals were
asked whether they received real or sham and their level of confidence (Likert scale, 110).

Behavioral priming before and during TMS
Exposure to cues prior to TMS can amplify treatment response (210-213). As
previously described (194), before delivery of TMS, individuals were instructed to recall
the last time they had used alcohol. The staff member asked a standard set of questions
tailored to the participant’s history, guiding them to describe the sensory aspects of the
experience (environment, social setting, the way the beverage made them feel). The staff
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member instructed the participant to “keep thinking about alcohol and the negative aspects
of how it makes you feel” during the session.

Structural & Functional Neuroimaging
High-resolution, T1-weighted structural scans (Inversion recovery, 3D spoiled gradient
echo, 1.0x1.0x1.0, field of view: 256mm, section thickness 1.0mm, no gap, in-plane
resolution: 256) and T2*-weighted images (multi-slice, gradient echo-planar sequence,
TR=2200ms; TE=35.0ms; 3.0x3.0x3.0mm; field of view: 192mm; resolution: 64) were
collected throughout the study.
Of the 50 randomized participants, neuroimaging data was available from 44
individuals (real cTBS n=23; sham cTBS n=21). Seven individuals were not scanned due
to a scanner upgrade. Within the real cTBS group, there were 23, 17, 16, and 16 fMRI
scans available, and within the sham group, there were 21, 17, 11, and 11 scans available
at baseline, 1, 2, and 3 month visits, respectively.

Alcohol-cue fMRI task
As previously reported (103, 194, 214) our alcohol cue task was administered through
E-Prime 2 software (Psychology Software Tools, Inc., Sharpsburg, PA). Images were
presented within a block design (12min: 24sec blocks, 4.8sec/image) wherein blocks
represented four conditions presented in a pseudorandom order: alcohol, neutral
beverages, blur (matching substance images in color and hue), and rest (fixation cross).
The task was described to participants prior to the scan. Participants were asked to rate
their level of alcohol craving following each block of images using an MRI-compatible hand
pad (Likert scale, 1-5).

Scalp-to-cortex (STC) distance
STC was extracted from FP1 for each subject using SIMNIBS v3.2.1 (215). Individual
STC measurements, representing the shortest distance between the cortex and the area
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immediately underlying the TMS coil, were extracted from SIMNIBS’ standard output when
modeling electrical fields at the left frontal pole.

fMRI preprocessing
All MRI data were processed using SPM12 (Wellcome Department of Cognitive
Neurology, London, UK) implemented in MATLAB 2017b (MathWorks, Inc, Natick, MA).
Before processing, images were converted from Dicom to 4D NifTii format. Structural, T1weighted images were segmented into their component parts (Gray matter, white matter,
CSF, skull, and background), bias-corrected, and normalized simultaneously (SPM:
segment). Gray matter, white matter and CSF tissue segmentations were then applied as
a combined mask to remove the skull from the anatomical image (SPM: imcalc). Field
map-derived voxel displacement maps were generated and co-registered to the functional
images (SPM: VDM). Functional images were then realigned with rigid-body six motion
parameter realignment to the first image in the series using a least-squares approach.
Previously calculated voxel displacement maps were used to unwarp the functional
images, reducing image distortion and preserving anatomical fidelity (SPM: Realign and
Unwarp). The functional images were then co-registered, through the mean T2* image, to
the skull-stripped anatomical (SPM: Coregister: Estimate). The co-registered images were
then normalized to standard MNI-152 space using the non-linear deformation maps
obtained during segmentation. Lastly, functional images were skull-stripped and
smoothed with an 8mm FWHM kernel to enhance the signal-to-noise ratio and reduce
inter-subject variability.

Functional Connectivity Analyses
Within-subject analysis: All fMRI data were preprocessed using SPM12 (Wellcome
Department of Cognitive Neurology, London, UK) implemented in MATLAB 2017b
(MathWorks, Inc, Natick, MA). The analytic plan for this dataset was based upon a
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previous publication wherein we demonstrated that a single session of cTBS to the frontal
pole decreased functional connectivity to cues in the cingulate, striatum, and insula (194).
The present study aimed to determine if multiple sessions of TMS also decreased
brain reactivity to alcohol cues and if these decreases were durable for 2-3 months after
the TMS. Consequently, we used the Conn functional connectivity toolbox (version 20.b)
to evaluate functional connectivity (216).
Standard preprocessing steps included: segmentation, skull-stripping, field map
correction, motion correction, and normalization to MNI-152 space. See Supplemental
Materials for expanded details. A weighted GLM, ROI-to-ROI analysis was performed on
the data from baseline, 1 month, 2 month and 3 month follow-up visits. Brain regions of
interest were restricted to those identified by Kearney-Ramos and colleagues (194). The
seed ROI, left frontal pole, was constructed using a 20mm, brain-masked region located
at the FP1 target (EEG 10-20 system).
Other ROIs in the analysis included: the left and right insula (AAL atlas: 29_Insula_L,
30_Insula_R), the bilateral anterior cingulate cortex (AAL atlas: 31_Cingulum_Ant_L,
32_Cingulum_Ant_R), left and right dorsal striatum (Oxford-GSK_Imanove connectivity
atlas), the left and right ventral striatum (Oxford-GSK_Imanove connectivity atlas) and the
left superior occipital cortex (AAL atlas: 49_Occipital_Sup_L; control region).
Fisher’s transformed correlation coefficients (z-scores) were extracted between FP1
(stimulation site) and each ROI. Functional connectivity associated with alcohol cue blocks
was compiled for each participant at all visits.
Between-group analysis: Data from above were entered into a group level mixedeffects general linear model (SPSS) to determine the effect of treatment, time and ROI on
change in FP1 functional connectivity relative to baseline. The model included covariates
for individual scalp-to-cortex distance, gender, state anxiety score (STAI, trait subscale),

38

depression score (BDI), and AUD severity (AUDIT). Estimated marginal means of the
main effects and interactions were quantified.
Prior to group-level multivariate regression, statistical outliers were identified using the
SPSS boxplot tool. Boxplots were constructed for change in functional connectivity for
each ROI. Extreme outliers (datapoints > (3rd quartile+ 3*interquartile range) and
datapoints < 1st quartile-(3*interquartile range)) were excluded from analysis, leaving
97.4% of all data included in analysis.
Secondary analysis: In the interest of facilitating future work in this area, wherein
investigators may require effect sizes to power larger, more definitive clinical trials, we
performed a posthoc analysis. We evaluated the influence of real versus sham TBS on
functional connectivity at each timepoint for each ROI. Effect sizes (Hedge’s g, weighted
for different sample sizes) were interpreted as follows: small-medium effect size, g<0.5;
medium-large effect size 0.5<g<0.8; large effect size g>0.8 (217).

BOLD signal magnitude analysis (whole-brain approach)
This study also assessed BOLD signal magnitude in response to alcohol cues
throughout the experiment. All whole-brain alcohol cue-reactivity analyses were
performed in SPM12. Briefly, for each participant, smoothed, normalized functional data
from each condition (alcohol, neutral beverages, blurred and fixation cross cues) were
concatenated. Motion parameters in 6 directions (x,y,z, pitch, roll, and yaw) were treated
as nuisance variables and regressed out of the data. Motion-adjusted contrast maps
representing relative beta weights were created for the alcohol cue-condition (as well as
the neutral beverage, blur, and fixation cross conditions). To assess fMRI BOLD response
to alcohol cues on the group level, a general linear model (GLM) of the alcohol cue
contrast maps was performed. A full-factorial model (adjusting for subject dropout) was
constructed with group (real or sham TBS) and time (Baseline, 1 Month, 2 Months, and 3
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months follow-ups) as fixed factors. Real and sham samples were assumed to be
independent, however within-group follow-up scans were considered dependent.
Variance was assumed to be equal between the groups at each timepoint. A binary,
explicit MNI mask (encompassing gray matter, white matter, and CSF) was applied to the
data. Contrasts comparing group-level beta weights within and between groups (e.g., real
only, sham only, and sham>real) were generated at each visit.

Behavioral analysis
Study enrollment: Standard odds ratios were calculated at each follow-up visit to
assess the likelihood of attendance following real or sham MPFC TBS.

Sobriety: One of the primary goals of this experiment was to determine if ten sessions
of cTBS to the frontal pole improved the likelihood of sobriety in treatment-seeking
individuals with Alcohol Use Disorder. We collected daily self-reported drinking from
participants (TLFB) and intermittent quantitative ETG measurements collected while they
were enrolled in the intensive outpatient treatment program. All individuals in the perprotocol sample with at least one heavy drinking day 30 days before TMS V1 (32 of 50)
were included in the analysis. For each time point, we compiled the number of drinking
days and the number of heavy drinking days (women: ≥4 & men: ≥5 standard drinks/day)
in the 30 days before that time point. The self-report measurements were cross-referenced
with outcomes from urine ETG (wherein either a positive self-report or a positive ETG level
(>100) was considered a drinking day). The odds of drinking (any drinking days in the
previous 30 days) were calculated using standard odds ratios. To deal with missing data
from a statistical perspective, the last observation carry forward (LOCF) method was used
(218). This is a standard statistical technique in longitudinal clinical trials likely most
appropriate when missing data is not equally distributed in the treatment and sham group
(e.g. missing not at random (MNAR)) (219).
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Change in behavioral assessments of interest: Mixed-effects general linear models
(time*treatment) were computed for secondary outcomes, including change in OCDS and
AUQ. Covariates included baseline score, individual scalp-to-cortex distance, and gender
were included in the model. Effect sizes reflecting the difference between groups at each
follow-up visit were calculated.
Change in depression (BDI), anxiety (STAI), and impulsivity (BIS): Mixed-effects
general linear models (time*treatment) were constructed for each variable: BDI, STAI
state, STAI trait, and BIS.

Results
Baseline demographics and behavior
There were no significant differences between groups at baseline, with the exception
of education (Table 2.1)
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Table 2.1 Participant demographics. There was no difference in demographic variables
between the real and sham groups, with the exception of education. Values represent
mean ± SD unless otherwise specified. Abbreviations: M, male; F, female; NH, NonHispanic; H, Hispanic; W, White; AA, African-American; A, Asian; RMT, Resting Motor
Threshold; MSO, Machine Stimulator Output; AUDIT, Alcohol Use Disorder Identification
Test; ARPS, Alcohol-related problems scale; OCDS, Obsessive-Compulsive Drinking
Scale; AUQ, Alcohol Urge Questionnaire; BDI, Beck’s Depression Inventory; STAI,
Spielberger Trait Anxiety Inventory; BIS, Barrat Impulsivity Scale; S, smoker; NS, nonsmoker; FNDS, Fagerström Nicotine Dependence Scale. *NA, no answer.
Real
(n=26)

Sham
(n=24)

Age
Education (Years)
Gender

45.7 ± 11.5
15.9 ± 1.7
16 M, 10 F

46.2 ± 12.1
14.7 ± 2.0
15 M, 10 F

Ethnicity
Race

26 NH, 0 H
23 W, 3 AA

22 NH, 1 H, 1 NA*
19 W, 4 AA, 1 A

47.8 ± 8.6

51.0 ± 8.1

AUDIT
Consumption

25.9 ± 5.7
10.2 ± 1.5

26.7 ± 5.3
10.0 ± 2.3

Dependence
ARPS
OCDS
Obsessive

6.8 ± 2.8
8.9 ± 3.7
15.6 ± 6.1
6.6 ± 2.9

7.5 ± 2.3
9.1 ± 3.7
10.8 ± 6.1
5.3 ± 3.3

9.1 ± 4.3

5.3 ± 3.5

11.0 ± 10.4

14.4 ± 9.5

10.9 ± 8.1

9.3 ± 8.5

8.9 ± 8.1
23.8 ± 14.7

7.8 ± 8.0
15.4 ± 9.0

Demographics

TMS parameters
RMT (% MSO)
Drinking & Craving

Compulsive
Days Since Last
Drink
Drinking Days
(last 30 days)
Heavy Drinking
Days (last 30 days)
AUQ

AUD-associated co-morbidity
16.9 ± 12.01
41.0 ± 14.9
45.5 ± 14.1

15.4 ± 10.8
43.3 ± 14.9
47.0 ± 14.7

BIS

67.7 ± 13.5

66.3 ± 13.6

Smoking
Current smoking
status

17 S, 9 NS

12 S, 13 NS

BDI
STAI (State)
STAI (Trait)
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Sham integrity
Of the 469 survey responses over the entire study, the accuracy of correctly guessing
was 50.11%, confirming the integrity of the sham. Participants endorsed moderate
confidence in their decision (6.7 ± 2.5 on a 1-10 scale).

Enrollment and sobriety
The CONSORT diagram (Figure 2.2) describes the study's enrollment and retention.
Although there was not a statistically significant difference, a greater portion of individuals
who received real TBS (1 month: 80.8%; 2 months: 77.0%; 3 months: 73.1%) remained
enrolled in the study, relative to sham (1 month: 80.0%; 2 months:52.0%; 3 months:
48.0%) at the 2 month (OR: 2.82, z=1.692, p=0.09) and 3 month (OR: 2.71, z=1.659,
p=0.10) follow up visits which may be clinically meaningful. There was no significant
difference in enrollment by gender.
Again, while there was not a statistically significant difference, a greater portion of
individuals who received real TBS (1 month: 53.3%; 2 months: 60.0%; 3 months: 73.3%),
remained abstinent from alcohol relative to sham (1 month: 52.9%; 2 months: 47.1%; 3
months: 47.1%) at 3 month (OR:3.09, z=1.487, p=0.14) follow up visit, which may be
clinically meaningful. There was no significant difference in sobriety by gender (Figure
2.3).
There was not a statically significant difference in return to heavy drinking in those who
received real TBS (1 month: 13.3%; 2 months: 26.7%; 3 months: 13.3%), relative to sham
(1 month: 17.6%; 2 months: 23.5%; 3 months: 17.6%). Further, there was no significant
difference in the time to first drink following completion of the TMS visits in the group
receiving real TBS (23.3 ± 21.4 days) relative to sham (12.2 ± 20.1 days; t14=1.05,
p=0.321) (Figure 2.3).
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Figure 2.2 CONSORT diagram of study participants. Consolidated Standards of
Reporting Trials (CONSORT) diagram showing flow of participants through the TBS
experiment. a: 34 participants excluded after consent and screening due to: recent abuse
of illicit substances other than marijuana (n=23), no contact after screening visit (n=6), met
criteria for substance dependence on Xanax (n=1), not eligible due to age (n=1),
participant withdrawn from outpatient program (n=1), participant currently taking
prescription opiates (n=1), failed metal safety screening (n=1). b: 5 subjects lost to followup at varying stages of Real TBS treatment (3 sessions completed, n=1; 6 sessions
completed, n=1; 7 sessions completed, n=2; 9 session completed, n=1) c: 4 subjects lost
to follow-up at varying stages of sham TBS treatment (2 sessions completed, n=1; 3
sessions completed, n=1; 4 sessions completed, n=1; 7 sessions completed, n=1).
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Figure 2.3 Study enrollment and sobriety following real versus sham TBS.
Individuals in the Real TBS group (black lines, circles) were more likely to remain enrolled
in the study and more likely to remain sober than the Sham group (grey lines, squares).
A) Percentage enrolled (1 month: Real, 80.1%; Sham, 80.0%; 2 months: Real, 77.0%;
Sham, 52.0%; Odd’s Ratio=2.82, z=1.672, p=0.1; 3 months: Real, 73.1%; Sham, 48.0%;
Odd’s Ratio=2.71, z=1.66, p=0.1). B) Percentage of individuals remaining sober (1 month:
Real, 31.0%; Sham, 42.9%; 2 months: Real, 45.5%; Sham, 42.9%; 3 months: Real,
72.7%; Sham, 47.6%; Odd’s Ratio=2.93, z= 1.66, p=0.1).
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OCDS and AUQ
Analysis of the OCDS (Figure 2.4) revealed a significant time*treatment interaction
(F3,67=3.961, p=0.012) and a main effect of time (F3,67=10.27, p<0.001). Baseline OCDS
score was a significant covariate in our model (F1,67=13.17, p<0.001). There was no
significant effect of gender (F1,67=0.0872, p=0.35) or scalp-to-cortex distance (F1,67=0.267,
p=0.61). At the 1-month visit, estimated marginal means of OCDS score were significantly
reduced in the real TBS group (2.4 ± 1.9), relative to sham (10.4 ± 1.7; t12=-3.065; p=0.01;
Hedge’s g=1.65). There was no main effect of treatment (F1,73=0.115, p=0.74) nor an
interaction (F3,73=1.394, p=0.25). Change in AUQ and OCDS sub-scales can be found in
Figure 2.4.
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Figure 2.4 Alcohol craving (OCDS and AUQ). There was a significant time x treatment
interaction in obsessive-compulsive drinking scores (top panel) which was driven by a
significant reduction in OCDS scores in the Real (black lines, circles) versus Sham group
(gray lines, squares) 1 month after treatment (t12=-3.065, p=0.01, Hedge’s g=1.65).
Baseline OCDS score was a significant covariate in the model (F1,67=13.172, p<0.001).
AUQ score (bottom panel) decreased in both groups across the experiment but was not
significantly different at any visit. Baseline AUQ score was a significant covariate
(F1,73=24.80, p<0.001). Gender and scalp-to-cortex distance were not significant
covariates. Results of general linear model analysis are embedded. Data plotted reflect
estimated marginal means. Error bars represent SEM.
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Change in depression (BDI), anxiety (STAI) and impulsivity (BIS)
While there were significant effects detected reflecting decreases in these variables,
at baseline, no individual met clinical criteria for severe depression (205) or anxiety (206).
Therefore, these effects are likely to have limited clinical utility (Figure 2.5).
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Figure 2.5: Behavioral variables across experiment. Average BDI, STAI (state and trait
sub-scores) and BIS were measured at each study visit. Black lines (circles) represent
real cTBS; grey lines (squares) represent sham cTBS. Dotted lines on the Y-axis represent
clinical thresholds for severe depression and anxiety. Average values for depression and
anxiety severity remained at or below clinical thresholds throughout the duration of the
experiment. Results of general linear model analysis are embedded. Error bars represent
SEM.
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Change in alcohol cue induced FP1 functional connectivity
There was a main effect of treatment (F1,547=14.235, p<0.001), time (F2,547=3.823,
p=0.02), and time*treatment interaction (F1,547=4.519, p=0.01). Gender emerged as a
significant covariate (F1,547=5.279, p=0.02). FP1 functional connectivity to the network of
ROIs as a whole was significantly lower at the 2-month follow-up (t25=-4.382, p<0.001;
Hedge’s g= 1.72) with the effects eroding at the 3-month follow-up (t25=-1.914, p=0.07;
Hedge’s g=0.75, Figure 2.5a, Figure 2.6). There was no treatment*ROI interaction
(F6,547=0.540, p=0.78), likely owing to the uniform effects of TBS on FP1 functional
connectivity to these regions (Figure 2.5b).
Secondary analysis: Effect sizes were calculated for each ROI to inform future clinical
trial design (Table 2.3). Real TBS decreased functional connectivity from FP1 to the left
dorsal striatum (2 months: g=0.589; 3 months: g=1.007), ventral striatum (2 months:
g=0.527; 3 months: g=0.981) and the left insula (2 months: g=1.046). There was no effect
on connectivity to the left occipital cortex (Figure 2.7). Given that gender emerged as a
significant covariate in the analysis, functional connectivity change scores organized by
gender across all ROIs were plotted in Figure 2.8.

Change in alcohol cue-induced BOLD signal
There were no significant differences in the magnitude of BOLD signal at the baseline,
1 month, and 3 month timepoints (Figure 2.9). At the 2 month follow-up visit, BOLD signal
was greater in the sham group relative to the real TBS group within two primary clusters:
c1, right insula and precentral gyrus (k=2,549, pFWE-corrected=0.004); c2, the right mid
cingulate (k=2,529, pFWE-corrected=0.004).
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Figure 2.5: Influence of real versus sham TBS over time and by region of interest.
Estimated marginal means across time (A) and regions of interest (B) are plotted with
respect to treatment (real TBS: black lines, circles; sham TBS: grey lines, squares). The
general linear model assessing change in functional connectivity included covariates for
scalp-to-cortex distance, gender, BDI, AUDIT, and trait anxiety. A) There was a significant
time*treatment interaction on frontal pole connectivity during alcohol cues (F1,547=4.519,
p=0.01), B) Across all ROIs, functional connectivity to alcohol cues was consistently lower
in the group receiving real TBS relative to sham. Error bars represent SEM. ACC= Anterior
Cingulate Cortex; Ins= Insula; VS= Ventral Striatum; DS= Dorsal Striatum.

51

Figure 2.6: Change in cue-induced functional connectivity relative to baseline. The
real TBS group had a reduction in connectivity 1, 2 and 3 months after the baseline visit.
The sham TBS group had an initial reduction, but then became more reactive to alcohol
cues at 2 and 3 months. Blue lines: lower connectivity relative to baseline; Red lines:
higher connectivity relative to baseline; White lines: no change in connectivity. The
intensity of the lines reflect magnitude of functional connectivity change: dark blue/red
indicates an absolute change in correlation coefficient ≥ 0.1; bright blue/red indicates an
absolute change in correlation coefficient ≥ 0.2; white lines indicate an absolute change in
correlation coefficient < 0.1. FP1= Left Frontal Pole; ACC= Anterior Cingulate Cortex; VS=
Ventral Striatum; DS= Dorsal Striatum; Occip= Superior Occipital Cortex.
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Figure 2.7. Longitudinal change in frontal-striatal and cingulate connectivity to
alcohol cues. There was a substantial reduction in connectivity to alcohol cues following
real (black lines, circles) versus sham (grey lines, squares) TBS to the left dorsal and
ventral striatum and the left insula cingulate at 2 months. Dorsal striatal connectivity and
ventral striatal connectivity to alcohol cues remained attenuated in the real TBS group at
3 months. There was no difference in the occipital cortex which served as a control region.
Error bars represent SEM. See Table 2.2 for associated effect sizes.
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Figure 2.8 Influence of gender on change in functional connectivity. Women (purple
lines) receiving sham cTBS (left panel) experienced a greater overall increase in alcohol
cue-induced functional connectivity at the 2- and 3-month follow-up visits, relative to men
(blue lines). Conversely, women receiving real cTBS (right panel) experienced a greater
reduction in alcohol cue-induced functional connectivity than men (blue lines). Data points
represent the average change in functional connectivity to all tested ROIs. Error bars
reflect SEM.
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Table 2.3: Change in FP1 functional connectivity to all tested ROIs (effect sizes).
Effect sizes (Hedge’s g) reflecting the difference in functional connectivity change in real,
relative to sham TBS, are shown for each ROI at each time point. The length of the overlaid
blue bars reflect the magnitude of effect size in difference between real and sham group
(scaled from 0.0 to 1.046).
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Figure 2.9: Alcohol cue reactivity (General Linear Model analysis). There was no
significant difference in alcohol cue-reactivity between the Real and Sham groups at the
baseline (V1), 1-month (V2) or 3-month (V4) visits (p<0.05, family-wise error multiple
comparisons-corrected). At the 2-month visit (V3), individuals in the Sham group had
greater alcohol cue-reactivity than individuals in the Real TMS group. The difference
(sham > real) in cue-reactivity was greatest in two clusters (cluster 1: k=2549, p=0.004;
cluster 2: k=2529, p=0.004). These differences were detected within the right insula and
right precentral gyrus (cluster 1) and the left mid cingulum and left postcentral gyrus
(cluster 2).

56

Discussion
The last decade has brought about a groundswell of enthusiasm to advance TMS as
a therapeutic option for individuals with substance use disorders. While the majority of
clinical trials have focused on stimulating the left dorsolateral prefrontal cortex (DLPFC),
there is growing evidence that the frontal pole may also be a fruitful treatment target given
its transdiagnostic role in drug-cue reactivity (220). Kearny-Ramos and colleagues
recently demonstrated that a single session of theta burst stimulation to the frontal pole
could decrease functional connectivity to drug and alcohol cues in a network of brain
regions (e.g. dorsal and ventral striatum, cingulate, insula)(194). As a logical next step in
the treatment development pipeline, we set out to determine if multiple sessions of TBS
delivered to the frontal pole could improve alcohol sobriety rates and brain reactivity to
alcohol cues in a cohort of treatment-seeking individuals with Alcohol Use Disorder. The
primary conclusions of this randomized, double-blind, sham-controlled longitudinal study
are that ten sessions of frontal pole TBS: 1) is well tolerated and feasible addition to an
intensive outpatient treatment program, 2) increased treatment engagement and sobriety
three months after treatment initiation and, 3) produced a significant and durable decrease
in alcohol cue associated functional connectivity from the frontal pole to the same network
of regions that were modified in the single-session study (194). These data suggest that
the frontal pole continues to be a promising clinical treatment target for individuals with
Alcohol Use Disorder and underscores the need for large multisite trials to evaluate this
as a treatment adjuvant.

Feasibility, tolerability
Following the FDA-clearance of theta-burst stimulation as a treatment tool for
depression (157), there has been growing interest in developing high potency forms of
brain stimulation that can be delivered relatively quickly (221-224). This high-density
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continuous protocol (193, 194) was not only well-tolerated over the frontal pole, but it also
resulted in a significant improvement in treatment engagement and alcohol sobriety in this
sample. In a recent study of 240 individuals that have come through our laboratory, patient
self-reported pain during TBS treatment over the left frontal pole was not statistically
different than DLPFC stimulation (225). The integrity of our active sham condition was
sound, with participant guesses regarding the received condition situated at near-chance
levels.

Current use of brain stimulation in Alcohol Use Disorders
While the FDA and NIAAA have recently begun to expand the definition of a positive
AUD treatment outcome to include a reduction in heavy drinking (226, 227), achieving and
maintaining abstinence remains a gold standard among treatment efforts for AUD. Further,
it is well known that obsessive and compulsive drinking behaviors are key features of AUD
(228). Here, individuals who received real TBS were 3 times more likely to remain sober
3 months after treatment initiation, relative to sham. Interestingly, this change in drinking
behavior is preceded by a precipitous drop in obsessive and compulsive features of
alcohol use 1 month after treatment, as well as a marked decrease in functional
connectivity to alcohol cues 2 months after treatment. These data suggest that TMS may
cause a cascade of changes in behavior and brain metrics, ultimately yielding an increase
in sobriety 3 months after treatment.
These results are supported by early brain stimulation therapeutic work targeting the
DLPFC which reduced ACQ-Now scores (177, 178) and alcohol consumption (180)
following treatment. Our results most closely align with that of Ceccanti et. al 2015
wherein, following 10 days of MPFC stimulation, alcohol consumption, craving, and brain
reactivity to alcohol cues decreased (192). These data, in concert with previous literature
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demonstrate that TBS applied to the MPFC is a durable and efficacious strategy to
decrease alcohol use and alcohol cue-reactivity.

Enrollment across and 3-month study
Participant dropout rates from standard, psycho-social interventions for AUD are high
(229). Further, drop out from AUD treatment is a robust predictor of future relapse to
alcohol (230), while adherence to treatment is associated with long-term improvement in
AUD severity (231). While enrollment in treatment is a clinically relevant variable, many
previous TMS-AUD trials have been unable to assess this metric as they occurred within
an inpatient, hospital setting, wherein attendance at treatment sessions was likely
mandated (177-180, 183). Here, we recruited individuals from an outpatient population
which offers the two-fold benefit of expanding the knowledge within the field regarding 1)
the influence of cTBS on longitudinal treatment engagement and 2) expands potential
treatment options for a larger portion of individuals with AUD outside the hospital setting.
In a recent TMS-AUD trial, wherein participants received 20 Hz deep MPFC rTMS
(without behavioral intervention), retention rates among those receiving real TMS at 2and 3-month follow-up visits were between 40-50% (192). Here, in applying TBS as an
adjuvant therapeutic to an intensive outpatient program, we demonstrate that, among
those receiving real TBS, retention rates at the 2 (77%) and 3-month (73%) follow-up visits
were high compared to this previous TMS-only intervention. Interestingly, among those
receiving sham TBS, retention rates were in line with previous psychosocial and TMS-only
efforts (52% and 48%, respectively). Taken together, these data suggest that TBS is a
very effective tool in maintaining subject enrollment and therefore may be a fruitful strategy
in improving longitudinal AUD treatment outcomes.
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Change in alcohol cue induced FP1 functional connectivity
Sophisticated preclinical tools, such as optogenetics, have been used to demonstrate
that, in rodents, manipulation of the prelimbic cortex (functionally analogous to the human
MPFC (232)) and downstream striatal targets changes alcohol and drug seeking behavior
in a causal manner (96-99). Converging clinical evidence has shown that brain reactivity
to alcohol cues, specifically within fronto-striatal circuitry, is a strong predictor of future
relapse to alcohol (100, 107, 108, 197-200).
To this end, we sought to decrease fronto-striatal connectivity in response to alcohol
cues. Despite the translational promise of this goal, the existing literature using TMS to
decrease brain response to alcohol cues within this circuit is sparse. In fact, only a few
existing studies have pursued this strategy (179, 189, 194). Here, we replicate results from
Kearney-Ramos et al, wherein a single session of TBS reduced FP1 alcohol-induced
functional connectivity to downstream targets such as the dorsal striatum, the ventral
striatum, and the insula (194). We further demonstrate that 10 days of TBS produces a
similar, yet durable reduction in FP1 alcohol induced functional connectivity to the same
striatal and insular targets. These data lend further support for the use of TBS as a brainbased treatment for AUD.
While we observed a robust decrease in alcohol cue-induced functional connectivity,
the magnitude of fMRI BOLD signal was not substantially reduced across the experiment
(Figure 4.9). This likely reflects a change in the temporal dynamics of MPFC circuitry,
rather than a change in magnitude of alcohol cue-induced BOLD signal. In line with these
results, Herremans and colleagues found no significant change in BOLD signal magnitude
during alcohol cues after 15 sessions of rTMS (20Hz, left DLPFC) (179).
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Clinical improvement in obsessive-compulsive drinking
Another important observation is that this protocol decreased OCDS scores. This is a
valuable addition to the growing literature pointing to the frontal pole as a target for
obsessive compulsive disorders. Using a very similar protocol, 600 pulses of TBS directed
to the frontal pole (in order to target the orbitofrontal cortex), Price and colleagues recently
demonstrated that a single session of frontal pole TBS improved compulsive behaviors in
a cohort of 69 individuals with OCD and that these effects lasted for up to 1 week (233).
Although the validity of the OCDS as a tool to predict future drinking behavior has been
questioned (234) it is still a mainstay of alcohol treatment evaluation, likely due to many
studies demonstrating its efficacy as a predictor of long term outcome (235, 236).
Considered from the perspective of research domain criteria this adds interest to the role
of the frontal pole and associated neural targets in mediating obsessive and compulsive
behaviors more broadly.

Limitations
While this study was not prospectively powered to assess the influence of gender, our
statistical model revealed gender as a significant source of variance in functional
connectivity change. Women receiving real TBS experienced the greatest initial reduction
in alcohol cue-induced functional connectivity (Figure 2.8). This result is in line with
recently published work form our group demonstrating that women have a shorter scalpto-cortex distance at the frontal pole, and therefore receive a substantially stronger
electrical field at this cortical target (215). Further, participant attrition and logistical issues
at the MRI scanner reduced the number of usable scans to study functional connectivity,
especially at follow-up visits. Due to this high drop-out rate, we were unable to perform a
robust statistical analysis of the relationship between change in behavior and alcohol cueinduced functional connectivity. To mitigate the influence of participant drop-out in future

61

clinical trials, the field might benefit from innovative strategies to improve participant
retention in longitudinal alcohol treatment trials.

Conclusions
This is the first randomized, double-blind, sham-controlled trial to deliver 10 days of
TBS to a patient population. The primary preregistered outcome was the effect of 10
sessions of TBS on brain reactivity to cues (a logical extension of our prior single session
TBS study). We observed a significant difference between the groups. A secondary
outcome was the effect of this protocol on drinking. While we did not observe a statistically
significant difference in sobriety, individuals that received real TMS were nearly 3 times
as likely to remain sober. Future clinical trials properly powered to measure drinking as a
primary endpoint are warranted.
Furthermore this is the first randomized, double-blind, sham-controlled trial to deliver
TBS to the frontal pole – a brain target which has garnered a lot of interest recently
following the promising work from Price and colleagues (233) that demonstrated TBS to
this target could improve symptoms of obsessive compulsive disorder. Finally, this TMS
trial demonstrates that it is possible to enhance alcohol treatment outcomes, drinking
behavior, and brain reactivity to alcohol cues for up to 3 months following treatment
initiation. As unique forms of TMS are gaining FDA-clearance for diseases such as OCD
and smoking cessation, this study is an important step forward in expanding the potential
indications for treatment of Alcohol Use Disorder.

62

Chapter 3: Regionally specific changes to grey and white matter
morphology in AUD and implications for non-invasive brain
stimulation
Introduction
As demonstrated in Chapter 2, MPFC-TMS is an effective treatment strategy to
enhance patient enrollment and sobriety, and to reduce alcohol cue-reactivity. While these
data provide strong support for the efficacy of TMS as a treatment tool for AUD, there is
considerable room for improvement. Three months after treatment, for instance, nearly
30% of individuals receiving real TBS had relapsed to alcohol. Similarly, the observed
reductions in alcohol cue reactivity generally waned after 3 months. There are several
dosing parameters known to influence TMS efficacy (e.g. frequency (147, 156, 237),
number of pulses (142, 238)), however sources of variability specific to the neurobiology
of AUD may have a critical influence on treatment outcome.
Specifically, there are at least three features of neural architecture that influence TMS
signal propagation to the striatum: 1) gray matter volume at the stimulation site (196, 239),
2) white matter integrity between the stimulation site and the striatum (196, 239), and 3)
scalp-to-cortex distance (240). There is well-documented evidence among AUD patients
however, that neural atrophy occurs with chronic alcohol use. Thus, these features of
neural architecture may require special attention in the AUD population.
As discussed in the Chapter 1, there are two leading strategies to applying TMS as a
treatment tool for AUD. The first is to enhance executive control by stimulating DLPFCdorsal striatal circuitry and the second is to reduce incentive salience by stimulating
MPFC-ventral striatal circuitry. Therefore, characterizing grey and white matter integrity
within these circuits among AUD patients is an important step in developing our
understanding of the sources of variability that influence TMS treatment response in this
population.
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The primary goals of this study were to evaluate the influence of alcohol on changes
to grey and white matter morphology within the whole-brain as well as within the frontostriatal circuits relevant to TMS-AUD. Standard voxel-based morphometry (VBM) and
diffusion weighted imaging methods were used to assess morphometric changes in a
large sample of high-risk drinkers and non-drug using controls (n=130). Group-level
statistical analyses were performed using a multiple linear regression, wherein the relative
influence of alcohol use could be interrogated while controlling for the influence of
concomitant polysubstance use (cocaine, nicotine) and demographic variables (age,
gender). Changes in white matter microstructure were further examined using diffusion
kurtosis imaging (DKI) – the first application of this advanced method in a population of
individuals with Alcohol Use Disorders.

Materials and Methods
Participants
Participants (Table 3.1): The goal of this study was to conduct a comprehensive
investigation of gray and white matter integrity in a cohort high-risk drinker (n=58, average
age: 47.6 ± 12.5; 42 males, 16 females), relative to healthy controls (n=72, average age:
55.8 ± 11.6; 18 males, 54 females). To this end, we aggregated data from several
previously conducted clinical trials which recruited heavy alcohol users specifically (44
heavy drinkers were aggregated from the clinical trial data presented in Chapter 2). To
increase statistical power and balance the samples, individuals recruited for clinical trials
for cocaine and nicotine users, who also met criteria for heavy alcohol use, were included
in analysis. For this experiment, high-risk drinkers were defined given an Alcohol Use
Disorder Identification Test (AUDIT) score  15, indicating a moderate to severe AUD (41).
17/58 individuals endorsed current cocaine use and 37/58 individuals endorsed current
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nicotine use in addition to drinking. In the absence of any above substance use, individuals
were designated as non-drug using healthy controls (n=72). Exclusion criteria included
the following: currently meeting criteria for a psychiatric condition other than alcohol,
cocaine, or tobacco use disorder (Mini International Neuropsychiatric Interview for DSM5 (241)), history of head injury, or neurologic condition requiring medical intervention, and
inability to receive an MRI scan for any reason (e.g. metallic implants, claustrophobia). All
experimental protocols were reviewed and approved by the Medical University of South
Carolina Institutional Review Board and were performed in accordance with the
Declaration of Helsinki on Ethical Principles for Medical Research.
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Table 3.1: Participant demographics. Average AUDIT score for the high-risk drinkers in
this study was in the moderate to severe range, indicative of the presence of AUD.
Consumption, dependence and alcohol related problems scores were also high within this
sample. Abbreviations: M, male; F, female; NH, Non-Hispanic; H, Hispanic; W, White; AA,
African-American; N/A, no answer.
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MRI sequences
Structural MRI sequence: All images were acquired on a Siemens 3T Prismafit MRI
scanner (Siemens Healthineers, Erlangen, Germany) using a 32-channel head coil. All
participants (n=130) received high-resolution, T1-weighted structural scans. Scans were
obtained using an inversion recovery 3D spoiled gradient echo (3DSPGR) sequence,
voxel size 1.0x1.0x1.0, field of view: 256mm, section thickness 1.0mm with no gap, giving
an in-plane resolution of 256.
Diffusion weighted imaging sequences. Diffusion Tensor Imaging (DTI) and Diffusion
Kurtosis Imaging (DKI) sequences were obtained using a single-shot, twice refocused
echo-planar sequence with 3 diffusion weightings (b=0, 1000, 2000 s/mm2) with 4 images
collected at b=0 and 30 images collected along 30 diffusion encoding directions (50 axial
slices, voxel size 2.5x2.5x2.5, 220x220 FOV, 74x74 acquisition matrix, TR=3100 ms, TE=
80 ms, slice thickness=2.5mm, partial Fourier encoding: 6/8, no interpolation). One b0
image was collected along the P>>A encoding direction to allow for distortion correction
using TOPUP.

Voxel-based morphometry
VBM was executed using the SPM12 and CAT12 toolboxes (242, 243). T1-weighted
images were first segmented into grey matter, white matter, CSF, skull, and background
components using unified segmentation in SPM12. Following initial affine registration of
grey and white matter segmentations to standard MNI-152 space, Geodesic shooting was
used to determine the nonlinear, diffeomorphic deformations needed to precisely align
each subject’s grey and white matter segmentation maps (244). “Modulated normalized”
grey and white matter images, where voxels were multiplied by the Jacobian determinate
derived from spatial normalization were used to allow for the measurement of absolute
amount of tissue (245). Grey and white matter images were then smoothed with an 8-mm
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FWHM, Gaussian kernel. Total intracranial volume was calculated using CAT12’s
Estimate TIV tool.

Diffusion-weighted imaging
Raw diffusion-weighted images were first quality checked for artifacts and excessive
head motion. Preprocessing for all DTI and DKI sequences was performed with
PyDesigner (246) under standard processing options with additional echo-planar imaging
correction using reverse-phase encoded b0 images. Briefly, preprocessing steps included:
MP-PCA denoising, Gibb’s ringing correction [Note: applied only to images with full Fourier
coverage], EPI distortion correction, eddy current correction, motion correction, outlier
replacement, B1 bias field correction, skull-stripping, smoothing (1.25 FWHM kernel) and
Rician noise bias correction. Diffusion and Kurtosis tensors were fit following IRLLS outlier
detection (247), outlier-excluded constrained tensor fitting (248), and brute-forced
apparent kurtosis coefficient (AKC) correction. Resulting FA and MK maps were further
reviewed for preprocessing errors.

Construction of population-specific diffusion tensor template
Diffeomorphic, deformable tensor-based registration was performed using DTI-TK
(249-251). Briefly, a bootstrapped, population-specific template was created from the input
diffusion-tensor images (TVMean). Images were resampled to a voxel size of
1.5x1.75x2.25 (TVResample) and affinely registered to the bootstrapped template
(dti_affine_population). A non-linear, deformable registration was then applied to improve
inter-subject alignment and to reduce local differences in size and shape of white matter
structure (dti_diffeomorphic_population). Individual, non-linearly aligned fractional
anisotropy (FA) maps were then calculated for each subject (TVtool -fa). Each subject’s
affine and non-linear transformation matrices were saved such that kurtosis parameter
maps (mean kurtosis) could be subsequently moved from subject to template space.
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[Note: This atlas was constructed using a larger dataset including current cocaine and
nicotine users in a separate line of analysis (n=172)]

Grey and white matter ROIs in TMS-AUD treatment
Region-of-interest analysis was performed using 3, 20mm binarized, MNI brain
masked ROIs representing the frontal pole (FP1), the left DLPFC (F3) and the motor cortex
(C3) based on the EEG 10-20 coordinate system as previously described (239, 252). DSI
studios (253) was used to construct 3, custom white matter tract representations of the
FP1-ventral striatal tract, F3-dorsal striatal tract, and the corticospinal tract (HCP-1065
brain, angular threshold=60 degrees, minimum tract length=10mm, max length=200mm;
consistent with Kearney-Ramos & Lench (239)). White-matter tract ROIs (created in MNI152 standard space) were co-registered to the population-specific diffusion tensor
template for subsequent analysis of FA and MK.

Statistical analyses
Whole-brain analyses: SPM12 was used to construct a general linear model (GLM),
whole-brain, voxel-wise analysis on 4 dependent variables: gray matter volume, white
matter volume, fractional anisotropy, and mean kurtosis. High-risk drinking and non-drug
using control samples were assumed to be independent and to have equal variance. Each
GLM was fit with binary covariates, reflecting high-risk drinking, current cocaine use, and
current nicotine use (0=not present, 1=present). For volumetric analyses, additional
regressors included age, gender, and total intracranial volume, in keeping with empirically
derived best-practices in VBM (254, 255). For diffusion weighted analyses, age and
gender were included as nuisance regressors, and images were proportionally scaled by
individual global signal to adjust for changes in gain or sensitivity between scanning
protocols (243).
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Volumetric results were examined using an explicit gray and white matter mask along
with an implicit masking threshold of 0.1 to correct for inhomogeneity in voxel intensity
near the grey-white matter interface. Diffusion weighted imaging results (FA and MK) were
examined using an implicit threshold of 0.3 such that only voxels within well-defined white
matter tracts were analyzed. All contrasts were weighted such that high-risk drinkers <
non-drug using healthy controls. Results were viewed using a statistical threshold of
p<0.01. Extent thresholds (k) were corrected at each value such that only clusters
surviving family-wise error correction (multiple comparisons correction) survived.
Region-of-interest analysis: Data were subsequently extracted using AFNI’s 3droistats
tool (256, 257). Gray and white matter volume were extracted from each ROI and
normalized by dividing each value by the given subject’s total intracranial volume.
Fractional Anisotropy and Mean Kurtosis were extract from each ROI and normalized by
dividing each value by the given subject’s mean signal. Univariate linear models with fixed
factors for brain region (Grey matter: FP1, F3 and C3; White matter: FP1-VS, F3-DS and
CST) and group were performed to assess differences in grey and white matter metrics.
Current cocaine use, nicotine use, age, and gender were included as covariates in each
model.

Results
Image and preprocessing anatomical image quality
Image and preprocessing metrics were assessed prior to subsequent VBM and
diffusion analyses. Anatomical image noise (85.3 ± 3.0), bias (94.1 ± 1.2), and weighted
quality average (85.3 ± 1.8) consistently ranked within the satisfactory to excellent ranges,
as per CAT12 quality control metrics. Note: One subject was rejected from analysis due
to low noise and bias scores and improper segmentation.
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Whole-brain VBM
At a statistical threshold of p<0.01, Family Wise Error multiple comparison-corrected,
relative to healthy controls, high-risk drinkers had significantly lower grey matter volume
in 1 large primary cluster: c1: bilateral orbitofrontal cortices, temporal lobes, the right
precentral and postcentral gyrus, the left putamen, the middle cingulate and precuneate
gyrus (pFWE-Corrected<0.001, k=127,847) (Figure 3.1, Table 3.2). Similarly, relative to nondrug using healthy controls, high-risk drinkers had significantly lower white matter volume
in 1 large primary cluster: c1 rostrum, genu, and body of the corpus callosum, as well as
within the forceps minor (pFWE-Corrected<0.001, k=14,146) (Figure 3.1, Table 3.2). There
were no significant increases in grey or white matter volume associated with high-risk
drinking.
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Figure 3.1 VBM analysis of grey and white matter volume in high-risk drinking,
relative to healthy controls. GM regions (left side) and WM regions (right side) showing
significantly less volume in the high-risking drinking sample are shown in blue/green.
Results were viewed using a voxel-wise threshold of p<0.01. Cluster level thresholds (k)
were adjusted such that only clusters surviving multiple comparisons correction are
shown. Color bar reflects t-scores.
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Table 3.2 Grey and white matter regions with significantly less volume among highrisk drinkers relative to healthy controls. Abbreviations: AUD, Alcohol Use Disorder;
BA, Brodmann’s Area; k= number of voxels; L, Left; Max t = Maximum t-value; MNI
Montreal Neurological Institute; R, right.
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Whole-brain fractional anisotropy and mean kurtosis
At a statistical threshold of p<0.01, Family Wise Error multiple comparison-corrected,
relative to healthy controls, high-risk drinkers had significantly lower fractional anisotropy
in 4 primary clusters: c1: corpus callosum, genu (pFWE-Corrected<0.001, k=1,496); c2 corpus
callosum, splenium (pFWE-Corrected<0.001, k=879); c3: left corticospinal tract (pFWECorrected<0.001,

k=840); c4: left inferior longitudinal fasciculus (pFWE-Corrected<0.001, k=303).

Relative to healthy controls, high-risk drinkers had significantly lower mean kurtosis in 1
cluster: c1: left and right corticospinal tract (pFWE-Corrected<0.001, k=2,035) (Figure 3.2).
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Figure 3.2 DWI analysis of fractional anisotropy and mean kurtosis of in high-risk
drinking, relative to healthy controls. Fractional anisotropy (left side) and mean kurtosis
regions (right side) are significantly reduced within white matter in the high-risking drinking
sample (shown in blue/green). Results were viewed using a voxel-wise threshold of
p<0.01. Cluster level thresholds (k) were adjusted such that only clusters surviving multiple
comparisons correction are shown. Color bar reflects t-scores.
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Grey and white matter integrity within common TMS-AUD targets
Univariate analysis of GMV within stimulation targets (Figure 3.3): The univariate GLM
was well fit to the data (Corrected model: F9,411=44.027, p<0.001). There was a main effect
of group (F1,411=10.909, p=0.001) and a main effect of ROI (F1,411=148.174, p<0.001),
wherein high-risk drinkers had 3.3% less GMV within FP1 (AUD: 0.203 ± 0.003; HC: 0.210
± 0.002, 2.92% less GMV within F3 (AUD: 0.233 ± 0.003; HC: 0.240 ± 0.002), and 6.89%
less GMV within C3 (AUD: 0.189 ± 0.002; HC: 0.203 ± 0.002). There was no ROI*group
interaction

(F2,411=1.808,

p=0.165).

Age

(F1,411=52.562,

p<0.001)

and

gender

(F1,411=9.316, p=0.002) were significant covariates in the model. Current cocaine
(F1,411=2.833, p=0.093) and nicotine (F1,411=0.338, p=0.561) use were not significant
covariates.
Univariate analysis of WMV within white matter tracts (Figure 3.4): The univariate GLM
was well fit to the data (Corrected model: F9,411=101.246, p<0.001). There was a main
effect of group (F1,411=29.482, p<0.001) and a main effect of ROI (F1,411=418.624,
p<0.001), wherein high-risk drinkers had 5.72% less GMV within FP1 (AUD: 0.280 ±
0.003; HC: 0.297 ± 0.003), 5.59% less GMV within F3 (AUD: 0.304 ± 0.003; HC: 0.322 ±
0.003), and 3.76% less GMV within C3 (AUD: 0.358 ± 0.003; HC: 0.372 ± 0.003). There
was no ROI*group interaction (F2,411=0.440, p=0.644). Age (F1,411=25.916, p<0.001),
gender (F1,411=4.620, p=0.032), current cocaine (F1,411=27.370, p<0.001) and nicotine use
(F1,411=5.165, p=0.024) were significant covariates.
Univariate analysis of FA within white matter tracts (Figure 3.4): The univariate GLM
was well fit to the data (Corrected model: F9,336=13.215, p<0.001). There was a main effect
of group (F1,336=9.994, p=0.002) and a main effect of ROI (F2,336=20.043, p<0.001),
wherein high-risk drinkers had 2.75% less FA within the FP1-VS tract (AUD: 2.370 ± 0.023;
HC: 2.437 ± 0.014), 2.12% less FA in the F3-DS tract (AUD: 2.313 ± 0.023; HC: 2.363 ±
0.014), and 3.00% less FA in the CST (AUD: 2.257 ± 0.023; HC: 2.327 ± 0.014), relative
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to healthy controls. There was no significant ROI*group interaction (F2,336=0.180,
p=0.836). Age (F1,336=45.392, p<0.001) and gender (F2,336=12.795, p<0.001) were
significant covariates in the model. Current cocaine (F1,336=1.164, p=0.281) and nicotine
use (F1,336=1.755, p=0.186) were not significant covariates.
Univariate analysis of MK within white matter tracts (Figure 3.4): The univariate GLM
was well fit to the data (Corrected model: F9,336=28.989, p<0.001). There was a main effect
of ROI (F2,336=103.120, p<0.001), but no main effect of group (F1,336=1.214, p=0.271), nor
a group*ROI interaction (F2,336=1.035, p=0.356). Gender (F1,336=2.439, p=0.119), age
(F1,336=1.898, p=0.169) and cocaine use (F1,336=4.748, p=0.030) were not significant
covariates. Nicotine use was a significant covariate in the model (F1,336=1.276, p=0.259).
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Figure 3.3 High-risk drinkers have less GMV at relevant cortical targets for TMS. A)
GMV is reduced by 3.3% at FP1 (maroon; t135= -1.998, p=0.048); B) GMV is reduced by
2.92% at F3 (blue; t135= -1.998, p=0.048) C) GMV is reduced by 6.89% at C3 (green; t135=3.996, p<0.001). GMV is expressed as units of voxel intensity. Data reflect EM means
wherein gender, age, cocaine, and nicotine use were included as covariates. ETOH=highrisk drinkers, solid bars; HC=non-drug using controls, striped bars. Error bars reflect SEM.
*p<0.05; ***p<0.001.
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Figure 3.4 High-risk drinkers have less WMV and FA within white matter tracts
relevant for TMS-AUD treatment. A) Within the FP1-ventral striatal tract (FP1-VS,
maroon), WMV is reduced by 3.3% (t135= -3.872, p<0.001) and FA is reduced by 2.75%
(t110= -2.558, p=0.012) among high-risk drinkers, relative to non-drug using controls. B)
Within the F3-dorsal striatal tract (F3-DS, blue), WMV is reduced by 5.59% (t135= -4.100
p<0.001) and FA is reduced by 2.12% (t110= -1.909, p=0.059) among high-risk drinkers
relative to non-drug using controls. C) Within the corticospinal tract (CST, green), WMV is
reduced by 3.76% (t135= -3.189, p=0.002) and FA is reduced by 3.00% (t110= -2.672,
p=0.009) among high-risk drinkers relative to healthy controls. There was no difference in
mean kurtosis between groups within these tracts. WMV is expressed as units of voxel
intensity. FA and MK data are scaled by individual global signal. Data reflect EM means
wherein gender, age, cocaine, and nicotine use were included as covariates. ETOH=highrisk drinkers, solid bars; HC=non-drug using controls, striped bars. Error bars reflect SEM.
*p<0.05; **p<0.01, ***p<0.001, #p<0.06.
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Exploratory analysis of sex/gender and high-risk drinking
Given that sex/gender emerged as a significant covariate in the analysis of grey and
white matter volume, as well as fractional anisotropy within the tested ROIs, an exploratory
post-hoc analyses was performed. The magnitude of gray matter volume loss at relevant
TMS-AUD cortical targets was similar among male and female high-risk drinkers relative
to same-sex, non-drug using controls (FP1: male, -3.85% decrease; female, -0.474%
decrease; F3: male, -2.52% decrease; female, -2.49% decrease; C3: male, -6.09%
decrease; female, -4.37% decrease).
The magnitude of white matter volume loss within TMS-AUD white matter tracts was
more pronounced in female high-risk drinkers, relative to same-sex non-drug using
controls. (FP1-VS: male, 0.7% increase; female, -5.08% decrease; F3-DS: male, 0.96%
increase; female, -6.56% decrease; CST: male, 2.5% increase; female, -4.32% decrease).
Similarly, the magnitude of FA reductions was more pronounced in female high-risk
drinkers, relative to same-sex non-drug using controls (FP1-VS: male, -1.77% decrease;
female, -2.78% decrease; F3-DS: male, 0.08% increase; female, -3.28% decrease; CST:
male, -0.92% decrease; female, -2.72% decrease).
[Note: Conservative statistical analyses were not performed on these data given the
large gender imbalance between high-risk drinkers and non-drug using controls, see Table
3.1]
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Discussion
Transcranial Magnetic Stimulation (TMS) has recently emerged as a promising, noninvasive neural circuit-based treatment for AUD (149). TMS signal propagation to
downstream targets such as the dorsal and ventral striatum, however, is dependent on
three features of neural architecture: 1) gray matter volume (GMV) (196, 239), 2) white
matter integrity (fractional anisotropy, FA) (196, 239), and 3) scalp-to-cortex distance (240)
[See: Chapter 4]. Given well-documented evidence that neural atrophy occurs with chronic
alcohol use, these features of neural architecture may require special attention in the AUD
population. This chapter presents the first study to comprehensively examine GMV, WMV,
FA and mean kurtosis across the whole brain and within discrete TMS cortical targets and
corresponding white matter tracts relevant to TMS-AUD treatment. The primary
conclusions are that high-risk drinkers have reduced: 1) frontal lobe grey and white matter
volume and 2) white matter tract integrity as measured by fractional anisotropy and
kurtosis. These reductions are present in common cortical TMS treatment targets as well
as the callosum and corticospinal tract which both facilitate TMS signal propagation.
Finally, an exploratory analysis revealed that female high-risk drinkers experienced the
most pronounced reductions in white matter volume and fractional anisotropy within these
white matter tracts. Taken together, these reductions to grey and white matter integrity
may indicated that individuals with AUD require a greater stimulation strength in order to
modulate downstream, subcortical targets. This may be particularly relevant for women
with AUD, who experienced the greatest reductions in grey and white matter.

Alcohol induced losses in grey and white matter structural integrity
Consistent with previous reports, we found that the high-risk alcohol use led to a
relative decrease in grey matter volume that was most prominent within the orbitofrontal
cortices, bilateral temporal poles, pre- and post-central gyri, putamen, middle cingulate
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and precuneate gyri (113-115, 117-123, 134, 258). We also report volumetric reductions
within the anterior corpus callosum (forceps minor) and cingulate, as well as reductions in
fractional anisotropy within the anterior and posterior corpus callosum – results which are
well supported by existing, MRI (117-119, 127-129) and post-mortem literature (259-261).
Mean kurtosis was bilaterally reduced within the corticospinal tracts, perhaps
demonstrating an initial loss of cellular structure that cannot be detected by standard
volumetric or diffusion tensor measurements alone (262).
Taken together, future TMS-AUD trials seeking to stimulate brain regions outside of
the prefrontal cortex, such as the precuneate or the temporal poles, may consider the
influence of reduced grey and white matter integrity on TMS efficacy. The ability of TMS
signal to travel bilaterally may also be reduced, as evidenced by reductions in callosal
integrity. Further, reductions to white matter integrity within the corticospinal tract may
influence the measurement of resting motor threshold, a critical dosing metric for TMS.
Future clinical trials, therefore, may consider raising the strength of stimulation to
overcome these effects within the AUD population and comprehensively examining the
resting motor threshold and motor cortex excitability among AUD patients specifically.
Alcohol induced reductions to neural integrity and non-invasive brain
stimulation
Grey matter volume was reduced within three discrete non-invasive brain stimulation
targets for AUD: the left frontal pole, the left DLPFC, and the left motor cortex. Reductions
in frontal pole, the DLPFC and motor cortex are consistent with previous reports (112-114,
117, 118, 120, 122, 123, 263), however there is some variability in the field (113, 119,
120, 123). Further, reductions in grey matter volume have shown clinical relevance among
brain stimulation treatments. For instance, among individuals with schizophrenia, there
was a significant positive relationship between gray matter volume at stimulation site
(temporoparietal junction) and TMS-evoked decreases in symptoms of auditory
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hallucinations (264). While experiments assessing GMV as a mediator of treatment
response are sparse, these results suggest GMV at the stimulation site may be a more
important mediator of TMS treatment response than previously anticipated.
White matter volume and integrity was reduced within the MPFC-ventral striatal, the
DLPFC-dorsal striatal and the corticospinal tracts. the corticospinal tract. Many groups
investigate the effects of TMS on the brain region directly under the coil, however, TMS
signal is known to propagate through white matter to reach monosynaptic targets. This is
shown most simply with the motor evoked potential, wherein TMS pulses to the motor
cortex travels through 1-2 monosynaptic connections to an effector muscle, eliciting a
motor evoked potential (139). Given that axonal bundles connecting two brain regions are
myelinated, it follows that TMS signal propagation is likely to be dependent on the
underlying microstructural properties of axons. In AUD, reductions to the integrity of white
matter may influence treatment outcome. A growing body of evidence has suggested that
white matter integrity exerts a strong influence over TMS-efficacy among patient
populations with AUD (196), cocaine use disorder (239), and PTSD/MDD (265). In
recognition of the importance of this variable, it has been suggested that diffusion
weighted imaging and tractography techniques may be used to select a cortical target with
structural connections to downstream, subcortical regions (266).
Considering these results, the field of brain stimulation may consider including metrics
of grey and white matter integrity as structural variables of interest when assessing the
efficacy of TMS treatment for AUD (and other disorders that influence brain structure).
Future research endeavors seeking to quantify the mathematical relationship between
TMS strength at the cortex, change in subcortical BOLD signal, and grey/white matter
integrity are likely to be of high value to the field. For example, if grey and white matter
integrity is reduced within a patient population, should researchers increase the strength
of TMS to enhance signal propagation to subcortical targets? And, if so, by how much?
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While this research question has not been definitively answered, it may be prudent in the
interim to deliver a stronger dose of TMS to AUD patients to overcome structural deficits.

Importance of sex and gender in AUD-related atrophy
Over the last decade, overall rates of AUD in the U.S. have increased by 49%, driven
largely by a disproportionate 84% increase in women (21). Few recent studies, however,
have investigated sex as a biological variable in their analyses of neural architecture.
Here, within TMS-relevant cortical targets and white matter tracts, female, high-risk
drinkers displayed the most pronounced reductions in white matter metrics, and similar
reductions to that of male high-risk drinkers among grey matter metrics. These results
extend and support a body of evidence suggesting that women are more vulnerable to the
neurotoxic effects of alcohol relative to men (267-270). Consensus in the field, however,
is mixed wherein some groups have suggested that women may experience increases
(271) or no change in brain volume (272) following chronic alcohol use (273). The present
work, like much previous research, did not initially make specific hypotheses about the
role of sex/gender in alcohol-induced atrophy and therefore is likely underpowered to
produce conclusive results. These data, however, suggest amongst women with AUD,
TMS-signal may not propagate to downstream targets as efficiently. Future clinical trials
should aim to prospectively assess the influence of sex/gender as a biological variable in
TMS signal propagation and treatment response.

Grey & white matter changes respective to other substance use
disorders
Many of the TMS strategies discussed within this dissertation have been used in the
treatment of cocaine and nicotine use disorder. It is worth discussing, therefore the
influence of these substances of abuse on brain structure. Cocaine use has been
consistently associated with grey matter volume reductions within the orbitofrontal cortex
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(274-276), the left DLPFC (276, 277), and the premotor cortex (278), which may influence
TMS-efficacy within the cocaine use disorder population. However, several well-powered
studies on the influence of protracted cocaine and stimulant use and grey matter have
suggested these substances may yield increases in subcortical brain volume within the
striatum (279-281). Characterizations of the influence of cocaine on white matter volume
and anisotropy are mixed, with some groups reported relative increases (282), no change
(274, 277, 283-286), or decreases (275, 278, 283, 287) in these metrics.
Existing literature examining the influence of nicotine on brain structure are similarly
mixed, with some suggesting nicotine increases grey matter volume (251, 288, 289) and
fractional anisotropy (290-293), while others have found nicotine-induced decreases
within these same metrics (251, 294-301). The variability within this field may stem from
the high prevalence of polysubstance among the nicotine using population (302). As TMS
is developed for substance use disorders more broadly, rigorous studies of the relative
influence of various drugs of abuse on brain structure are critical for future development
of the field.

Limitations
There are, of course, several limitations to the impact and generalizability of this
chapter based on the chosen design. The compromises to grey and white matter integrity
observed among high-risk drinkers, for example, are not necessarily permanent and may
dynamically change through the alcohol use, abstinence, and relapse process. Further,
due to experimental limitations at the time of data collection, covariates used to adjust for
polysubstance use (cocaine and nicotine) were binary in nature. Future research may
elaborate on the relative influence of each of these drugs in a more continuous manner.
Lastly, while this chapter presents sex/gender differences in brain structure, the
distribution of sex/gender between the high-risk drinking and non-drug using control
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groups was imbalanced. Prospective, age- and gender- balanced research in this area is
urgently needed as TMS advances as a treatment tool for many psychiatric disorders.

Conclusions
This chapter extends a well-established body of literature demonstrating the
relationship between heavy alcohol use and reduced grey and white matter integrity.
Specifically, grey and white matter integrity are reduced within the frontal cortex and
throughout the corpus callosum. This study also represents the first use of Diffusion
Kurtosis Imaging on a sample of heavy drinkers, providing a novel addition to the field.
We further highlight these compromises to white and grey matter integrity within current
TMS-AUD cortical targets and their corresponding white matter tracts. Lastly, female highrisk drinkers may experience more pronounced reductions in grey and white matter
integrity. Taken together, this chapter underscore the need to consider neural architecture
and gender as variables of interest when tailoring brain stimulation protocols to treat
psychiatric disorders – especially those which may influence brain structure directly.
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Chapter 4: Scalp-to-cortex distance and electrical field models in
AUD and healthy controls: an age- and gender-matched analysis
Introduction
As demonstrated in Chapter 3, individuals with AUD experience reductions in grey and
white matter integrity within the frontal-striatal circuits relevant to TMS and AUD treatment.
Given that TMS signal propagation is directly related to these features of neural
architecture, individuals with AUD may require a higher dose to sufficiently modulate
subcortical targets. Further, women with AUD had the greatest reductions in white matter
integrity, suggesting women may need to receive an even greater dose of TMS. The
following dissertation chapter will evaluate a third feature of neural architecture relevant
to the development of TMS for AUD – scalp-to-cortex distance.
One of the most important biological variables that influence the TMS effects on the
scalp-to-cortex (STC) distance, the distance from the TMS coil to the cortical target. As
Maxwell described in the mid-1800s (138), the strength of an electromagnetic field decays
exponentially with distance. The application of this 19th century principle to 21st century
therapeutic brain stimulation has been elegantly described by leaders in the field TMS
field (240). For a given TMS pulse strength (% machine output), cortical regions closer to
the scalp receive a stronger electric field than brain regions that are farther from the scalp.
This relationship can now be readily assessed using electrical field modeling, wherein
scalp-to-cortex distance is the strongest determining factor in quantifying the strength of
TMS reaching the cortex (303).
Cortical atrophy following chronic alcohol use, however, may lengthen the distance
from the scalp to the cortex. Specifically, the frontal atrophy observed in the previous
chapter may create more distance between the TMS coil and common TMS targets such
as the MPFC, DLPFC, and motor cortex. An increased distance, in this case, would result
in a lower dose of stimulation being delivered to AUD patients, relative to healthy controls.
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Women with AUD experienced the greatest volumetric reductions, which may further
reduce the strength of TMS reaching the cortex in this group.
The primary goals of this chapter were to 1) evaluate scalp-to-cortex distance among
AUD patients at the common cortical stimulation sites for TMS: the left frontal pole (FP1),
the left dorsolateral prefrontal cortex (F3) and the left motor cortex (C3) and 2) assess
sex/gender differences in STC distance at these targets. These analyses were performed
by leveraging existing data from our lab wherein high-resolution structural magnetic
resonance (MR) images were collected from a large sample of individuals with AUD and
age-matched healthy controls (total n=88; AUD, n=44; healthy controls, n=44).

Materials and Methods
Participants
Forty-four treatment-seeking individuals with Alcohol Use Disorder (44.3 ± 12.1,
average age ± SD; 29M, 15F) were recruited from an intensive outpatient treatment run
through the Center for Drug and Alcohol Programs at MUSC. [Note: the individuals with
AUD used in this experiment are the same individuals who were later enrolled into the
clinical trial presented in Chapter 2]. Exclusion criteria included: current or prior substance
dependence other than alcohol or tobacco use disorder, currently meeting criteria for a
psychiatric condition other than Alcohol Use Disorder or Tobacco Use Disorder (Mini
International Neuropsychiatric Interview for DSM-5 (304)), receiving a score of <15 on the
Alcohol Use Disorder Identification Test (AUDIT) indicating mild to no current AUD, history
of head injury or neurologic condition requiring medical intervention, unable to receive an
MRI scan for any reason (e.g. metallic implants, claustrophobia). Demographics of the
AUD and healthy control groups can be found in Table 4.1. The experimental protocols
were reviewed and approved by Medical University of South Carolina Institutional Review
Board (MUSC IRB) and were performed in accordance with the Declaration of Helsinki on
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Ethical Principles for Medical Research. Each participant provided written informed
consent prior to participation in each study (n=88).
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Table 4.1: Participant Demographics.
Participant demographics. Abbreviations: AUD, alcohol use disorder; HC, healthy
controls. ‘a’ indicates data was only available from a subset of the healthy control
sample (n=28).
AUD

HC

Demographics

(n=44)

(n=44)

Age

44.3 ± 12.1

44.1 ± 12.6

29, 15

21, 23

Alcohol Use Severity (AUDIT)

25.3 ± 5.5

3.6 ± 2.3

Days since last drink at scan

18.2 ± 15.0

N/A

Heavy drinking days last month

10.1 ± 8.2

N/A

26 (59.0%)

7 (15.9%)

Sex (M, F)
Alcohol Use

Smoking status
Active Smokers
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a

Measuring scalp-to-cortex distance and modeling TMS-induced
electrical fields
SIMNIBS version 3.2.1 was used to measure scalp-to-cortex distance at three EEG
10-20 cortical targets in TMS-AUD clinical trials: FP1 (left frontal pole, MPFC), F3 (left
DLPFC), and C3 (left motor cortex). [Note: while the motor cortex is not typically a
treatment target for TMS-AUD, it commonly stimulated to determine the resting motor
threshold, a standard TMS dosing metric]. Prior to the measurement of scalp-to-cortex
distance and modeling of electrical fields, individual head-mesh models were constructed
using the ‘headreco’ command within SIMNIBS (305). Briefly, this first step segmented
T1-weighted anatomical images into gray matter, white matter, CSF, skull, skin and
background components with the SPM12 toolbox (243). Surface mesh reconstructions of
these components (sans background) were then created using the computational
anatomy toolbox (242) wherein a tetrahedral mesh was constructed by filling in the spaces
between tissue surfaces using Gmsh (306).
Surface reconstructions or ‘head mesh models’ were used to simultaneously measure
scalp-to-cortex distance and model TMS-induced electrical fields via the finite element
method (303). Several TMS administration parameters were modeled in SIMNIBS to
reflect standard TMS administration to each cortical target. Briefly, at FP1, the coil was
modeled to be positioned perpendicular with the eyebrow with the coil handle pointing
upward. At F3 and C3, the coil was positioned on a 45-degree angle with the coil handle
in the anterior-posterior direction. All models were constructed using a representation of
the MagVenture B70, butterfly, cooled sham coil. Rate of change of the coil current (dI/dT)
was set to 87.6 A/s, reflecting a standard stimulation intensity of 60% Machine Stimulator
Output (Magventure X100). [Note: a uniform intensity was chosen for this experiment to
allow for the assessment of the influence of scalp-to-cortex distance alone. 60% MSO also
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reflects 120% of the typical, average resting motor threshold (50 %MSO) using the
Magventure, as previously demonstrated in our lab (142)]. Standard tissue conductivity
values were used according to existing literature: WM 0.125 S/m, GM 0.275 S/m, CSF
1.654 S/m, Bone 0.010 S/m, and Scalp 0.465 S/m (307). Subject-space electric fields were
interpolated to Nifti format for subsequent region-of-interest analysis.
Scalp-to-cortex distance, output directly from SIMNIBS during the modeling process,
was recorded for each cortical target. This distance reflects the minimum distance from
the center of the coil to the closest point on the cortex. A distance of 4mm was used as a
standard to reflect the space from the scalp to the center of the coil. Therefore, 4mm was
subtracted from each individual coil-to-cortex measurement to produce accurate scalp-tocortex measurements.
Electric field strength and size at each cortical target was manually extracted from the
resulting electrical field models using the FSL tool fslmaths (308) and the AFNI tool
3Droistats (256, 257). Briefly, individual brain masks were applied to each electric field
model (in Nifti format). Given recent evidence that 35 V/m may be the minimum voltage to
induce physiological change with TMS (309), brain-masked electric fields were
thresholded such that only voxels with an intensity ≥ 35 V/m were analyzed. AFNI’s
3Droistats was used to extract the average intensity (average electric field strength) and
the number of non-zero voxels (electric field size) within the masked, thresholded electric
field models. Peak electric field strength was defined as the average V/m within the 99th
percentile of voxels within the brain (extracted from SIMNIBS directly).

Statistical analyses
Univariate linear models with fixed factors for stimulation site (FP1, F3, and C3) and
group (AUD and HC) were performed to assess the differences in 4 dependent variables:
Scalp-to-cortex distance (mm), average electric field strength (V/m), peak electric field
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strength (V/m), and electric field size (number of voxels). Each linear model included sex
(male=0, female=1) and active smoking status (non-smoker=0, smoker=1) as covariates.
To further explore the relationship between STC at various cortical targets, Pearson’s
correlation coefficients were calculated to assess the similarity between C3, F3 and FP1
STC distance. Lastly, Post-hoc tests to assess the influence of sex/gender on scalp-tocortex distance and electrical field characteristics were performed when sex/gender was
found to be a significant covariate. All analyses were performed in SPSS v.23; IBM.

Results
Image quality and preprocessing
Image and preprocessing quality metrics were assessed before subsequent analysis.
Anatomical image noise (AUD: 85.88 ± 0.42, HC: 86.46 ± 0.54) and bias (AUD: 85.91 ±
0.44, HC: 85.63 ± 0.46) following preprocessing and segmentation consistently ranked
within the satisfactory to excellent ranges, as per CAT12 quality control metrics.

Scalp-to-cortex distance and TMS electric field characteristics in AUD
and Healthy Controls
There was a main effect of site in all 4 univariate models (STC distance: F2,264=24.657,
p=0.000; peak electric field strength: F2,264= 191.059, p=0.000; average electric field
strength: F2,264=100.124, p=0.000; electric field size: F2,264=328.447, p=0.000). There was
no effect of group in all 4 univariate models (STC distance: F1,264=1.712, p=0.192; peak
electric field strength: F1,264=1.370, p=0.243; average electric field strength: F1,264=2.515,
p=0.114; electric field size: F1,264=0.004, p=0.950), nor a site*group interaction in any
univariate model (STC distance: F2,256=0.248, p=0.781; peak electric field strength:
F2,264=1.114, p=0.330; average electric field strength: F2,264=1.510, p=0.223; electric field
size: F2,264=0.060, p=0.942). The observed effects of site were driven by FP1 having the
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longest STC, weakest electrical fields, and smallest electrical fields, relative to the other
sites (Figures 4.1 and 4.2).
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Figure 4.1 Scalp-to-cortex (STC) distance at TMS targets in AUD and healthy
controls. STC distance at the MPFC (FP1, maroon), DLPFC (F3, navy), and the Motor
Cortex (C3, Green) did not differ between individuals with AUD (solid bars) and agematched healthy controls (striped bars). STC distance was longest at the MPFC relative
to the DLPFC and MC. Error bars represent standard deviation.

95

Figure 4.2 TMS electric field characteristics. A) Representative TMS-induced electrical
field models among individuals with AUD (top row) and age-matched healthy controls
(HCs, bottom row). Individuals with the weakest, median and strongest electrical fields
within each group did not demonstrate qualitative differences at the MPFC (maroon
square), DLPFC (navy square), or MC (green square). Color bar provided below for scale
of TMS-induced V/m. B) Average electrical field strength did not significantly differ
between AUD and HCs. However, the MPFC (FP1), experienced the weakest electric field
strength on average. C) Average electrical field size did not significantly differ between
AUD and HCs. Error bars for panels B and C represent standard deviation.
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Active smoking status did not emerge as a significant covariate in any of the 4
univariate models (STC distance: F1,264=2.790, p=0.096; peak electric field strength:
F1,264=0.585, p=0.445; average electric field strength: F1,264=0.076, p=0.783; electric field
size: F1,264=0.176, p=0.676). Sex was, again, a significant covariate in our univariate
analyses of scalp-to-cortex distance (F1,264=11.556, p=0.001) and peak electric field
strength (F1,264=6.159, p=0.014).

Gender differences in STC distance at FP1 and TMS electrical fields
A post-hoc analysis (Figure 4.3) revealed that women in both groups had
significantly shorter scalp-to-cortex distances than men at FP1 (female: 15.88 ± 2.8 mm;
male: 17.79 ± 3.18 mm; t87=2.938, p=0.004), but not at F3 (female: 14.49 ± 2.26 mm; male:
15.04 ± 2.50 mm; t87=1.054, p=0.289) or C3 (female: 14.02 ± 1.83 mm; male: 14.75 ± 2.52
mm; t87=1.49, p=0.138). Subsequently, the ratio of FP1/C3 scalp-to-cortex was
significantly different between genders (female: 1.10 ± 0.13; male: 1.17 ± 0.16, t86= 2.146,
p=0.036). The ratio of F3/C3 scalp-to-cortex distance was not different between genders
(female: 1.03 ± 0.09; male: 1.02 ± 0.10, t86= -0.334, p=0.740). A trend toward significance
emerged wherein women experienced a peak electrical field strength 5-7 V/m greater than
men at the frontal pole (female: 80.24 ± 12.42 V/m; male: 75.84 ± 10.5 V/m; mean
difference 4.4 ± 2.44 V/m; t86= -1.797, p=0.076).

97

Figure 4.3 Gender differences in FP1 STC distance and TMS electrical fields. A)
Women aggregated from both samples (n=38, solid bar) have a significantly shorter scalpto-cortex distance at the left frontal pole compared to men (n=50, checkered bar). B) The
ratio of STC distances between FP1 and C3 was significantly smaller in women. C)
Representative electrical fields in a male (31 years old, rMT=54) and female (38 years old,
rMT=50) subject. Electrical fields were modeled at 110% rMT. Error bars represent
standard error of the mean. **p<0.01, *p<0.05
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Scalp-to-cortex distance at C3 (dosing target) relative to F3 and FP1
In a complimentary, exploratory analysis, the relationship between scalp-to-cortex
distance at the motor cortex (C3) and common TMS treatment targets (F3 and FP1) was
assessed within the whole sample (n=88). Scalp-to-cortex distance at C3 explained 48%
of the observed variance in scalp-to-cortex distance at F3 (r2= 0.48, p<0.001), but only
32% of the variance in STC at FP1 (r2=0.38, p<0.001) (Figure 4.4). A qualitative view of
Figure 4.5 illustrates higher variability among electrical fields at FP1, than observed at F3
and C3.
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Figure 4.4 Existing RMT-based dosing strategies may have limited efficacy for
stimulation protocols applied to the frontal pole. Motor cortex STC strongly predicts
DLPFC-STC (left), but not MPFC-STC (right). A representative electrical field model was
obtained from one subject. The models presented in bottom right quadrant of each graph
represents C3 stimulation at 110% of rMT. Efield model presented in top left of each figure
represents DLPFC and MPFC electrical fields for the same participant, at the same
stimulation intensity, respectively.
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F)

Figure 4.5 Individual TMS-electrical field models at FP1, F3 and C3 among AUD
patients and age-matched healthy controls. A) Age-matched healthy controls, FP1; B)
AUD, FP1; C) Age-matched healthy controls, F3; D) AUD, F3; E) Age-matched healthy
controls, C3; F) AUD, C3. Electrical fields scaled from 0-120 V/m. Note: Subject SF2017
failed head reconstruction necessary for electrical field modeling due to a segmentation
error.
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Discussion
This chapter presents three novel findings highly relevant to the development of TMS
as a therapeutic tool for Alcohol Use Disorder as well as a variety of psychiatric disorders.
The first of the findings suggests that AUD-associated atrophy is not severe enough to
increase the cortical distance at the frontal pole, dorsolateral prefrontal cortex, or the motor
cortex. This is a positive indication suggesting that equitable electrical fields are realized
at the cortical surface among AUD patients. The second of these findings, that females
have a shorter scalp-to-cortex distance specifically at the frontal pole, leads to an increase
in electrical field strength of 5-7 V/m on average. The last of these findings suggests that
TMS-calibrations performed at the motor cortex may have limited efficacy at the frontal
pole. Taken together, as frontal pole TMS is developed as a treatment strategy for various
psychiatric disease, the field of brain stimulation may need to reconcile individual
variability in TMS dosing at this particular cortical target.

AUD, scalp-to-cortex distance, and electric field characteristics:
While widespread cortical atrophy has been well documented in association with AUD,
to the best of our knowledge, this study is the first to examine its relationship with scalpto-cortex distance and subsequent brain stimulation treatment implications. Based on the
fundamental principles of Maxwell’s equations, the scalp-to-cortex distance should be the
strongest factor affecting the realized electrical field at any given cortical location.
Unsurprisingly, this metric has clinical relevance as TMS studies have shown that
individuals with shorter scalp-to-cortex distances are more likely to show robust
improvements following TMS treatment for depression (310, 311), schizophrenia (264),
and AUD (196).
Despite the prominent gray matter loss observed among AUD patients within the last
chapter, scalp-to-cortex distance remained similar to age-matched controls. This may

107

indicate that individuals with AUD have atrophy patterns that are somewhere on the middle
of a spectrum – wherein they are severe enough to be detectable compared to agematched controls, but not yet severe enough to cause a detectable increase in the
distance from the scalp to the apex of the gyral folds. This spectrum of atrophy is
supported by a recent study demonstrating that in individuals with mild cognitive
impairment, gray matter volume reductions precede increases in cortical distance and
reductions in modeled electrical field strength (312). The results from this study in AUD
suggest that while severe reductions in GMV can influence the received dose of brain
stimulation, the individuals with AUD in this sample have not yet met this threshold. Further
investigations into the spatial evolution of atrophy in AUD is warranted.

Sex/gender differences in scalp-to-cortex distance
While the presence of AUD did not affect scalp-to-cortex distance, women, on
average, had a shorter distance at the frontal pole. Further, due to this short distance,
women received an electrical field that is between 5-7.5 V/m stronger than that of their
male counterparts. In chapter 3, women with AUD experienced the greatest reductions in
grey and white matter integrity, suggesting that TMS signals may not propagate as readily
in women. It is possible, however, that this increase in TMS strength may partially mitigate
the effects of reduced grey and white matter integrity. Notably, in Chapter 2, women
experienced the greatest reduction in frontal pole connectivity, perhaps suggesting that
this increased dose offers clinical utility.
This sex/gender based effect is likely to be due to differences in the shape of the skull,
rather than the shape of the brain (313). Specifically, patterns of frontal bone topography
are likely important for TMS dosing. In males, the declination angle of the frontal bone
(spanning the apex to the nasion) is smaller, leading the forehead to appear more
rounded. By contrast, in females, the frontal bone is sharper, leading the forehead to
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appear flatter (314). This leads to a situation wherein the distance from the prefrontal
cortex to the external surface of the skull is greater for males than females. This is likely
to be especially relevant within the rostral and medial aspects of the prefrontal cortex,
wherein the prominent brow protrusion in males likely increase scalp to cortex distance
(314). The shape of the skull, however, does not differ between genders at the motor
cortex or dorsolateral prefrontal cortex – consistent with the result that STC was equivalent
between genders at these sites and that the resting motor threshold does not differ
between genders (315).
Few studies in the field of brain stimulation have sought to sex/gender differences in
scalp-to-cortex distance. Several other scientific disciplines, however, including
archeology (316), medical forensics (317), and craniofacial reconstructive surgery (318)
have reported sex/gender differences in skull morphology. Within this literature,
sex/gender differences in skull geometry occur not only in the frontal bone, but also in the
orientation of the orbits, the size of the zygomatic bone, tapering of the mandible, and the
prominence of the inion (314). These data suggest that in addition to TMS strategies
targeting the frontal pole, TMS strategies applied to the temporal and visual cortices may
need to consider gender and scalp-to-cortex distance in their dosing protocols.

RMT-based dosing strategies may not be ideally suited for the frontal
pole
Resting motor threshold (RMT) is a patient-tailored calibration broadly used to
determine the relative strength or dose (percent machine stimulator output) required to
depolarize an individual’s cortical surface. It is known that increasing the space between
the coil and the cortex causes sharp, linear increases in RMT (319). To overcome the
increased scalp-to-cortex distance at the prefrontal cortex caused by the fronto-sagittal
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sinuses, it has been suggested researchers deliver TMS at an intensity of 110-120% of
RMT (320)
Many large scale, multisite clinical trials stimulating the prefrontal cortex have adopted
this technique (157, 321). The results of this chapter suggest that this strategy is effective
for stimulation applied the dorsolateral prefrontal cortex (e.g. STC at the motor cortex
explains nearly half of the variance in STC at the DLPFC). The success of this technique
can be further observed in a qualitative view of Figures 3.5c-f. Wherein TMS electrical
fields modeled at F3 and C3 appear relatively consistent across participants.
Scaling of the resting motor threshold, however, may have limited efficacy in
standardizing TMS dose at the frontal pole. For example, STC at the motor cortex explains
only about a third of the variance in STC at the frontal pole. The impact of this difference
can be further observed in a qualitative view of Figures 3.5a-b, wherein TMS electrical
fields modeled at FP1 are highly variable. A portion of this variability is likely due to
sex/gender differences in the skull (discussed above). Well-developed evidence from the
field of medical forensics, however, suggests that there is an extremely high degree of
individual variability in the size and shape of the frontal bone and sinuses (which constitute
much of the STC at the frontal pole). Within this field, upon recovering otherwise
unidentifiable human remains, pre- and post-mortem radiographs of the frontal bone and
sinuses can be matched to specific individuals with the same accuracy as a fingerprint
(317, 322). The makeup of this space is related not only to gender, but also age (314) and
geographic ancestry (323). As frontal pole TMS continues to be efficacive in the treatment
of a variety of psychiatric disorders (220), individualized electrical field modeling may be
necessary to reduce inter-subject variability.
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Limitations
There are, of course, several limitations to the impact and generalizability of this
research based on the chosen design. As a result of current software capabilities,
standard tissue conductivity values were applied for gray and white matter. This may not,
however, accurately capture the influence of microstructural tissue degradations present
in chronic alcohol users on electrical field strength or size. Further, for the primary
analyses within this study, electrical field models were modeled at a standard 60%
machine stimulator output, as resting motor threshold for many of healthy controls in this
sample was collected across various TMS coils and/or missing from record.

Conclusions
In a large, age- and gender-matched analysis (n=88), this chapter demonstrates that
scalp-to-cortex distances among AUD patients and healthy controls are relatively
equivalent. This finding is a positive indication for TMS in AUD, as it suggests cortical
atrophy is not so severe as to increase this distance. Subsequently, AUD patients were
found to realize equitable electrical field strengths at the frontal pole, dorsolateral
prefrontal cortex, and the motor cortex. Women are also likely to receive a stronger dose
of TMS at the frontal pole, due to a shorter scalp-to-cortex distance. Lastly, these data
highlight a current challenge in the field of brain stimulation: individual variability in frontal
pole scalp-to-cortex distances. High degrees of variability in skull morphology at this site
may require the field to develop new calibration processes, such that variability in electrical
fields among participants is reduced.
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Chapter 5: Integrating electrical field maps and alcohol cue
reactivity patterns – a retrospective analysis of a TMS-AUD
clinical trial
Introduction
While the clinical outcomes presented in Chapter 2 of this dissertation are
encouraging, there is considerable room for improvement. Specifically, nearly 30% of
those who received real TMS relapsed to alcohol within 3 months of treatment. Chapters
3 and 4 laid a critical groundwork in exploring individual features of neural architecture
among the patients enrolled in this trial. One emergent source of structural variability
discussed within these chapters is the strength of TMS electrical fields at the frontal pole.
Yet another possible source of variability, however, may be stem from individual functional
brain responses to alcohol cues. The following chapter will consider both of these
structural and functional sources of variability and their influence on the clinical trial
outcomes observed in Chapter 2.
As previously described, scalp-to-cortex distance (and therefore electrical field
strength) is a considerable biomarker of TMS treatment efficacy. Among several TMS
clinical trials for depression (310, 311), schizophrenia (264), and AUD (196), individuals
with shortest scalp-to-cortex distances experienced the greatest improvements in clinical
outcome. Post hoc analysis of the electrical fields within the AUD patients enrolled into
our TMS-AUD clinical trial, however, were highly variable. As such, individual electrical
field strength is a viable candidate biomarker for TMS treatment outcome in AUD.
Individual, functional brain response to alcohol cues may be another evidence-based
biomarker of TMS treatment efficacy. In the aggregate, individuals with AUD display robust
alcohol cue-reactivity within the medial prefrontal cortex and striatum (100-102) – key
brain regions involved in salient reward processing. Further, elevated fMRI BOLD signal
in response to environmental alcohol cues has been associated relapse (108, 197, 198,

112

200, 201, 324). On the individual level, however, not all AUD patients have significantly
elevated BOLD signal in response to alcohol, versus neutral beverage cues. For example.
in a recent analysis of 156 substance users (alcohol, cocaine, and nicotine), 53 individuals
(33.9%) did not have a significant response to drug cues relative to neutral images (102).
Given previous literature demonstrating the relationship between elevated alcohol cuereactivity and likelihood of future relapse, individual alcohol cue-reactivity is a viable
candidate biomarker for TMS treatment outcome in AUD.
While both of these variables (electrical fields and alcohol cue-reactivity) are likely to
play a role in TMS treatment outcome, it is also possible that the combination of structure
and function may influence treatment outcome among AUD patients. For example, a
guiding strategy of the development of TMS for AUD has been to reduce elevated BOLD
response to alcohol cues. However, not all individuals may have an elevated BOLD
response to alcohol cues within the stimulation site, and some individuals may not be
reactive to alcohol cues at all. Preliminary evidence from the field of brain stimulation for
other psychiatric diseases has suggested that stimulation at individualized sites of peak
fMRI activity may yield an improved outcome. Collectively, within Chapter 2 of this
dissertation, it is possible that not all individuals received an electrical field that overlapped
with individual pattern of response to alcohol cues.
This chapter presents an exploratory, retrospective analysis of the influence of 1)
electrical field strength, 2) alcohol (versus neutral beverage) fMRI cue-reactivity and 3)
overlap between these two maps on the clinical trial outcomes observed following 10 days
of MPFC-TMS. Baseline structural and functional neuroimaging (n=44) data were used to
test the hypothesis that the following characteristics would result in improved treatment
outcome: stronger frontal pole electrical fields, greater cue-reactivity, and spatial overlap
between these structural and functional maps.
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Methods and Materials
Participants
The participants assessed in this retrospective analysis are identical to those
assessed in Chapter 2 of this dissertation. However, of the 50 individuals enrolled in the
clinical trial, baseline neuroimaging data was available from only 44 individuals (real cTBS,
n=23; sham cTBS, n=21). Further details regarding the parent clinical trial can be found in
Chapter 2: Materials and Methods.

Functional neuroimaging analysis:
fMRI Preprocessing: Details regarding fMRI preprocessing can be found in Chapter 2,
Materials and Methods, fMRI preprocessing.
Individual ETOH>BEV cue-reactivity maps: All whole-brain alcohol cue-reactivity
analyses were performed in SPM12. Briefly, for each participant, smoothed, normalized
functional data were concatenated from each condition: alcohol (ETOH), neutral
beverages (BEV), blurred and fixation cross. Motion parameters in 6 directions (x,y,z,
pitch, roll, and yaw) were treated as nuisance variables and regressed out of the data.
Motion-adjusted contrast maps representing relative beta weights were created for the
ETOH>BEV cue-condition. Each individual ETOH>BEV cue contrast map was examined
using a voxel-wise threshold of p<0.01. Extent thresholds (k) were corrected for each
participant such that only clusters surviving Family-Wise Error correction (multiplecomparisons correction) remained. Thresholded ETOH>BEV beverage cue-reactivity
maps for each participant were saved for subsequent analysis. Individuals who had at
least 1 cluster of elevated BOLD signal surviving statistical corrected were deemed “cuereactive”. Individuals with no significant clusters following statistical correction were
deemed “non cue-reactive”.
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Group level ETOH>BEV analysis: A group level analysis of BOLD signal in response
to alcohol versus neutral cues was performed to confirm that the individuals in this sample
had a similar, aggregate response to previous research. A general linear model of the
ETOH>BEV cue contrast maps from each participant (n=44) was assessed via one-way
t-test. Contrasts weights for group-level positive (increased) BOLD signal and negative
(decreased) BOLD signal in response to the contrast condition were modeled. A binary,
explicit MNI mask (encompassing grey matter, white matter and CSF) was applied to the
data.
Structural Neuroimaging Analysis:
Modeling TMS-induced electric fields: The software SIMNIBS version 3.2.1 was used
to model the TMS- induced electric fields via the finite element method (largely accounting
for STC distance) (303). Electric fields were modeled at the left frontal pole (FP1). All
modeling parameters for this experiment were consistent with those reported in Chapter
4. However, to accurately reflect electrical fields produced within the clinical trial,
stimulation intensity for these models was adjusted to 110% of individual resting motor
threshold. Electric field maps were then normalized to standard MNI-152 space in
conjunction with each subject’s high-resolution T1-weighted image using a trilinear
approach.

Overlapping alcohol cue-reactivity and electrical fields maps:
FSL’s fslmaths tool was used to extract the overlap between alcohol-cue-reactivity
maps and electrical field representations (308). Briefly, individual cue-reactivity maps were
masked with individual electrical field models such that the only remaining voxels from the
alcohol cue-reactivity map were within the bounds of the electrical field. The size of this
overlap was quantified using AFNI’s 3dROIstats (256, 257). Individuals were grouped as
‘overlapping’ given that ≥ 5 voxels were shared between the cue-reactivity and electrical
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field maps. Given that this is the first report to assess overlap between alcohol cuereactivity and electrical field models, a relatively liberal threshold of 5 overlapping voxels
was used. Overlap was secondarily confirmed by visual inspection of these maps using
MRIcroGL.

Statistical analysis
Two primary endpoints from the parent, randomized, double-blind sham-controlled
clinical trial were chosen for these exploratory analyses: enrollment and alcohol sobriety
at each visit. The influence of 1) ETOH>BEV cue-reactivity, 2) electrical field strength and
3) overlap between ETOH>BEV and electrical field maps were analyzed as follows:
1) Influence of ETOH>BEV cue-reactivity: Standard odds ratios were calculated at
each follow up visit to assess the likelihood of enrollment and sobriety among cuereactive and non cue-reactive individuals. Two sets of odds ratios were calculated
to assess the relative difference between 1) cue-reactive and non cue-reactive
individuals who received real TMS and 2) cue-reactive and non cue-reactive
individuals who received sham TMS. From a conceptual perspective, the effect of
baseline cue reactivity on future treatment outcome is likely to be confounded by
the treatment type received (real or sham TMS). In other words, given that real TMS
changes cue-reactivity (193, 194, 325), differences in clinical outcome between
cue-reactive individuals (at baseline) who received real and sham TBS are likely
have limited clinical utility. Statistical analysis was therefore performed within, rather
than between groups.
2) Influence of electrical field strength: Average baseline electrical field strength
among those who remained enrolled (versus lost to follow-up) and sober (versus
relapsed) were analyzed (two-sample t-test). These analyses were performed at
the 3 month follow up visit, when the difference in enrollment and sobriety following
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real versus sham TMS was greatest within the parent clinical trial. From a
conceptual perspective, modeled electrical field strength within the sham group
(who did not receive stimulation) is unlikely to have an influence on treatment
outcome. Statistical analysis was therefore performed only among individuals
receiving real TMS.
3) Influence of overlap between electrical field maps and ETOH>BEV cue-reactivity:
Standard odds ratios were calculated at each follow up visit to assess the likelihood
of attendance and sobriety. Two sets of odds ratios were calculated to assess the
relative difference between 1) individuals who had an overlap between alcohol-cue
reactivity and electrical field maps and those who received sham TMS and 2)
individuals who had no overlap between alcohol cue-reactivity and electrical field
maps and those who received sham. From a conceptual perspective, individuals
who received sham TBS cannot have an overlap between these maps, as
stimulation were not delivered to the cortex. Sham individuals were therefore not
categorized by overlap or no overlap.

Analysis of sobriety: For these exploratory analyses of cue-reactivity and electrical fields,
sobriety was analyzed using the intent to treat sample wherein all individuals had 1) a
complete neuroimaging data set and 2) at least 1 heavy drinking day in the last 30 days
prior to TMS V1, leaving 38 of 50 participants. For analyses of overlap between these
maps, individuals in the sham group were not required to have a complete neuroimaging
dataset, leaving 40 of 50 participants. As performed in Chapter 2 of this dissertation, selfreport measurements were cross referenced with outcomes from urine ETG (wherein
either a positive self-report or a positive ETG level (>100) was considered a drinking day).
To deal with missing data from a statistical perspective, the last observation carry forward
(LOCF) method was used (218). This is a common statistical technique in longitudinal
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clinical trials likely most appropriate when missing data is not equally distributed in the
treatment and sham group (e.g. missing not at random (MNAR)) (219).

Results
Individual variability in ETOH>BEV cue-reactivity
Group-level analysis (n=44) revealed significantly elevated BOLD signal in response
to ETOH>BEV cues within two primary clusters: c1, bilateral occipital cortex, pFWEcorrected<0.001,

k=2,534; bilateral medial prefrontal cortex, pFWE-corrected<0.001, k=2,016;

voxel-wise threshold: p<0.01, Family-wise error multiple comparisons corrected.
Subject-level analysis demonstrated significantly elevated ETOH>BEV BOLD signal
within 26 individual baseline scans (average size: 2,914 ± 2,678.7 voxels; p<0.01, Familywise error multiple comparisons corrected). Cue-reactivity was localized to the medial
prefrontal cortex (n=19) and the occipital cortex (n=7). The remaining 18 individuals in the
sample did not have significant ETOH>BEV cue-reactivity, as no clusters survived
statistical correction (Figure 5.1). There was no significant BEV>ETOH cue-reactivity
within this sample.
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Figure 5.1 Variability in individual ETOH>BEV beverage cue-reactivity. Left: Grouplevel BOLD signal in response to the ETOH>BEV contrast condition was significantly
elevated within the medial prefrontal and occipital cortices. Top right: 19/44 (43.2%) of the
individuals within the sample demonstrated significant ETOH>BEV cue reactivity within
the medial prefrontal cortex. Middle right: 7/44 (15.9%) of individuals within the sample
were ETOH>BEV cue-reactive elsewhere. Bottom right: 18/44 (40.9%) of individuals in
the sample had no significant ETOH>BEV cue-reactivity. Voxel-wise threshold for group
and individual was set to p<0.01, Family-wise error corrected. Color bar reflects t-scores.
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ETOH>BEV cue-reactivity and clinical outcome
Among individuals randomized to receive real TBS, 15 were cue-reactive, having at
least 1 significant ETOH>BEV cluster and 8 were non-cue reactive. Among individuals
randomized to receive sham TBS, 10 individuals were cue-reactive and 11 were non-cue
reactive. 6 individuals had not engaged in heavy drinking within 30 days prior to TMS V1
and were excluded from analysis, leaving the following sample sizes: Real TMS, cuereactive: n=14; Real TMS, non cue-reactive: n=5; Sham, cue-reactive: n=10; Sham, non
cue-reactive: n=9.
Clinical outcome following Sham TMS (Figure 5.2): A greater portion of cue-reactive
individuals (1 month: 100.0%, 2 months: 70.0%, 3 months: 60.0%) remained enrolled,
relative to non cue-reactive individuals (1 month: 72.7%, 2 months: 45.5%; 3 months:
45.5%). Although not statistically significant, the odds of remaining enrolled was greatest
at the 1 month (OR=8.6, z=1.365, p=0.17) and 2 month (OR=2.8, z=1.22, p=0.26) follow
up visits.
Similarly, a greater portion of cue-reactive individuals (1 month: 60.0%; 2 months:
50.0%; 3 months: 40.0%) remained sober, relative to non cue-reactive individuals (1
month: 22.2%; 2 months: 22.2%; 3 months: 33.3%). Although not statistically significant,
the odds of remaining sober were greatest in the cue-reactive group at the 1 month
(OR=5.25, z=1.611, p=0.11) and 2 month follow ups (OR=3.5, z=1.227, p=0.22).
Clinical outcome following Real TMS: A greater portion of cue-reactive individuals (1
month: 80.0%, 2 months: 80.0%; 3 months: 73.3%) remained enrolled, relative to non cuereactive individuals (1 month: 75.0%, 2 months: 62.5%; 3 months: 75.0%). Although not
statistically significant, the odds of remaining enrolled were greatest in the cue-reactive
group at the 2-month visit (OR=2.4, z=0.898, p=0.37).
Similarly, a greater portion of cue-reactive individuals (1 month: 71.4%; 2 months:
57.1%; 3 months: 64.3%) remained sober, relative to non cue-reactive individuals (1
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month: 0.0%; 2 months: 40.0%; 3 months: 60.0%). The odds of remaining sober were
greatest in the cue-reactive group at the 1 month (OR=25.6, z=2.053, p=0.04), 2 month
(OR=2.0, z=0.654, p=0.51) and 3 month follow ups (OR=2.7, z=0.928, p=0.35). [Note: the
small sample size in the real TBS, non-cue reactive group (n=5) likely biased these odds
ratios, limiting the clinical utility of these data].
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B)

Figure 5.2 ETOH>BEV cue reactivity and clinical outcome. A) Cue-reactive individuals
(dotted red lines) were 3-8 times more likely to remain enrolled than non-cue reactive
individuals (dotted grey lines), following sham TMS. B) Cue-reactive individuals were 3-5
times more likely to remain sober relative to non-cue reactive individuals, following sham
TMS. Note: Enrollment and sobriety following real TMS, split by cue-reactivity, are not
plotted, due to lack of effects and an imbalance between sample sizes.
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Electrical field strength and clinical outcome
Among those receiving real TBS, there was no significant difference in baseline
electrical field strength among those who remained enrolled (versus lost to follow up) at 3
month follow up visit (Enrolled: 72.7 ± 10.2 V/m; Lost to follow up: 78.0 ± 17.8 V/m;
t20=0.896, p=0.38). Similarly, there was no significant difference in baseline electrical field
strength among those who relapsed (versus remained sober) 3 month follow up visit
(Sober: 74.4 ± 10.4; Relapsed: 74.0 ± 17.8; t20=-0.072, p=0.94).
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Figure 5.3 Electrical field strength and sobriety. Baseline peak electrical field strength
did not differ among those who went on to relapse versus those who remained sober. A)
A qualitative view of the electrical field models among those who remained sober (green
square) and those who relapse (red square) 3 months after receiving real TMS. B)
Average electrical field strength was not different among those who remained sober
(green bar) versus those who went on to relapse (red bar) 3 months after receiving real
TMS. Plotted data represent peak electric field strength, the average V/m within the 99 th
percentile of voxels. Error bars represent standard deviation.
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Overlapping ETOH>BEV cue-reactivity and electrical fields and clinical
outcome
Among individuals randomized to receive real TBS, 13 individuals had overlapping
alcohol cue reactivity and electrical fields, while 10 individuals did not have overlap
between these maps (Figure 5.4). 6 individuals had not engaged in heavy drinking within
the 30 days prior to TMS V1 and were excluded from analysis, leaving the following
sample sizes: Real TBS, overlap: n=12; Real TBS, no overlap: n=7; Sham TBS, n=21.
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Figure 5.4 ETOH>BEV cue reactivity and electrical field overlap. Top row:
Individualized electrical field (left) overlaid with significant MPFC ETOH>BEV cue
reactivity (middle) produced a spatial overlap in 13 individuals receiving real TMS. Bottom
row: individualized electrical field (left) overlaid with non-cue reactive individuals did not
produce an overlap between maps in 10 individuals receiving real TMS. Statistical
thresholds used to produce each map are listed briefly: electrical field models, voxels with
an intensity greater than 35 V/m; alcohol cue-reactivity, voxel-wise threshold p<0.01,
Family-wise error corrected; integration, at least 5 voxels of spatial overlap.
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A greater portion of individuals with overlapping maps remained enrolled (1 month:
93.0%; 2 months: 93.0%; 3 months: 86.0%), relative to individuals who received sham (1
month: 80.0%; 2 months: 52.0%; 3 months: 48.0%). Individuals with an overlap were more
likely to remain enrolled at the 1 month (OR=2.6, z=0.814, p=0.42), 2 month (OR=11.0,
z=2.149, p=0.03) and 3 month (OR=6.0, z=2.069, p=0.04) follow up visits. Individuals with
no overlap between these maps (1 month: 60.0%; 2 months: 50.0%; 3 months: 60.0%)
were not substantially more or less likely to remain enrolled, relative to sham
Similarly, a greater portion of individuals with overlapping maps remained sober (1
month: 1 month: 75.0%; 2 months: 58.3%; 3 months: 75.0%), relative to individuals who
received sham (1 month: 42.9%; 2 months: 38.1%; 3 months: 38.1%). Individuals with an
overlap were substantially more likely to remain sober at the 1 month (OR=4.00, z=1.1734,
p=0.08), 2 month (OR=2.27, z=1.114, p=0.26) and 3 month (OR=4.875, z=1.97, p=0.05)
follow up visits. Individuals with no overlap between these maps (1 month: 13.3%; 2
months: 42.9%; 3 months: 42.9%) were not substantially more or less likely to remain
sober at any follow up visit, relative to sham.
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Figure 5.5 ETOH>BEV cue reactivity and electrical field overlap improves clinical
outcome. A) Individuals with overlapping maps (solid purple line, circles) were 6-12 times
more likely to remain enrolled relative to individuals receiving sham TBS (dotted grey line,
squares). Individuals with no overlap between these maps (solid grey line, circles) did not
have substantially different rates of enrollment relative to sham. B) Individuals with
overlapping maps (solid purple line, circles) were approximately 2-5 times more likely to
remain sober, relative to individuals receiving sham TBS (dotted grey line, squares).
Individuals with no overlap between these maps (solid grey line, circles) did not have
substantially different rates of sobriety relative to sham. * Indicates odd’s ratio p-value ≤
0.05.
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Discussion
Building upon the analyses presented throughout this dissertation, this chapter
assessed the influence of two, novel sources of variance within a completed TMS-AUD
clinical trial: 1) electrical field strength at the frontal pole and 2) individual alcohol cuereactivity patterns. This chapter also assessed the influence of spatial overlap between
alcohol cue-reactivity and electrical field maps on clinical outcome – a novel, multimodal
integration of brain function (alcohol cue-reactivity) and structure (TMS electrical fields).
Interstestingly, neither alcohol cue-reactivity nor electrical field strength alone strongly
influence TMS treatment outcome in AUD. Individuals with a spatial overlap between
alcohol cue-reactivity and electrical fields, however, greatly improved treatment outcome.
These suggest MRI-based TMS targeting and dosing strategies may be highly effective in
the treatment of AUD and provide critical groundwork for future, prospective trials.

Electrical field strength and clinical outcome
The efficacy of any given TMS treatment approach is likely to depend on a
constellation of parameters such as frequency (147, 156, 237), number of pulses (142,
238), or cortical targeting technique (266) – all factors which vary by specific indication or
treatment approach. One invariable TMS dosing parameter which may influence treatment
outcome is the realized electrical field strength reaching the cortex. Prior to the availability
of robust electrical field modeling, clinal TMS studies associated shorter scalp-to-cortex
distances (an indirect measure of electrical field strength) with more robust clinical
improvements (196, 264, 310, 311). Surprisingly, however, within this analysis we do not
find a direct relationship between electrical field strength at the cortex and clinical outcome
for TMS and AUD. While a robust, large-scale analysis of the influence of electrical field
strength on clinical outcome has not yet been performed, these results are in line with

129

existing literature which have failed to find a TMS dose-response relationship among
patients with Tobacco Use Disorder (326) and depression (327).
Given that we find substantial clinical improvement within our AUD sample, but also
high variability in electrical field strength, it may be the case that a stronger dose of TMS
is not necessarily better. Instead, it may be possible that a minimum threshold is needed
to be reached to facilitate physiological change with TMS. For instance, Zmyenka and
colleagues have suggested that a dose of 35-50 V/m applied at the motor cortex was
sufficient to induce changes in neural spike timing (309). Future research may consider
aiming to determine the minimum threshold dose required to influence drinking behavior
in TMS. For the time being, however, there does not appear to be compelling clinical
evidence that increased electrical field strength will enhance treatment outcome.

Alcohol cue-reactivity and clinical outcome
Among AUD patients who are not enrolled in psychosocial or pharmacological
treatment programs, elevated fMRI BOLD signal in response to alcohol cues (versus
neutral beverage cues) has consistently been used to predict future relapse (108, 197,
198, 200, 201, 324). Within this body of research, in the absence of any standard AUD
treatment, individuals with the greatest extent of cue-reactivity are most likely to relapse
while individuals with low cue-reactivity are less likely to relapse (108, 199, 200, 324).
While cue-reactivity did not significantly influence treatment response in this analysis, it is
interesting that cue-reactive individuals in the sham group were the most likely to remain
enrolled and sober. This result may suggest that individuals with high alcohol cuereactivity are more likely to respond to outpatient programming. Larger clinical trials
assessing this trend may comprehensively assess the influence of the magnitude and
extent of alcohol cue-reactivity on response to various forms of pharmaceutical and
psychosocial intervention.
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The initial framework of the parent clinical trial for this dissertation chapter aimed to
reduce alcohol cue-reactivity within the MPFC as a strategy to improve treatment outcome
in AUD. It is worth consideration, therefore, that not all individuals who enrolled in the
study were ‘cue-reactive’, having at least one cluster of significantly elevated BOLD signal
in response to alcohol>neutral beverage cues. Consistent with findings from Hanlon and
colleagues, approximately 40% of individuals enrolled in the parent clinic trial were not
cue-reactive at baseline (102). As the field of brain stimulation continues to guide cortical
target selection based on functional neuroimaging, future clinical trials may consider
investigating individual BOLD signal as a clinical covariate of interest. This is likely to be
particularly relevant for target engagement trials, wherein baseline brain activity may
greatly influence whether increases or decreases in BOLD signal are observed (328).

Overlap and clinical outcome
Neither electrical field strength nor alcohol cue-reactivity alone were significantly
related to TMS treatment outcome in AUD. Spatial overlap between these two factors,
however, led to significant improvements in enrollment and sobriety. For instance,
individuals who had an overlap between maps maintained 2-to-3-month enrollment rates
that 13-20% greater than observed following real TMS alone.
From a clinical perspective, in a high-volume outpatient clinic for AUD, the application
of MPFC-TMS in conjunction with standard programming may yield an increase in
retention of about 15-25% (difference in enrollment rate between real and sham groups at
2- and 3- month follow ups). Integrating structural and functional neuroimaging maps,
however, may further increase retention by approximately 38-41% (difference in
enrollment rate between overlap and sham groups at the 2- and 3-month follow ups).
Given that attendance at treatment is associated with improved AUD outcome (231), these
improvements in enrollment are likely to be of high clinical value.
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Limitations
The generalizability and scope of this work are of course limited by several factors.
Grouping individuals by electrical field strength, alcohol cue-reactivity and overlap
between maps resulted in modest sample sizes within each group and may have led to
skewed distributions in some cases. Further, future prospective (rather than retrospective)
analyses may more appropriately assess the influence of these factors on both binary
outcomes (relapse) and continuous outcomes (number of drinks, for instance) in AUD.
Lastly, it is not certain that overlap between alcohol cue-reactivity maps and electrical
fields is the only factor contributing to treatment outcome (See: Chapter 2). Future work in
this area may consider integrating other clinical (e.g. AUD severity) and biological
variables (e.g. gender, age) in the prospective, fMRI guided analyses to improve treatment
outcome.

Conclusions
The results of this dissertation chapter demonstrate that neither alcohol cue-reactivity
nor electrical field strength alone influence TMS treatment outcome in AUD. Interestingly,
however, spatial overlap between these maps significantly improved the likelihood of
enrollment (6-11X) and sobriety (3-5X) 2 and 3 months following TMS. From a conceptual
perspective, the positive influence of overlapping maps found here may fit within the
context of a broader literature using individual fMRI guided TMS strategies. Briefly,
stimulating patient specific cortical targets which show maximal correlation or anticorrelation to downstream brain regions has shown considerable efficacy in treating
depression (221, 329), OCD (330), and traumatic brain injury (331). A future, prospective
analysis of the influence of electrical field and cue-reactivity overlap is warranted as a
strategy to enhance treatment outcome in AUD.
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Chapter 6: Conclusions and Future Work
The series of studies presented thus far demonstrates that delivering multiple sessions
of TMS to the medial prefrontal cortex has strong potential as a neural circuit-based
therapeutic for AUD. In a double blind, sham-controlled clinical trial of 50 individuals with
AUD, 10 sessions of theta burst stimulation (3600 pulses/session; 1 session/day)
delivered to the left frontal pole improved 3-month sobriety rates and decrease brain
reactivity (functional connectivity) to alcohol cues (Chapter 2). While relapse rates were
lower in the group that received active versus sham TMS, nearly 30% of individuals who
received real TMS still relapsed within 3 months.
In recognition of this high degree of individual variability, the remainder of this
dissertation focuses on areas for improvement and methods refinement in future studies.
Specifically, three sources of variability which may contribute to treatment outcome in AUD
are described: grey and white matter integrity (Chapter 3), scalp-to-cortex distance
(Chapter 4) and the spatial topography of brain reactivity to alcohol cues (Chapter 5).
In summary, grey and white matter volume are reduced in AUD, which may suggest
that individuals with AUD require a higher dose of TMS in order to modulate neural circuits.
This result is particularly relevant for women with AUD, who experienced the greatest
reductions in cortical volume (Chapter 3). While there is considerable grey matter loss at
various cortical targets for TMS, this loss is not so severe as to increase the cortical
distance (or reduce electrical field strength). Interestingly, women, on average, receive
stronger electrical fields at the frontal pole which may mitigate detriments incurred by grey
matter loss (Chapter 4). Finally, in a retrospective analysis of Chapter 2, individual patterns
of brain reactivity to alcohol cues and electrical field strength alone do predict treatment
outcome. When integrated together, however, the presence of an overlap between alcohol
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cue-reactivity and electrical field maps significantly improves enrollment and sobriety
rates.
The following chapter will address four remaining topics critical to the advancement
of TMS for AUD: 1) fitting TMS into current AUD treatment practices, 2) improving future
TMS-AUD clinical trials, 3) addressing sex/gender-based differences in treatment
response, and 4) speculating about the future of TMS and brain stimulation as treatment
for AUD.

Where are we now? MPFC-TMS and standard AUD treatment
As discussed, there are several existing behavioral and pharmacotherapeutic
treatments for AUD. These treatments, however, have shown modest success in
improving alcohol sobriety rates and preventing relapse. Introducing a new treatment tool,
such as MPFC-TMS, into the treatment toolbox for AUD may substantially improve overall
sobriety rates.
Before TMS is introduced into this toolbox, it is important to compare the relative
efficacy of MPFC-TMS to standard AUD treatment. Likely the best evidence for the
efficacy of standard AUD treatments in preventing relapse comes from the COMBINE
study, which rigorously tested various combinations of pharmaco- and psychosocial
therapies (63). The most effective treatment arms in this study were cognitive behavioral
intervention alone, naltrexone alone, and the two combined. 4 months after the completion
of treatment, Anton and colleagues reported that individuals randomized to these
conditions were about 2 times more likely to remain sober (Figure 6.1).
MPFC-TMS holds the potential to greatly enhance sobriety rates. In Chapter 2, for
instance, individuals receiving real MPFC-TMS and psychosocial treatment were nearly 3
times more likely to stay sober after treatment (3 month follow-up). These data are similar
to a recent report by Harel et. al in 2021 (195). Using an H-coil positioned over the medial
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prefrontal cortex, 15 sessions of 10 Hz rTMS led to 80% sobriety 3 months after TMS
treatment. Importantly, the participants enrolled in this trial did not receive psychosocial
intervention in conjunction with TMS. The strong clinical effect of this trial may have been
due to the increased number of TMS sessions (15 daily TMS sessions; 5 follow-up
sessions) or the TMS coil used (H-coil, broader and deeper stimulation profile). Taken
together, these trials underscore the clear efficacy of MPFC-TMS in improving sobriety
rates.
MPFC-TMS may hold even more potential in improving sobriety than currently
realized. For instance, integration of individualized alcohol cue-reactivity and electrical
field maps may improve the likelihood of sobriety by a factor of 5. While this is still an
active area of research, this result highlights the tremendous potential MPFC-TMS holds
in improving sobriety (Figure 6.1).
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Figure 6.1 3-to-4-month odds of sobriety are improved with TMS, relative to
standard interventions. Individuals receiving cognitive Behavioral Therapy (CBT),
naltrexone, and CBT+naltrexone (grey squares) are twice as likely to remain sober,
relative to those receiving placebo. Individuals receiving MPFC-TMS (in conjunction with
outpatient programming, green circle) are nearly 3 times as likely to remain sober relative
to those receiving psychosocial intervention only. Individuals with overlapping alcohol cuereactivity and electrical field maps (purple circle) are nearly 5 times as likely to remain
sober, relative to individuals receiving psychosocial intervention only. Data obtained from
COMBINE study represent odds of maintaining either complete abstinence or moderate
drinking. Data from McCalley refer to complete abstinence (3 months after treatment). It
is likely that the odds of achieving complete abstinence within the COMBINE trial are
slightly lower shown here, however this data was not reported. [Note: Odds ratios from the
Harel et al. study were not included in this figure, as total counts of sobriety and relapse
among participants were not reported]
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In the future, MPFC-TMS may be effective either as a standalone treatment or an
adjuvant therapy for common psychosocial interventions. Given the favorable safety (332)
and tolerability (225) profiles of MPFC-TMS, this emergent treatment may be best suited
as a front-line intervention for AUD. From a patient perspective, TMS may be more
tolerable than pharmaceutical treatment, which is accompanied by substantial side effects
and low adherence (52, 58). With continued success in this domain, clinicians may
consider prescribing MPFC-TMS and cognitive behavioral intervention prior to attempting
pharmaceutical interventions.
It may also be fruitful to combine MPFC-TMS treatment with pharmacological
treatment, however, safety concerns regarding seizure risk should be of high priority. An
increased risk of TMS-induced seizure can occur among patients taking medications
which affect seizure threshold (332). Preliminary evidence suggests that naltrexone and
acamprosate may not substantially increase seizure risk (177, 333, 334), however, a
comprehensive study assessing this risk has not yet been performed. Disulfiram can
increase seizure risk (335) and is likely to remain a contraindication for TMS for the
foreseeable future.

Recommendations for future TMS-AUD clinical trials
The efficacy of TMS reported in this dissertation clearly warrant the continued
development of non-invasive brain stimulation as a therapeutic tool for AUD. Several
themes have emerged within this dissertation that are likely to accelerate the development
pipeline for TMS and brain stimulation in AUD.

Incorporating structural neuroimaging
Future clinical trials for AUD may consider structural neuroimaging prior to the
administration of TMS. As discussed in Chapter 3, grey and white matter integrity are likely
to have an impact on the propagation of TMS signal and treatment outcome. Features of
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grey and white matter, therefore, ought to be considered as covariates of interest in future,
large-scale clinical trials. Future research leveraging interleaved TMS techniques may
seek to explore the exact relationship between grey matter volume, white matter integrity
and BOLD signal change such that practical clinical decisions can be made. For instance,
given reduced grey and white matter integrity, can machine stimulator output be increased
by a fixed amount such that resulting BOLD signal is equivalent across participants? A
definitive answer to this question can guide clinicians in selecting individual TMS dose
(machine stimulator output) for AUD patients.
Structural neuroimaging also enables a more individualized approach to spatial
targeting and TMS (e.g. given variance in scalp-to-cortex distance). Improved spatial
targeting can be accomplished via neuronavigational tools. These tools incorporate
individualized structural images such that cortical targets can be anatomically defined.
This enables researchers to set and save coordinates for an individual target, such that
the TMS coil is consistently placed on the same location on the scalp with the same
orientation across treatment visits. The value of reliable spatial targeting is further
underscored by recent evidence demonstrating that small changes in the angle of a TMS
coil can dramatically change resulting electrical fields (336).
Structural neuroimaging may also facilitate TMS dosing through reverse-calculation of
TMS-induced electrical fields. Electrical field modeling can be performed on each
anatomical image prior to TMS, such that the same a priori voltage can be delivered to all
individuals. On the group level, a standardized electrical field strength would remove most,
if not all, of the variance associated with electrical field strength. This approach, put
forward by Caufield and colleagues, has been described in standardizing dosage across
tDCS and TES research studies and can be readily applied to TMS research (337).
Standardizing electrical fields across participants in a TMS-AUD trial may be critical in
defining the optimal parameters for TMS-AUD treatment. Specifically, this technique could
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be used to define the minimum dosage required to reliably improve treatment outcome
across individuals.
Lastly, structural imaging may be incorporated into longitudinal TMS trials such that
potential changes to brain structure can be observed. Given that TMS can induce
neuroplastic changes, multiple sessions of TMS may increase grey and white matter
integrity. Accordingly, several groups have now demonstrated that fractional anisotropy
(338-341) and gray matter volume (342) are increased following rTMS for Major
Depressive Disorder. Given that increases in grey and white matter integrity in AUD are
associated with enhanced sobriety rates (122, 135), understanding the direct influence of
TMS on brain structure over time may inform the development of future TMS-AUD clinical
trials. For instance, a novel TMS strategy for the treatment of AUD may be to increase
grey or white matter integrity more rapidly such abstinence is more effectively maintained.

Incorporating functional neuroimaging: patient tailored TMS for AUD?
fMRI-guided selection of cortical targets has become increasingly popular in the
development of TMS for various psychiatric disorders. While the analysis presented in
Chapter 5 did not prospectively select a cortical target based on fMRI, the results provide
compelling food for thought as TMS continues to be developed for AUD. Specifically, there
are two essential questions that remain unanswered regarding how functional
neuroimaging may best be integrated to achieve optimal patient outcome:
1) Should TMS be applied to individualized loci of alcohol cue-reactivity by
moving the coil to the area of the brain displaying the greatest BOLD signal in
response to alcohol?
Selecting individualized cortical targets within the DLPFC based on functional MRI
(resting state connectivity) may substantially enhance TMS treatment response for
depression (221, 329), OCD (330) and traumatic brain injury (331). Given the success of
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these previous trials, it is possible that a prospective evaluation of fMRI-guided TMS
targeting may yield improved outcomes. Presumably, in AUD, this target would be
selected based on alcohol cue-reactivity maps. As illustrated in Chapter 5, however, not
all individuals display significantly elevated BOLD response to alcohol versus neutral cues.
It may be more prudent to select a cortical target with maximal alcohol cue-induced
functional connectivity to a subcortical target, such as the striatum. While not every
individual will be cue-reactive, every individual will have a unique cortical location with
maximal connectivity to the striatum.
2) Should a broader profile of TMS be applied to the prefrontal cortex, such that
the likelihood of overlap between elevated BOLD signal and electrical fields is
maximized?
While this question has not been tested directly, it is notable that two recent trails for
TMS and alcohol and nicotine use disorders have used H-coil designs (195, 210) which
stimulate substantially more surface area than standard Figure-of-8 coils (343). It is
possible that the success of these treatments is due to the increased likelihood of
stimulating a functionally relevant substrate for a given patient. In fact, two TMS clinical
trials using H-coil designs have led to FDA approval for smoking cessation and OCD
treatment (210, 212). In theory, this less focal approach is more easily scaled, as it does
not require specialized information from patient-level fMRI data.

A moving target? Does spatial topography of AUD change with a shift
from craving to habit
The clinical progression of Alcohol Use Disorder is characterized by a shift in cravingdirected to habit-directed drinking behaviors (83). This clinical change coincides with a
ventral-dorsal shift in reward and drug-cue processing within the striatum. In rodents,
activation of the orbitofrontal cortex and its afferent projections in the ventral striatum
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promotes goal-directed alcohol and drug seeking. Conversely, inactivation of this same
circuit reduces goal-directed behavior (74). Elevated activity within the dorsal striatum has
shown increased activity during compulsive, habit-like behaviors in rodent models (74). In
human neuroimaging studies, alcohol cues evoke ventral striatal activity among
individuals with more less severe AUD. Among individuals with more severe AUD, alcohol
cues more reliably evoke activity in the dorsal striatum (75). In recognition of this ventraldorsal striatal shift, Dunlop and colleagues have suggested that brain stimulation efforts
be tailored based on clinical severity. Within this framework, TMS treatments for
individuals with mild AUD and severe AUD should aim to modulate the ventral or dorsal
striatum, respectively (344).
To this end, TMS for AUD may consider capitalizing on the topographic organization
of the fronto-striatal circuitry. Specifically, dorsal regions of the medial prefrontal cortex
project onto the dorsal striatum, while ventral regions of the MPFC project onto the ventral
striatum (232). In future clinical trials, individual ventral and dorsal striatal response to
alcohol cues may guide which cortical site to stimulate. For example, an individual with
greater activity within the ventral MFPC-ventral striatal circuit in response to alcohol cues
may respond most readily to TMS applied to FP1 (ventral MPFC). An individual with
greater activity within the dorsal MPFC-dorsal striatal circuit, however, may most readily
respond to TMS applied to a more dorsal region, such as F3 (DLPFC) or FPZ (dorsal
MPFC).

Diving into dosing: how much TMS is enough to improve drinking?
It remains largely unknown which combination of TMS parameters may be the most
efficacious for reducing drinking. One commonality among treatments which have
successfully reduced drinking and alcohol craving however, is an increased number of
TMS sessions. 10 studies have applied at least 10 sessions of TMS. Of these, 8/10 have
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successfully reduced alcohol craving and 6/10 have reduced alcohol drinking for several
months [See: Chapter 1, Table 1.1.].
This mirrors effects observed for TMS for depression, in which a single TMS session
generally does not impact mood. Repeated sessions, however, can substantially reduce
clinical symptoms. As the field continues to develop TMS as a therapeutic treatment for
AUD, applying at least 10 stimulation sessions, may be critical element in improving
patient outcome.

Moving past the PFC: new cortical frontiers
Broad networks of brain regions are involved in the processes of incentive salience,
executive control, binge/intoxication, and withdrawal. Yet, few studies have applied TMS
to brain regions outside the PFC. The development of TMS coils that can penetrate to
deeper areas of the brain opens new potential therapeutic avenues to directly stimulate
previously unreachable targets. At least 2 stimulation targets may hold promise in treating
AUD: the anterior insula and the posterior cingulate cortex.
Structurally, the anterior insula has direct structural projections to cortical
(orbitofrontal, anterior cingulate) and subcortical (striatum, amygdala) structures that
mediate incentive salience and negative affect during withdrawal (345, 346). Functionally,
preclinical and clinical evidence has implicated the anterior insula in directing attention to
salient stimuli (345). The insula may also have a causal influence on the maintenance of
addiction. Naqvi and colleagues for example observed that individuals with insular lesions
were substantially more likely to quit smoking (347). Subsequent research in the field of
smoking and brain stimulation demonstrated that manipulation of the insula could improve
treatment outcome among smokers (210, 211).
Only one TMS trial has been completed assessing the efficacy of insula stimulation in
improving AUD outcome. While this trial did not find any difference between those
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receiving real or sham TMS, there were several methodological decisions which may
require further exploration. Specifically, Perini and colleagues applied 15 sessions of 10Hz
to the anterior insula using a custom H8 BrainsWay coil (348). Unlike many other H-coils,
the authors report their customized coil stimulated only the insula without rostral PFC
stimulation. Given the central role of the insula in addiction, future research may still
consider this a viable stimulation target. It is possible, for instance, that attenuating forms
of TMS (e.g. 1Hz) or broad stimulation of the PFC and insula will yield improves AUD
treatment outcomes.
The posterior cingulate cortex has direct structural projections to the medial prefrontal
cortex and the dorsal portions of the striatum (349, 350) – brain regions mediating the
processes of habitual drug seeking (74). BOLD signal within the posterior cingulate cortex
is consistently elevated in response to alcohol cues (100) and predicts relapse to alcohol
(100, 351-353). To date, only one study has stimulated the posterior cingulate (and
precuneate cortex) as a strategy to treat substance use disorders. In a sample of heavy
cannabis users, following one session of high-frequency TMS, individuals receiving real
TMS had a reduced brain response to cannabis-related stimuli (354). Taken together,
stimulation of the posterior cingulate cortex may be a fruitful treatment avenue for future
clinical trials for alcohol and substance use disorder.

Moving past craving: successful outcomes can include enrollment and
complex drinking patterns
Many trials of TMS as a therapeutic intervention for AUD have focused on reductions
in alcohol craving as a primary dependent variable (177, 178, 184, 185). Subjective reports
of craving, however, are not reliably related to relapse and drinking patterns (355, 356).
As such, the field shift its focus from craving to more concrete AUD treatment outcomes:
attendance/enrollment and complex changes in alcohol drinking patterns.
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Enrollment and continued attendance within a treatment program is strongly correlated
with achieved and maintained sobriety (230, 231). Outpatient treatments, which require
voluntary (often daily) attendance are among the most popular forms of treatment sought
out by individuals with AUD (6). Dropout rates within these programs, however, are high
(229). As demonstrated in Chapter 2 of this dissertation, enrollment can be substantially
improved following MPFC-TMS. In future, longitudinal TMS-AUD clinical trials, maintained
enrollment at follow-up visits may be a useful measure of treatment outcome. Future
clinical trials may also seek to measure attendance not only at study visits, but also at
extra circular treatment efforts, such as AA meetings.
Many groups have used TMS as a tool to reduce alcohol consumption and prevent
relapse within the first 1-3 months following treatment (180, 181, 192, 195). Within these
trails, most groups measure relapse or total number of drinking days in the months
following treatment. These measurements, however, likely do not capture the complexity
of drinking patterns. For instance, a shift from frequently heavy drinking prior to treatment
to lightly drinking treatment may still be considered a negative outcome. This is elegantly
described by Witkiewitz and colleagues, who demonstrate that after a relapse, individuals
are likely to resume one of three drinking patterns: frequent heavy drinking, 2) infrequent
heavy drinking and 3) light drinking (37). AUD and brain stimulation field, then, might
consider assessing return to drinking using more continuous or ordinal, rather than binary
definitions of relapse.
Lastly, there is evidence that maintained sobriety within the first year following
treatment is a critical determinant of AUD recovery (31, 32). In considering both of the
above recommendations, the TMS-AUD field might consider expanding the timeframe of
longitudinal follow up to 12 months.
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Women in brain stimulation: improved outcomes in AUD and beyond
Women have experienced a disproportionate, 84% increase in AUD prevalence within
the last decade (21). Despite this increase, women are less likely to seek treatment for
AUD (6). Among women who do seek treatment, however, treatment outcomes and
sobriety rates are generally improved relative to men (49). It is currently unclear how these
clinical gender differences may influence TMS treatments for AUD.
Many of the chapters in this dissertation present compelling evidence that brain
stimulation has a different impact on men and women. Specifically, electrical fields at the
frontal pole are substantially stronger in women than in men. Perhaps owing to this
difference, the greatest reductions in alcohol cue-induced functional connectivity were
observed among women. Collectively, these results suggest a prospective, balanced
study exploring gender as a biological variable in TMS-AUD treatment response is
needed.
While not specific to AUD, similar sex/gender differences have been observed
following TMS for depression. In fact, in a meta-analysis performed over a span of 16
years (1997-2013) and 54, sham-controlled research studies, there was a positive, linear
relationship between percentage of females enrolled in clinical trials and overall reduction
in depression severity (357). Taken together, sex/gender is likely a critical variable that
influences TMS efficacy to AUD and various psychiatric disorders. As in the neuroimaging
field (358), clinical TMS trials should systematically evaluate sex/gender as a contribution
to the main effects of the study and report the results of the analysis regardless of
statistical significance.

The future of brain stimulation and AUD
The field of brain stimulation is rapidly advancing, and Transcranial Magnetic
Stimulation is just one treatment tool in the clinical toolbox. In parallel to the development
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of TMS for AUD, other approaches such as transcranial direct current stimulation, vagus
nerve stimulation and deep brain stimulation have shown promise as therapeutic tools to
reduce drinking (149, 359).
One interesting therapeutic opportunity for the field of brain stimulation in AUD is the
prospective ability of TMS to temporarily open the blood brain barrier (360). Such specific
and transient openings in the blood brain barrier may allow for drug delivery to specific
brain regions implicated in the disease. In the case of AUD, it is conceivable that
naltrexone, delivered specifically to the striatum, may yield a different treatment outcome
that when delivered globally.
Another interesting development in the field of TMS research is the use of ‘accelerated’
protocols. Within these accelerated treatments, up to 10 sessions of TMS are given in a
day, over a span several weeks. Recent accelerated TMS trials have shown laudable
efficacy in improving depression and OCD symptoms (330, 361). It is conceivable that
accelerated treatment protocols may further improve the TMS treatment outcomes
reported here.
Overall, the trajectory of TMS as a treatment for AUD is positive. TMS offers favorable
safety and tolerability profiles, while improving sobriety rates. The existing treatment
landscape of pharmaceutical and behavioral interventions for AUD may likely be
intimidating to many patients, wherein it is well-known that the odds of achieving and
maintaining sobriety are low. The development of TMS for AUD stands to offer renewed
hope and opportunity to patients who need it. It has been an immense honor to take part
in this development process.

146

Supplemental Chapter 1: Determining the optimal pulse number
for Theta Burst induced change in cortical excitability
Introduction
Human Theta Burst Stimulation (TBS) is a form of transcranial magnetic stimulation
(TMS) in which TMS pulses are delivered in triplets that occur 5 times per second. Initial
support for TBS arose from in vitro electrophysiology research which demonstrated that
theta burst stimulation to the hippocampus can induce long-term potentiation (LTP)(152155). In 2005, Huang and colleagues delivered theta burst stimulation to humans via a
conventional figure of eight TMS coil (156). Since then TBS has been widely embraced
by researchers and clinicians due to its relatively high efficiency as a brain stimulation tool
(157). It also received Food and Drug Administration (FDA) clearance for use in treating
medication resistant major depressive disorder (MDD) in 2018. Amidst this enthusiasm
however, several questions remain unanswered regarding the optimal parameters of TBS.
One open question involves the optimal number of pulses that should be applied to
the cortex during each session. The majority of studies apply 600 pulses of TBS to the
cortex in either a continuous (cTBS) or intermittent (iTBS) manner. The initial study in 9
individuals demonstrated that 600 pulses of iTBS amplified cortical excitability and 600
pulses of cTBS attenuated excitability (156). A subsequent study in 2010 by Gamboa et
al. demonstrated that doubling the number of TBS pulses led to a paradoxical reversal of
these effects - 1200 pulses of iTBS decreased excitability and 1200 pulses of cTBS
increased excitability(238). These results, however, have been inconsistent(362). In
addition to 600 and 1200 pulses, some groups have chosen 1800 pulses(363, 364) and
3600 pulses(193) as a TBS dose.
To date, however, there has not been a prospective, randomized, sham-controlled
evaluation of these emerging TBS protocols and their impact on cortical excitability. The
primary goal of this study was to evaluate the effect of escalating pulse number on TBS147

associated modulation of the motor cortex. As with most of the studies in this field, the
motor cortex was chosen as the model system to modulate cortical excitability, wherein
the amplitude of motor evoked potentials (MEPs) was the primary dependent measure.
Healthy, right-handed adults were recruited from the community without regard to their
genotype in order to maximize generalizability to a heterogenous population of young to
middle aged adults.

Materials and Methods
Overview
Sixty right-handed individuals from 21-35 years old with no history of neurologic injury
were recruited from the Charleston, SC metropolitan community to participate in one of
two non-invasive brain stimulation experiments. These experiments were approved by the
Medical University of South Carolina Institutional Review Board and were performed in
accordance with Declaration of Helsinki on Ethical Principles for Medical Research. Each
participant gave informed written consent prior to study participation.
In Experiment 1 at each visit, participants received one of three doses of intermittent
TBS (600, 1200, 1800 pulses) or sham TBS (600 pulses) in a randomized order (n=30,
20F, 10M, 24.4 ± 3.7, mean age ± SD). In Experiment 2 at each visit, participants received
one of four doses of continuous TBS (600, 1200, 1800, and 3600 pulses) or sham TBS
(600) in a randomized order (n=30, 18F, 12M, 25.0 ± 3.4, mean age ± SD). Each visit was
separated by at least 2 days to prevent carry-over effects. Electromyography (EMG) was
used at each visit to record MEPs of the abductor pollicis brevis (APB) muscle in the right
hand before and after a dose of TBS. Handedness was confirmed using the Edinburgh
Handedness Inventory (86.7 ± 14.1; mean EHI score ± SD)(365).
At each study visit, Ag-AgCl surface electrodes (Natus Neurology Incorporated,
Middleton, Wisconsin) were placed with a belly-tendon montage on the APB muscle of the
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right hand. The TMS coil was then positioned in a posterior-anterior (PA) direction at a 45degree angle over the left motor cortex. To determine the motor ‘hotspot’ (defined here as
the cortical location evoking the largest EMG response in the target muscle), a series of
single pulses of TMS were applied with a grid-based searching system starting from the
C3 location (EEG 10-20 system) and extending in 1-2cm increments in 4 directions with a
minimum 4 second interval between TMS pulses. All TMS procedures were performed
using Magventure’s X100-Magoption equipped with a COOL-B65 figure-of-eight coil with
an outer winding diameter of 75mm (Magventure Inc., Farum, Denmark). Raw EMG
signals from a CED four-channel electrode adapter box were amplified, band-pass filtered
(100-10,000 Hz) and sampled (5000 Hz) using a CED 1902 amplifier, a CED Micro1402
analog-to-digital converter, and CED Spike 2 software (Cambridge Electronics Design,
United Kingdom). The motor hotspot for each participant was recorded using
neuronavigation software (Brainsight; Rogue Research Incorporated, Montreal, Quebec,
Canada) such that the same cortical location could be accurately stimulated across
timepoints and study visits.
After the localization of this motor ‘hotspot’, a series of standard metrics were acquired
including the resting motor threshold (rMT), active motor threshold (aMT), and the
stimulator intensity needed to reliably obtain an average peak-to-peak amplitude of
approximately 1mV (SI1mV) (Figure S.1.1). All three measures were found using parameter
estimation by sequential training (PEST), an automated algorithm used to determine TMS
thresholds (143). During the rMT and 1mV threshold, participants were instructed to relax
their right hand on a pillow. During the aMT, participants were instructed to touch their
thumb to their pointer finger (making an O.K. sign), thereby slightly flexing the APB muscle.
To standardize measurement thresholds, an automated TMS-EMG-PEST feedback
system was programmed using Spike2 software (Cambridge Electronic Design Limited,
Cambridge, England). Baseline cortical excitability was determined by applying 3 blocks
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of 20 single pulses of TMS separated by 5 intervals (Experiment 1) or 1 block of 20 single
pulses of TMS (Experiment 2) at the predetermined 1mV threshold. An additional 5-minute
rest interval was introduced between the baseline measurement and application of TBS.
Following TBS administration (see details below), blocks of 20 MEPs were collected
at 0, 10, 20, 30, 40, 50, and 60 minutes (Figure S.1.1). During periods of stimulation and
recording, participants were instructed to keep their hand still and relaxed. To maintain a
relatively fixed level of vigilance though the 60-minute session, in between the EMG
sampling intervals, participant viewed episodes from a nature documentary (Planet Earth,
Public Broadcasting System, 2006).
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Figure 1: Diagram of experimental design for iTBS and cTBS experiments

Figure S.1.1. Diagram of experimental design for iTBS and cTBS experiments. This
diagram represents the flow of assessments performed on a given visit. Each visit began
with resting, active and 1mV thresholds. Next, 20 baseline MEPs were collected prior to
TBS administration (for participants in the iTBS experiment this was performed 3 times).
A dose of iTBS or cTBS was administered at 80% aMT. Directly following stimulation 20
MEPs were collected and repeated at 10-minute intervals thereafter. Only a subset of
participants during Experiment 2 received sham stimulation.

1
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Theta-burst stimulation protocols
Experiment 1 – intermittent TBS (iTBS):
iTBS was administered at 80% of each participant’s aMT in a burst-firing pattern (3
pulses at 50Hz) for a 2 second train, followed by an 8 second period of rest. During each
visit, participants received one of three intermittent theta-burst protocols or a sham
stimulation protocol in a randomized order: 1) 600 pulses (190 seconds), 2) 1200 pulses
(380 seconds), 3) 1800 pulses (570 seconds), and 4) a sham stimulation protocol (366) in
which a 3 cm foam spacer was placed in between the coil and the participant’s scalp,
thereby increasing the coil-to-cortex distance while preserving the sensory aspects of
iTBS.
Experiment 2– continuous TBS (cTBS):
cTBS was administered at 80% of each participant’s aMT in a burst-firing pattern (3
pulses at 50Hz) with a repeated frequency of 5Hz (200ms intervals). During each visit,
participants received one of four continuous theta-burst protocols in a randomized order:
1) 600 pulses (40 seconds), 2) 1200 pulses (80 seconds), 3) 1800 pulses (120 seconds),
4) 3600 pulses (1800 pulses, 60 second break, 1800 pulses). 5) A sham stimulation
protocol(367) which included electrodes placed at the hairline (Natus Neurology
Incorporated, Middleton, Wisconsin). Sham data were collected from 10 of the individuals.

Data analysis
TMS parameter stability: Test-retest reliability of the TMS parameters was evaluated
by assessing the degree of absolute agreement as measured by across session intraclass
correlation coefficient (2-way mixed-model, alpha=0.05) for the following measurements:
rMT, aMT, SI1mV threshold, and average baseline MEP amplitude (SPSS v.23, IBM).
Intraclass correlation coefficients (ICCs) were interpreted as follows: excellent reliability
≥ 0.75; moderate to good reliability 0.74–0.40; and poor reliability < 0.40 (368).
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Effect of TBS dose on change in motor cortex excitability: All MEP amplitudes were
quantified using MAVIN, an automated open source tool for EMG quantification (369).
Using the TMS trigger artefact, MAVIN identifies a window of EMG activity directly
following the test pulse and calculates the peak-to-peak amplitude of each MEP. Any
visual artefacts were rejected before data were exported from MAVIN to excel for data
organization. MEPs that did not elicit a response greater than 0.3 mV outright were
removed from analysis. Following removal of low-amplitude MEPs, MEPs which reflected
a change from baseline of ± 2.5 STDEV from the mean of all post-TBS observations were
excluded(161).
A linear mixed-effects model was created for each experiment using the MEP data,
wherein MEP is nested within timepoint (Baseline, 0, 10, 20, 30, 40, 50, and 60 minutes)
and timepoint is nested within dose (iTBS: 600, 1200, 1800 pulses or sham; cTBS: 600,
1200, 1800, 3600 or sham) for each participant (Supplementary Fig. S2).
These models were estimated using the Matlab function ‘fitlme’ with REML estimation
predicting change from baseline MEP amplitude following each TBS dose with respect to
sham (Matlab, R2020a, The MathWorks Inc). Each model fit fixed-effects for TBS (iTBS:
sham, 600, 1200, 1800 doses and cTBS: sham, 600, 1200,1800, 3600) and time (minute,
as a continuous variable ranging from 0 to 60) as well as their interaction, and covaried
each individual’s rMT. Treatment included the sham condition for both iTBS and cTBS. As
described above, the following random effects were included: the mean change from
baseline was allowed to vary by subject, treatment within subject, time within treatment,
and individual MEP within time independently. Given that most experiments in the TBS
field investigate a single dose of TBS, univariate analyses for each dose relative to time
were performed within the multivariate linear mixed model.
Exploratory analysis of variability: Given prior reports of individual variability in TBS
studies, we performed a qualitative secondary analysis to assess individual variability in
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TBS response patterns. We classified each individual’s response to TBS as ‘excitatory’ or
‘inhibitory’ or ‘no change’. In line with Perellon-Alfonso et al.(160), this was done by
calculating the sum of all MEPs in the 60 minutes after TBS and dividing the by the total
number of MEPs collected. An ‘excitatory’ response was defined as greater than 20%
increase in MEP amplitude, an ‘inhibitory’ was defined as a greater than 20% decrease in
MEP amplitude. Otherwise, the response was designed ‘no change’.

Results
Baseline measurements
There was high test-retest reliability of the baseline measurements of rMT (Exp 1:
ICC=0.964, 95% CI=0.935-0.982; Exp 2: ICC=0.965, 95% CI=0.940-0.982), aMT (Exp 1:
ICC=0.958, 95% CI=0.925-0.979; Exp 2: ICC=0.935, 95% CI=0.887-0.966), SI1mV (Exp 1:
ICC=0.975, 95% CI=0.954-0.987; Exp 2: ICC=0.965, 95% CI=0.938-0.982) and average
baseline MEP amplitude (Exp 1: ICC=0.747, 95% CI=0.549-0.873; Exp 2: ICC=0.599,
95% CI=0.291-0.794) as revealed by intraclass-correlation coefficient. Mean motor
thresholds and mean baseline MEP amplitudes are shown in Table S.1.1. Active motor
thresholds were 10.3% less than rMT for iTBS and 10.1% less than rMT for cTBS. 1mV
thresholds were 15.3% greater than rMT for iTBS and 16.3% greater than rMT for cTBS.
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Table S.1.1. Motor thresholds and baseline MEP amplitudes. Mean (±SD) resting
motor threshold (%MSO), active motor threshold (%MSO), 1mV stimulus intensity
threshold (% MSO), and recorded baseline MEP amplitude (mV).

Experiment 1: iTBS

V1

V3

V4

Resting Motor
Threshold

48.62
50.48
47.93
48.70
± 9.28 ± 10.81 ± 10.58 ± 9.94

Active Motor
Threshold

42.28
45.48
43.18
43.67
± 9.07 ± 9.81 ± 9.34 ± 9.25

V5

N/A
1 mV Stimulus
57.38
58.03
55.29
54.85
Intensity
± 11.67 ± 14.13 ± 12.50 ± 11.47
Baseline MEP
amplitude (1mV)

Experiment 2: cTBS

V2

1.57
1.47
± 0.96 ± 0.60

1.30
± 0.66

1.44
± 1.05

Resting Motor
51.77
53.27
53.32
50.57
48.0
Threshold
± 12.15 ± 12.20 ± 10.86 ± 10.86 ± 14.41
Active Motor
Threshold

46.10
46.73
48.18
46.18
43.27
± 12.69 ± 11.58 ± 10.07 ± 11.06 ± 14.31

1 mV Stimulus
60.47
61.70
59.61
60.00
55.45
Intensity
± 14.38 ± 13.98 ± 12.95 ± 14.90 ± 17.83
Baseline MEP
amplitude (1mV)

1.54
1.55
± 0.80 ± 0.81
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1.57
± 0.60

1.46
± 0.59

1.52
± 0.77

Experiment 1 – iTBS
The MEP data for each dose over time is shown in Figure S.1.2a. There was a
significant main effect of time (F1,

13,338=5.3473,

p=0.02) and a significant time*dose

interaction (F3, 13,338=3.8296, p=0.01) relative to the sham condition. There was a main
effect of 1200 pulses (t13,388= -2.1374, p=0.03) as well as a time*1200 pulse interaction
(t13,338=3.1267, p=0.001), wherein 1200 pulses was net inhibitory relative to sham at 0
(t858.6=-3.155, p=0.002), 10 (t1,053=-4.663, p=4.0*10-6), 30 (t1,032=-4.96, p=8.15*10-7) and 50
(t1,011=-3.10, p=0.002) minute timepoints.
There was no main effect of the 600 pulses (t13,338=0.0586, p=0.95) or 1800 pulses
(t13,338=1.415, p=0.15), nor a time*600 pulse interaction (t13,338=-1.3564, p=0.17) relative to
sham. There was borderline time*1800 pulse interaction (t13,338= -1.9368, p=0.053).

Experiment 2 – cTBS
The MEP data for each dose over time is shown in Figure S.1.2b. When all doses were
considered in aggregate relative to sham, there was no main effect of time (F1,
17,098=0.0692,

p=0.79) or dose (F4, 17,098=0.0871, p=0.97) nor a significant time x dose

interaction on MEP data following cTBS (F4, 17,098=1.1513, p=0.33), relative to sham.
When each does was considered independently relative to sham (as is the typical
design in TBS experiments), there was a significant 3600 pulse*time interaction
(t17,098=2.0880, p=0.04), wherein 3600 increased excitability relative to sham at the 20
(t747.97 = 2.465, p=0.014), 30 (t666.20= 4.556, p=6.0*10-6), 40 (t

701.06=3.908,

p=0.0001), 50

(t870.28=2.936, p=0.003) and 60 (t717.87= 3.688, p=0.0002) minute timepoints.
There was no significant main effect for the other cTBS doses (cTBS (600):
t17,098=0.1611, p=0.87; cTBS(1200) t17,098=0.5041, p=0.61; cTBS(1800) t17,098=-0.1749,
p=0.86; cTBS(3600): t

17,098=-0.2851,

p=0.76), nor a significant dose*time interaction
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(cTBS (600) t17,098=-0.1092, p=0.91; cTBS(1200) t17,098=-0.5479, p=0.58; cTBS (1800) t
17,098=-0.5892,

p=0.56).

[Note: While univariate analyses are typically only performed if there are main effects
or interactions in the multivariate model, a univariate comparison of each dose relative to
sham accurately mimics typical experimental design in the TBS field. While this may not
be technically correct from a conservative statistical perspective, not reporting these
results may do a disservice to the field.]
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Figure 2: Change in MEP amplitude over time

a)

b)

Figure S.1.2: Change in MEP amplitude over time. Line graph showing the A. Effect
of
2
iTBS (Experiment 1) doses and sham on average change from baseline MEP over time
and B. Effect of cTBS (Experiment 2) doses and sham on average change from baseline
MEP over time. Error bars represent ± SEM (standard error of the mean). Average change
in MEP for post iTBS and cTBS time points were calculated by subtracting the average
baseline MEP amplitude from all MEPs post-treatment. Shapes represent each MEP
assessment time point following the 600 pulses (circle), 1200 pulses (triangle), 1800
pulses (diamond), and 3600 pulses (X’s) of iTBS and cTBS. TBS protocols that were
significantly different than sham stimulation over time are depicted by black lines. Sham
stimulation is represented with a dotted line and squares for each time point. The results
of the LME are embedded in the graph above.
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Exploratory analysis of individual variability
We evaluated within-subject consistency of responding in a given manner to iTBS or
cTBS. As shown in Figure S.1.3, only 3 individuals demonstrated a consistent response
to the tested real iTBS protocols (1 consistently demonstrating no change and 1
consistently inhibitory). Similarly, only 2 individuals demonstrated a consistent response
to the tested real cTBS protocols (1 consistently demonstrating no change and 1
consistently inhibitory).
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Figure S.1.3. Individual Response to TBS protocols. Colored grid shows the
breakdown of inhibitory (blue), excitatory (red) or no change (grey) responses following A.
iTBS and B. cTBS doses in each individual. ^ indicates individuals who consistently
responded in the same direction to all real TBS protocols.
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Discussion
Here we present the first parametric sham-controlled study to explore the relationship
between TBS pulse number (both cTBS and iTBS) and motor cortex excitability. The goal
of these experiments was to systematically evaluate the effect of TBS dose on the change
in motor cortex excitability. As a refinement of previous studies, we also included an active
sham condition. The primary conclusions are that 1) within iTBS protocols, 1200 pulses is
significantly different from sham, resulting in a net inhibition of cortical excitability, and 2)
within cTBS protocols, 3600 pulses is different than sham, resulting in a net increase in
excitability. We did not, however, find significant effects of the other doses relative to
sham. This may be due to a high degree of intra- and inter-individual variability – a finding
which has been reported by many other studies in the TBS field.

iTBS (1200 pulses) decreases motor cortex excitability
The primary finding of our investigation is that 1200 pulses of iTBS causes a significant
decrease in cortical excitability. This observation complements and extends prior work
from Gamboa et. al 2010 wherein 1200 pulses of iTBS decreased cortical excitability
(whereas 600 pulses had increased excitability). They also found that 1200 pulses of cTBS
increased excitability (whereas 600 pulses had decreased excitability) (238). Hsu et. al 2011
also evaluated the effect of 600 versus 1200 pulses of TBS on excitability and failed to
find an effect of pulse number on excitability (362). Notably, both of these groups used
relatively small sample sizes in their analyses (n=14 & 10 respectively), did not incorporate
an active sham control, and one group pre-selected individuals with a Val/Val genotype
for BDNF7. Here, with a much larger sample, we failed to find a difference between 600
pulses of iTBS or cTBS and sham, but, consistent with Gamboa and colleagues, 1200
pulses of iTBS produced a significant attenuation of cortical excitability.
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The directionality of 600 pulses of iTBS and cTBS on cortical excitability
As mentioned in the introduction, early studies presented by Huang et. al and others
led to the widespread adoption of 600 pulses of TBS in manipulating motor cortex
excitability. Indeed, to date, at least 139 studies (iTBS: 86; cTBS: 90; both: 37) have
utilized this 600-pulse dose in their investigations of the impact of TBS on motor cortex
excitability in healthy controls. On the whole, the majority of published work demonstrates
an “LTP-like” effect of 600 pulses of iTBS and an “LTD-like” effect of 600 pulses of cTBS
(as measured by an increase or decrease in MEP amplitude post treatment, respectively).
The current study suggests that in healthy controls, 600 pulses of cTBS or iTBS does
not produce a significant change in motor cortex excitability relative to sham stimulation.
In fact, iTBS tends to have a net inhibitory effect on cortical excitability – which is driven
primarily by the 1200 pulse condition, and cTBS tends to have a net excitatory effect on
cortical excitability – driven by an effect of 3600 pulse condition. This can be seen both
through the multivariate model as well as a qualitative view of the results in Figure S.1.2.
While the lack of facilitation with iTBS(600) and inhibition with cTBS(600) is contrary
to many previously published studies, there are several key differences between our
experimental protocols and the prior work in this field. Foremost, among the previously
published work (n=139), only 25 studies (approximately 18%) have incorporated a sham
or control condition (160, 162, 263, 362, 370). While many of them have reported
significant changes in motor cortex plasticity following TBS, relative to sham, many of the
sham strategies used (stimulating alternate brain regions, tilting the coil away from the
head, or applying sham tDCS) do not robustly model the somatosensory experience of
receiving TMS in a given location. Indeed, in a recent, sham-controlled study
(incorporating a sham that accurately mimics the somatosensory aspects of TMS),
Perellon-Alfonso et. al (160) were unable to detect a significant difference in iTBS-induced
(relative to sham-induced) change in motor cortex plasticity, even when 600 pulses of
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iTBS were applied for 5 consecutive days. Similar active, sham-controlled studies have
found no change (162) or very small decreases (161) in motor cortex excitability following
600 pulses of cTBS.
Further, we note that several studies pre-select participants based on intrinsic
biological variables such as BDNF genotype (173, 238, 370-373), TRPV1 mutation (374),
APOE3 mutation (167) or COMT (375). Given that the current study recruited from the
community and did not filter for a specific genotype, our results many not be directly
comparable to these works. Lastly, we note that among the existing literature,
approximately 26% of existing works have incorporated sample sizes greater than 20
young, healthy controls. Among these works, many groups have been unable to find a
significant reduction in MEP amplitude following 600 pulses of cTBS (163-171) or a
significant increase in MEP amplitude following 600 pulses of iTBS (171-176).

Inter- and Intra-subject variability
A growing body of evidence has emerged suggesting a high degree of inter- and intraindividual variability exists in response to TBS protocols. Several groups have observed
variable responses to TBS in that some individuals demonstrate no change in motor cortex
excitability following TBS, or an “opposite” effect of TBS wherein cTBS and iTBS produce
an increase or decrease in cortical excitability, respectively (160, 167, 171, 174, 175, 376378).
Following 600 pulses of TBS, we find that the proportion of individuals experiencing
the expected inhibition or excitation following cTBS or iTBS, respectively, are comparable
to proportions reported by several large-scale studies when applying similar thresholds in
defining an individual’s response to TBS as excitatory or inhibitory (±1% change in MEP
amplitude after TBS treatment). Hamada et. al reports only 42% of individuals displaying
the expected inhibitory response to cTBS and others report 43%-52% displaying the
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expected excitatory response to iTBS (171). Applying the same threshold to our data, we
find a comparable 40% of individuals showing an inhibitory response to 600 pulses of
cTBS, and 33% showing an excitatory response to 600 pulses of iTBS. Interestingly, a
recent a position paper from Huang and colleagues has speculated that the probability of
producing the expected inhibitory or excitatory response to various patterns of TMS
(including TBS), may be less than 50% (159), in line with the results presented here. Taken
together, the results from our experiments, and from a number of others demonstrating
substantial degrees of individual variability underscore the need for a clear path forward
for future research regarding TBS, motor cortex excitability, and potential best practices.
TMS-administration related variables such as sample size, sham controls, and coil
orientation are known factors that may contribute to variability. We find that the substantial
variability observed here is mostly congruous with TBS experiments wherein sample sizes
exceeded 20 healthy controls receiving real TBS. As such, we recommend a standard of
at least 20 individuals to be enrolled in these types of studies. Further, we find that many
groups either do not incorporate a sham condition or apply a sham that does not accurately
mimic the somatosensory effects of active TBS, potentially unblinding participants. Given
that the impact of participant expectation towards real or sham treatment remain largely
unknown, we recommend that active sham systems (such as those methods reported
here) become the standard in field of TBS and motor cortex excitability. Lastly, as
previously mentioned, Hamada et. al 2013 and other have suggested that small changes
in coil orientation may recruit distinct populations of interneurons, potentially skewing
results or introducing variability. Future studies may consider incorporating contemporary
neuronavigational systems to rigorously standardize coil placement across visits and
across timepoints within an experiment.
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Limitations
We note several limitations in our experimental design which may limit the scope of
our work. Primarily, the present studies collected motor-evoked potentials only and did not
perform more complex measures such as SICI or ICF and can therefore only assess
changes in corticospinal excitability rather than direct neuroplastic changes in circuits
intrinsic to the motor cortex. We are therefore unable to extensively speculate on the
neurobiological mechanisms which may mediate our results. Additionally, the sham
condition for the two experiments was slightly different, wherein 10 individuals received
surface electrode stimulation on the scalp and 30 received stimulation with a 3cm foam
padding placed between the coil and the scalp. While we do not expect that these sham
conditions to produce disparate results, future research should incorporate a consistent,
rigorous sham for all participants given the substantial variability in response to TBS. We
also note that the current studies recruited primarily young adults. While this is seemingly
the standard in the field, we cannot generalize these results to middle-aged or older adults.
Lastly, our interpretations of these data are limited as they apply only to the use of TBS in
a single session, rather than across consecutive days, as is often the case in studies using
TBS to treat psychiatric disorders.

Conclusions
To the best of our knowledge, this is the first sham-controlled study to parametrically
investigate the relationship between multiple TBS doses (with varying pulse numbers) on
motor cortex excitability. Prior to this report, only two groups had directly examined the
impact of pulse number on TBS-related change in motor cortex excitability in a single,
uninterrupted TBS session (238, 362). The current study reflects the results of 241
individual experiments/observations, 60 participants, and 38,571 collected motor evoked
potentials. The primary results from this study demonstrate that 1) 1200 pulses of iTBS
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has a significant inhibitory effect on motor cortex excitability 2) 3600 pulses of cTBS has
a significant excitatory effect on motor cortex excitability and 3) individual response to a
given cTBS or iTBS protocol (e.g. 600 pulses) is inconsistent with the same individual’s
response to another cTBS or iTBS protocol (e.g. 1200 pulses). This study supports a
growing body of literature suggesting that directed modulation of cortical excitability using
TBS requires a highly controlled environment and may not be ideally suited for
heterogenous patient populations.
Given the growing popularity of TBS as a novel tool to treat psychiatric and motor
disorders alike (for review, see Burke et. al 2019 (379)), we suggest that more emphasis
be placed on the 1200 pulse iTBS and 3600 pulse cTBS conditions as these protocols
had significant effects on cortical excitability relative to sham – even in the presence of
high individual variability.
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